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Sum m ary o f Thesis 
'Renal sodium-dopamine relationship and the effects of sodium loading 
on natriuretic and hormonal responses in Chinese'
Thomas Yan Keung Chan
Dopamine (DA) is an important intrarenal natriuretic, vasodilatory substance 
in the body. In my work, my main objective was to establish whether Chinese have 
an efficient renal DA system that will enable them to handle a salt load effectively 
without showing an increase in blood pressure (BP). A reduction in sympathetic 
nervous system activity, which is reflected by a fall in urinary free noradrenaline 
(NA) output, and enhanced renal kallikrein production, as indicated by increased 
urinaiy kallikrein output, may also contribute to the natriuretic response to salt 
loading. The relative importance of these two mechanisms in sodium homeostasis in 
Chinese were also studied. In my studies, urinary free DA and NA were measured 
by HPLC with electrochemical detection.
If DA is an important intrarenal natriuretic substance in Chinese and dietary 
sodium is the major determinant of its intrarenal synthesis, there should be a positive 
correlation between 24-hour urinary sodium and free DA outputs even under basal 
conditions. There should be a marked and sustained increase in urinary free DA 
output during the natriuretic response to salt loading. Their renal DA system should 
also be sensitive to small and gradual increases in oral salt intake.
In my first cross-sectional study, 89 normotensive subjects (BP <140 mmHg) 
with (5 M, 25 F, aged 48.3 ± 1.3 years) or without (21 M, 38 F, aged 43.4 ± 2.0 
years) a family history of hypertension and 24 hypertensive patients (8 M, 16 F, aged
45.5 ±1.7 years, systolic BP >160 and/or diastolic BP >95 mmHg) were recruited in
vin
1989-1991. There was a positive correlation between 24-hour urinary sodium and 
free DA outputs in normotensives without a family history of hypertension (r=0.42, 
p<0.001). However, such a relationship was not seen in normotensives with a family 
history of hypertension (r=0.22, p<0.5) or hypertensives (r=-0.02, p>0.5). In my 
second cross-sectional study, 85 normotensive subjects (BP <120/80 mmHg) with 
(14 M, 13 F, aged 39.1 ±1.4 years) or without (23 M, 35 F, aged 42.1 ±1.2 years) a 
family history of hypertension and 47 hypertensive patients (25 M, 22 F, BP >140/90 
mmHg). were recruited in 1996-1998. A positive correlation between 24-hour 
urinary sodium and free DA outputs was seen in both normotensives (r=0.57, 
p-0.004 and r=0.36, p=0.006) and hypertensives (r=0.44, p=0.002). Variations in 
findings between these two studies could be in part due to differences in the 
inclusion criteria (BP and its measurement), recruitment method and subject 
characteristics (age, body weight, BP levels and salt intake). Hypertensives in the 
second study were slightly younger and had less severe hypertension than 
hypertensives in the first study. Perhaps, a positive urinary sodium-ffee DA 
relationship is seen only in the earlier stages or when the hypertension is less severe. 
In the second study, hypertensives had a higher 24-hour urinary free DA output than 
normotensives. This hyperdopaminergic response may represent an early 
antihypertensive compensatory mechanism.
Forty-three sibling-pairs discordant for hypertension were also studied under 
basal conditions. The normotensives (14 M, 29 F, aged 39.0 ± 1 . 0  years, BP 
<120/80 mmHg) and hypertensives (21 M, 22 F, aged 40.0 ± 0.9 years, BP >140/90 
mmHg) were significantly different with regarding to their body weight (62.7 ±1.6 
vs 69.1 ± 1.7 kg), BP (120.0 ± 1.3 / 71.8 ± 1.2 vs 147.0 ± 2.5 / 91.4 ± 1.5 mmHg) 
and urinary free DA output (1,457 ± 107 vs 1,765 ±1 0 8  nmol/day). A positive
IX
correlation between 24-hour urinary sodium and free DA outputs was seen in both 
groups (r=0.54, p=0.0000 and r=0.37, p=0.015).
I also studied the effects of large acute changes in dietary salt intake in eight 
healthy Chinese males (aged 22-24 years, body weight 58.3 ± 1.9 kg) without a 
family history of hypertension. They were given a constant diet containing 20 mmol 
sodium/day for 10 days (days —4 to 0 and days 1 to 5). On days 1 to 5, they also 
received 'Slow sodium' tablets equivalent to 200 mmol sodium/day. Urine was 
collected for 24 hours before and throughout the high salt intake period. After salt 
loading, their mean arterial blood pressure (MAP) remained unchanged (76.8 ±1.8 
and 75.0 ± 2.8 mmHg, p>0.05) and there was an 8- to 9-fold increase in sodium 
excretion (p<0.01). There was an 8-17% increase in urinary free DA output during 
the first three days of salt loading (p<0.05). There was a 22% reduction in urinary 
free noradrenaline (NA) output on the last day of salt loading (p<0.05). A similar 
renal DA response was seen in seven healthy Chinese males (aged 21-31 years, 75.5 
±3 .4  kg) with a family history of hypertension. On changing from a 20 to 220 
mmol/day sodium diet, there was a 7- to 10-fold increase in sodium excretion 
(p<0.02). They also showed a 23% increase in urinary free DA output on day 1 
(p<0.05). From day 2 to day 5 of the high salt intake period, the increase in urinary 
free DA output also became attenuated (12-15% higher than the baseline) but still 
reached statistical significance (p<0.05) on days 2 and 5. Unlike those without a 
family history of hypertension, urinary free NA remained unchanged and there was a 
3.7% increase in MAP (80.1 ± 2.5 and 83.1 ±2.1 mmHg, p<0.05). In contrast, when 
changing from a low (90-40 mmol/day) to high (220-340 mmol/day) sodium intake, 
Cacasians in previous studies showed a much greater increase in urinary free DA 
output (26-59%) and the urinary free DA output remained elevated throughout the
high salt intake period. These findings suggest that renal DA contributes only partly 
to the early natriuretic response to dietary salt loading in Chinese. A reduction in 
SNS activity towards the end of the high salt intake period might help offset any 
tendency to hypervolaemia-related increases in BP in normotensives without a 
family history of hypertension.
Seven healthy Chinese males (aged 23-25 years, 70.2 ±3 .1  kg) without a 
family history of hypertension received a constant diet containing 20 mmol/day of 
sodium for 12 days (days -3 to 0 and days 1 to 8). From day 1 to day 8, they also 
received 'Slow sodium' tablets equivalent to 50 mmol sodium on day 1, 100 mmol on 
day 2, 150 mmol on day 3, 200 mmol on day 4, 250 mmol on day 5 and 300 mmol 
on days 6 to 8. Urine was collected for 24 hours before and throughout the high salt 
intake period. Following salt loading, their MAP was unchanged (79.4 ± 0.5 on day 
0 and 81.6 ± 2.1 mmHg, p>0.05). By day 8, there was a 13-fold increase in sodium 
excretion. However, urinary free DA output remained unchanged. Despite a sodium 
intake of 320 mmol/day on the last three days of the high salt intake period, there 
were no significant changes in urinary free DA output (1,907 ± 250 on day 0 vs 
1,967 ± 261 on day 6, 2,020 ± 282 on day 7 and 2,122 ± 278 nmol on day 8, p>0,05). 
In contrast, there was a 19.9-26.5% reduction in free NA output (226.5 ± 17.0 on day 
0 vs 180.5 ± 22.6 on day 4 and 165.5 ± 12.3 nmol on day 6, p<0.05). These findings 
suggest that the renal DA system in Chinese is insensitive to gradual and small 
increases in oral salt intake. The late reduction in SNS activity may help offset any 
tendency to hypervolaemia-related increases in blood pressme.
When seven healthy Chinese males (aged 23-25 years) were given an 
intravenous infusion of 0.9% saline (1,000 ml over two hours), hourly urinary free 
DA outputs during (71.0 ± 5.7 and 74.4 ± 3.5 nmol) and after (69.8 ± 7.0 and 73.5 ±
XI
6.8 nmol) the saline infusion were not different (p>0.05) from the baseline (67.2 ±
4.9 nmol). Hourly urinary free NA outputs also remained unchanged. In contrast, 
hourly urinary kallikrein (measured by an amidolytic assay) showed an increase of 
103.0-140.4% during the saline infusion (0.27 ± 0.05 at baseline vs 0.55 ± 0.13 in 
hour 1 and 0.65 ±0.11 KU, p<0.05). Urinary kallikrein was still 74% higher than 
the basal level one hour after completion of the infusion (0.47 ± 0.08 KU, p<0.05).
In summary, my findings suggest that Chinese do not have an efficient renal 
DA system. Their renal DA response is insensitive to gradual, small increases in 
oral salt intake and a modest intravenous salt load. Even sudden, large increases in 
oral salt intake is associated with a relatively small and unsubstained renal DA 
response. The absence of early changes in urinary free NA output following salt 
loading may suggest that the natriuresis is not mediated by a reduction in SNS 
activity. However, a reduction SNS activity towards the end of high salt intake 
period may help offset any tendency to hypervolaemia-related increases in blood 
pressure. In contrast, the increase in urinary kallikrein during the natriuretic 
response to a modest intravenous salt load may suggest that the renal kallikrein-kinin 
system is the more important natriuretic system in Chinese.
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Chapter 1 Salt balance, renal dopamine and hypertension
1.1 Salt intake and hypertension
Both genetics and environmental factors as well as their interactions are 
thought to be important in the development of hypertension (1). In westernised 
societies, the most important modifiable environmental risk factors are high salt 
intake, alcohol intake, obesity and low physical activity (2). Recent data have also 
shed light on how stress can affect blood pressure (BP) (3).
Meta-analyses of observational data have confirmed and quantified an 
association between salt intake and high BP both between populations (4) and within 
populations (5). A difference in sodium intake of 100 mmol/day is associated with 
an average difference in systolic blood pressure (SBP) that ranges from 5 mmHg at 
age 15-19 years to 10 mmHg at age 60-69 years. The differences in diastolic blood 
pressure (DBP) are about half as great. Meta-analyses of randomised controlled 
trials have confirmed the favourable effect of a reduction in salt intake on BP (6,7). 
Thus, in people at age 50-59 years, a reduction in daily sodium intake of 50 mmol 
will, after a few weeks, lower SBP by an average of 5 mmHg, and by 7 mmHg in 
hypertensive subjects with a SBP of 170 mmHg (6). DBP will be lowered by about 
half as much.
High salt intake may theoretically induce hypertension through increases in 
cardiac output and effects on vascular reactivity and contractility (see Section 2.5). 
However, not all individuals respond to the same extent to alterations of sodium and 
extracellular fluid (ECF) volume status with corresponding increases or decreases in 
BP (8). In normotensive as well as hypertensive subjects, BP can be judged to be 
'salt-sensitive' when observed to vary directly and substantially with the net intake of
sodium chloride (see Section 2.6.1). Subjects not showing such a phenomenon can 
be regarded as 'salt-resistant'.
Certain individuals are known to be more salt-sensitive (e.g. patients with 
hypertension and their first-degree relatives, blacks, older subjects, obese subjects, 
diabetic patients and patients with renal failure) (9). These individuals generally 
have a relative inability to handle a salt load efficiently, due to dysregulation of the 
natriuretic systems and/or antinatriuretic systems in the body (see Chapter 2).
1.2 The discovery of renal DA as an endogenous natriuretic factor
Dopamine (DA) was once regarded simply a metabolic precursor of 
noradrenaline (NA) and adrenaline. The role of DA as an intrarenal natriuretic, 
vasodilatory substance was not explored earlier because of the uncertainty of the 
origin of urinary DA and difficulties in measuring plasma DA (10).
Overall the past 30 years, the pioneer work of several investigators strongly 
suggests that renal DA is an important natriuretic factor in the body. [A detailed 
account is given in Chapter 3.] McDonald et al. (11) have shown that intravenous 
infusion of DA in pharmacological doses evokes a marked natriuresis and diuresis in 
humans. Alexander et al. (12) have shown that oral salt loading or intravenous 
infusion of 0.9% saline increases the urinary excretion of sodium and free DA in 
healthy subjects. Oates et al. (13) have shown that urinary free DA output increases 
after oral salt loading while plasma DA is unchanged. The calculated clearance 
values for DA far exceeds renal plasma flow. Both observations indicate that DA is 
formed inside the kidney. Using micropuncture techniques, Baines & Chan (14) 
have shown in rat kidney that L-dopa, the precursor of DA, is converted actively into
urinary free DA. Ball & Lee (15) have shown in healthy subjects receiving a high 
salt diet that inhibition of renal DA synthesis using carbidopa results in decreased 
urinary free DA excretion as well as attenuation of the natriuresis. The kidney has 
abundant DA receptors (16). Krishna et al. (17) have shown in healthy subjects that 
blockade of these receptors attenuates the natriuretic responses to ECF volume 
expansion by saline infusion. Aperia et al. (18) have shown that proximal tubular 
Na'^-K^-ATPase, the enzyme responsible for sodium transport, is reversibly inhibited 
by DA and L-dopa.
1,3 Defects in renal DA production can cause hypertension
Lee (19) proposed in 1981 that the kidney 'fault' in essential hypertension 
may be a failure to mobilise adequately renal DA when dietary sodium intake is 
increased. His hypothesis was based on several observations.
Firstly, the Dahl salt-sensitive rat kidney does not seem to possess the same 
capacity to vasodilatation as Dahl salt-resistant rat kidney when the animal is given 
an oral salt load (20). Lee suggested that Dahl salt-sensitive rat might have a limited 
capacity to produce intrarenal vasodilatory and natriuretic substances such as DA.
Secondly, Lufr et al. (21) studied the responses of normotensive blacks and 
whites to sodium intakes ranging from 10 to 1,500 mmol/day. With higher salt 
intakes, BP increases in both blacks and whites, but the increase is greater in blacks. 
Lufr et al. (22) have also shown that blacks do not excrete an intravenous salt load as 
well as whites do, and their baseline plasma renin activity (PRA) is more suppressed. 
The concept of a genetic predisposition of salt sensitivity is supported by the 
observation that American blacks have a higher incidence of hypertension than
American whites, although both groups consume similar quantities of dietary salt
(23).
Thirdly, many primitive communities have a daily sodium intake of less than 
20 mmol. Therefore, when the ambient temperature is high, they are faced with the 
risk of salt depletion through sweating. It would be advantageous to be able to retain 
some of the sodium chloride. The evolutionary benefit of diminished salt excretion
(24) from inability to mobilise renal DA is obvious (19). Two hundred years ago, 
the situation changed dramatically. Salt became readily available. The genes that 
previously protected against salt depletion are at a disadvantage with salt intake in 
excess of, say, 150 mmol/day. [Subsequent work by Lee, Critchley and co-workers, 
as detailed in Chapter 3, confirmed that sub-Sahara African populations do not show 
a positive correlation between the 24-hour urinary sodium and free DA output and 
their urinary free DA output does not rise in response to oral salt loading.]
Fourthly, the work by Lee and by others indicates that renal DA is an 
important natriuretic factor in the body (see Chapter 3).
Lee (19) has concluded that some individuals may be less efficient in 
excreting a salt load as a result of defective renal DA production. Such individuals 
may develop essential hypertension if  presented with high salt loads by mouth during 
the critical inductive phase of childhood and adolescence. The kidney fault may be 
marked by a relatively low PRA and a relatively high plasma aldosterone level.
1.4 Other defects in the renal DA system can also cause hypertension
Apart from a reduction in renal DA production, defects in the transduction of 
renal tubular DA signal or renal vascular DA signal may lead to hypertension (25)
(see Section 4.1.3). This is not surprising since DA, via different DA receptor 
subtypes, regulates cardiovascular functions by its actions on the central and 
peripheral nervous systems, vascular smooth muscle, the heart and the kidney (see 
Section 3.1.2).
Jose et al. (26) described several human and animal models of hypertension 
in which there is a reduction in renal DA production and/or defects in coupling 
between DA, receptors and associated first messengers (see Section 4.1). They 
pointed out that this defect is: (a) genetic, since it precedes the onset of hypertension 
and co-segregates with the hypertensive genotype; (b) receptor-specific, since it is 
not shared by other humoral agents; (c) organ and nephron segment selective, since it 
occurs in proximal tubules but not in cortical collecting ducts or the brain.
1,5 Dietary changes and hypertensive diseases in Hong Kong Chinese
In Hong Kong, the local Chinese diet used to be low in fat and cholesterol 
and relatively high in carbohydrates and fibres (27). However, household surveys in 
the 1990s documented dietary shifts in the population from diet predominately of 
rice and small portions of meat, vegetables and fish to that with larger portions of all 
foods but rice and eggs (28). It is worth noting that the dietary sodium intake in the 
local population (29,30) is now approaching that of many western societies (31). For 
example, in my study of the relationship between sodium and potassium intakes and 
BP among healthy subjects mainly from the Shatin district in the late 1980s (29), the 
average sodium and potassium intakes were 145 and 40 mmol/day in men and 135 
and 41 mmol/day in women. As part of her study of the metabolic syndrome in 
Chinese subjects, Lee (30) recruited healthy controls mainly from the Shatin district
in the late 1990s. The average sodium and potassium intakes then were 173 and 43 
mmol/day in men and 162 and 42 mmol/day in women.
During 1988-1989, Woo et al. (31) studied the prevalence of hypertension 
among 1,513 Chinese employees of a public utility company and non-medical 
personnel of the Prince of Wales Hospital, the general teaching hospital for Shatin 
and the neighouring districts. The prevalence of hypertension, defined as SB? >140 
or DBP >90 mmHg, or a past history of hypertension, was 17% in men and 5% in 
women.
During 1995-1996, Janus et al. (32) studied the prevalence of cardiovascular 
risk factors and dietary intakes among 7,730 subjects aged 25-74 years randomly 
recruited from the whole of Hong Kong. Some of these subjects were selected for 
blood sampling and arthropometric measurements. About one in 10 men and one in 
nine women had 'definite hypertension' (SBP >160 and/or DBP >95 mmHg or on 
drug treatment for hypertension). About 34% of men and 29% of women with 
hypertension were untreated. About one in 12 men and 1 in 16 women were 
considered having 'borderline hypertension' (SBP 140-159 and/or DBP >90-94 
mmHg). About one in 100 men and one in 67 women had untreated isolated systolic 
hypertension (SBP >160 and DBP <90 mmHg).
The work of my colleagues at the Chinese University of Hong Kong provides 
further evidence that hypertension is very common among Hong Kong Chinese. Kay 
et al. (33) reported that intracerebral haemorrhage accounts for 27% of all strokes in 
Shatin and the neighouring districts. Intracerebral haemorrhage is seen between two 
to three times more frequently in Hong Kong Chinese than in westerners. Sanderson 
et al. (34) reported that hypertension is the most important identifiable risk factor 
(37%) in patients with congestive heart failure requiring admissions to the Prince of
7Wales Hospital. Yip et al. (35) reported that diastolic heart failure is more common 
than systolic heart failure in Chinese patients with congestive heart failure requiring 
hospitalisation. They attributed their findings to older age at presentation and the 
high prevalence of hypertension in this community.
1.6 Do Chinese have an efficient renal DA system?
With the westernisation of their diets, Chinese in Hong Kong have a higher 
salt intake than before. Because of this and other undetermined factors, hypertension 
and hypertensive diseases are (increasingly) common (Section 1.5).
Therefore, several questions need to be addressed. Are Chinese particularly 
salt-sensitive with a significant rise in BP after an increase in salt intake? Do Chinese 
have a renal DA mechanism that will enable them to handle a salt load efficiently? 
If not, do they have other mechanisms? The ftrst-degiee relatives of hypertensive 
patients are known to be more prone to hypertension. Will they respond to a salt 
load differently compared to the offspring of normotensive subjects? It is with these 
questions in mind that my M.D. studies have been planned and performed (see 
Chapters 5 to 10).
1.7 The layout of this thesis
In Chapter 2, I have described the natriuretic and antinatriuretic systems in 
the body and the pathophysiological basis for salt-induced hypertension. This will 
allow a better appreciation of the relative importance of the renal DA system in ECF 
volume, sodium and BP homeostasis. In Chapter 3 ,1 have summarised the evidence
supporting the role of DA as an intrarenal natriuretic substance. In Chapter 4, 1 have 
discussed how the dysregulation of the renal DA system may contribute to sodium 
and fluid retention and salt sensitivity in some common conditions such as 
hypertension and diabetes mellitus. With such background information, it would 
then be possible to compare and contrast my findings in Hong Kong Chinese with 
those from previous studies.
From Chapter 5 to Chapter 10,1 have described the background (see Section 
1.6) and objectives of my studies and discussed the main findings. I have focused on 
the renal DA system. With further developments of our assays that would allow the 
simultaneous measurements of urinary free NA and kallikrein, the role of these 
neurohormones in sodium and BP homeostasis have also been examined.
In Chapter 11 ,1 have summarised my findings in Chinese and discussed the 
significance of these findings.
All the data in this thesis are presented as mean ± SEM unless stated 
otherwise.
Chapter 2 Natriuretic and antinatriuretic systems and pathophysiological 
basis for salt-induced hypertension
Sodium chloride is the major ionic component that determines plasma and 
extracellular osmolality, and as such it exerts direct control on the ECF volume and 
plasma volume. The ECF represents about 20% of the body weight (36). Its two 
major compartments are the plasma (5% of body weight) and the interstitial fluids 
(15%).
2.1 Integrated responses of the kidney to changes in ECF volume
A comprehensive account of this subject has been described by Gonzalez- 
Campoy & Knox (37). In brief, sodium loading or depletion produces corresponding 
changes in the ECF volume and plasma volume. Changes in the ECF volume, 
plasma volume and parallel, concomitant changes in circulatory filling pressures are 
sensed by mechanoreceptors and baroreceptors distributed throughout the thoracic 
and abdominal visceral organs. The body mounts an integrated response aiming at 
counteracting any such changes, thus maintaining its internal environment constant. 
The kidneys are the ultimate effectors of the body’s response to changes in ECF 
volume (Figure 2a). Thus, the ECF volume is tightly maintained by the balance of 
several haemodynamic (Section 2.2), natriuretic (Section 2.3) and antinatriuretic 
(Section 2.4) mechanisms not only within the kidney but in the body as a whole.
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Figure 2a. Mechanisms whereby renal perfusion pressure (RPP) and intrarenal 
hormone systems regulate the ECF volume.
Adapted from Gonzalez-Campoy & Knox (37).
n2.2 Arterial pressure-natriuresis
A central component of the feedback system for control of ECF volume and 
arterial pressure is the pressure-natriuresis mechanism, whereby acute changes in 
renal arterial pressure induce alterations in sodium excretion and urine flow (38). 
These changes occur in the absence of concomitant changes in whole-kidney blood 
flow or glomerular filtration rate (GFR). An alteration in renal medullary 
haemodynamics and/or changes in renal interstitial hydrostatic pressure during 
changes in renal arterial pressure may be responsible for this phenomenon (39).
Recent studies indicate that endothelium-derived nitric oxide (NO) (see 
Section 2.3.5) is by far the most important intrarenal mediator of pressure-natriuresis 
(40,41). Increases in renal arterial pressure increase NO formation, which inhibits 
sodium reabsorption via direct effects on the tubules as well as haemodynamically 
mediated effects (see Section 2.3.5). The pressure-natriuresis mechanism may also 
interact with a variety of endocrine, paracrine and neural factors, not only within the 
kidney but also in the body as a whole.
2.3 The natriuretic systems
By modulating the renal and systemic vascular resistance and acting on the 
renal tubules, circulating or locally produced vasoactive neurohormonal factors may 
regulate the renal excretion of sodium and water, the ECF volume and BP. Those 
with natriuretic properties are discussed in this section.
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2.3.1 The natriuretic peptides
The natriuretic peptide family consists of structurally homologous peptides 
with natriuretic-diuretic and vasorelaxant properties: atrial natriuretic peptide (ANP), 
brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP) and urodilatin 
(ularitide) (42,43). Three natriuretic peptide receptors (NPR) have been cloned (44). 
ANP has the highest affinity for NPR-A, followed by BNP and CNP. The order is 
reversed for NPR-B (CNP, BNP, ANP). NPR-C is the most prevalent of the three 
receptors and is regarded by some (45) as a storage-clearance binding site, regulating 
plasma natriuretic peptide concentrations. BNP has a much lower affinity than ANP 
for NPR-C, explaining the longer half-life of BNP. All three peptides exert actions 
via cyclic guanosine monophosphate (cGMP).
ANP, BNP and CNP are also degraded by neural endopeptidase, which has a 
wide tissue distribution, including the lung and the kidney. It has a greater affinity 
for CNP than for ANP and the affinity for BNP is much lower than those for the 
other two peptides (46).
Atrial natriuretic peptide
The cardiac atria are the major source of ANP. Atrial stretch is the primary 
stimulus for ANP secretion. ANP affects the kidney through NPR-A receptors. 
Increased GFR together with direct and indirect effects on the renal tubules are 
responsible for natriuresis and diuresis. The effect of ANP on GFR is accompanied 
by an increase in glomerular capillary hydraulic pressure, which is associated with a 
decrease in afferent arteriolar resistance and an increase in efferent arteriolar 
resistance. ANP also indirectly influences the kidney fimction and renal tubular
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sodium and water handling by decreasing BP and suppressing the renin-angiotensin 
system (RAS), sympathetic nervous system (SNS) activity and vasopressin release.
Contraction of the plasma volume following salt restriction (47) or blood 
donation (48) decreases intra-atrial pressure and atrial stretch, reducing cardiac 
secretion and plasma ANP levels. Conversely, expansion of the ECF volume 
following oral salt loading (49,50) or intravenous saline infusion (48,51) increases 
atrial stretch and a rise in plasma ANP levels, producing marked natriuresis and 
diuresis. Infusion of ANP to healthy subjects in a dose to achieve physiological 
plasma levels results in natriuresis, decreased PRA and plasma aldosterone 
concentrations and a fall in BP (52).
Brain natriuretic peptide
BNP is synthesised predominantly in the ventricle. The release of BNP may 
involve a stretch-pressure mechanism and may be co-secreted with ANP. Like ANP, 
BNP is natriuretic in humans at physiological levels (53). Plasma BNP and ANP 
concentrations increase with oral sodium loading in healthy subjects (50,54). Plasma 
BNP levels fall during fluid removal by haemodialysis or ultrafiltration in patients 
with chronic renal failure and fluid overload (55,56). Acute intravenous saline 
infusion causes an increase in plasma ANP concentrations with no detectable 
increase in plasma BNP (50,54), suggesting a different regulation of BNP and ANP 
in normal subjects. The inhibitory effect of BNP on the RAS also contributes to its 
natriuretic effect.
Plasma ANP and BNP levels are markedly elevated in conditions associated 
with: (a) intravascular volume overload; (b) increased central venous pressure; (c) 
tachycardia; (d) reduced renal function (57). The levels are higher in hypertensive
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patients, particularly in those with left ventricular hypertrophy (58). Plasma ANP 
and BNP increase with the severity of congestive heart failure (59). Plasma BNP 
measurement is better than ANP for the diagnosis of left ventricular systolic (60) or 
diastolic (61) dysfunction.
C-tvpe natriuretic peptide
CNP is regarded as the enothelial component of the natriuretic peptide 
system (62). It is produced by vascular endothelium and may regulate vascular tone 
and growth in an autocrine/paracrine manner. It is also found in human kidney, 
mainly in the proximal tubules. Together with ANP and BNP, CNP may form a 
renal natriuretic peptide system that participates in the local regulation of sodium and 
water transport and the renal circulation, CNP is found in plasma of normal subjects 
at much lower concentrations than ANP and BNP.
Plasma CNP levels are increased in patients with chronic renal failure (63) 
and cor pulmonale (64), raising the possibility that CNP may be a circulating 
counter-regulatory hormone in conditions with overactive RAS. CNP has systemic 
cardiovascular actions, which include reductions in cardiac filling pressures and 
output, secondary to vasorelaxation and decreases in venous return, but has minimal 
renal actions (65). It is also a potent coronary vasodilator.
Urodilatin fularitidel
Urodilatin is synthesised in the kidney and is detected only in the urine (66). 
Urodilatin exerts its renal effects in a paracrine manner. After its secretion from the 
distal tubular cells, it acts on the luminally located NPR-A in the collecting duct. 
cGMP generation is followed by an interaction with apical amiloride-sensitive
15
sodium channels (which mediate sodium entry across the apical membrane), 
resulting in natriuresis and diuresis. Urodilatin is more potent than ANP as a 
natriuretic and diuretic agent when given intravenously.
In healthy subjects given a high salt meal, urinary urodilatin excretion, but 
not plasma ANP, parallels the postprandial natriuresis (67). The natriuretic and 
diuretic responses to urodilatin infusions are enhanced during high salt intake (68). 
Other actions which may contribute to urodilatin’s diuretic and natriuretic properties 
include suppression of the RAS (69).
Urinary urodilatin excretion increases with the severity of congestive heart 
failure, suggesting that renal urodilatin synthesis may be stimulated to counteract 
sodium and water retention (70).
Urodilatin has been used prophytactically against acute renal failure related 
to major surgery with some encouraging results (71). Urodilatin improves sodium 
and urine output in cirrhotic patients with or without ascites by enhancing fluid 
delivery from the proximal tubules in addition to inhibiting fractional sodium 
reabsoprtion in the distal nephron (72). It may also be effective in patients with the 
hepatorenal syndrome (71). However, urodilatin fails to improve renal function in 
patients with established acute renal failure (73).
2.3.2 Endogenous inhibitors ofNa^,fC-ATPase
De Wardener et al. (74) first suggested in 1961 that sodium homeostasis is, in 
part, attributable to a hormone, which can increase natriuresis by reducing sodium 
reabsorption in the nephron. There followed an extensive literature demonstrating 
that ECF volume expansion is associated with a substance in the plasma or urine 
which decreases the activity of the sodium transport enzyme Na^,K^-ATPase, and the
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natriuresis of ECF volume expansion is the result of tubular rejection of sodium 
through inhibition of this sodium pump (75).
Endogenous inhibitors of Na^,K^-ATPase that can be found in the circulation 
include: certain fatty acids such as linoleic acid and oleic acid, ouabain, digoxin and 
bufodienolides (76). There is evidence that such inhibitors may be present in the 
brain and may have a local action.
The hypothalamus may be the source of a sodium pump inhibitor (76). It is 
released in response to ECF volume expansion during salt loading. Once in the 
circulation, it inhibits the Na'* ,^K^-ATPase in the renal tubules and increases the renal 
excretion of sodium. Salt restriction and contraction of plasma volume appear to 
diminish the circulating levels of this hormone, leading to renal retention of sodium.
In healthy subjects given a single-dose intravenous ouabain, no changes in 
renal blood flow, GFR, urinary excretion of sodium, water and potassium are seen 
(77). If ouabain has an important influence on electrolyte and BP homeostasis, its 
action are likely to have a slow time course (77).
McDougall & Yates (78) have recently reviewed the natriuretic actions of 
ouabain. The natriuretic effect of renal arterial infusion of ouabain is relatively slow 
in onset and is sustained. The natriuretic effect of ouabain is markedly enhanced by 
acute ECF volume expansion or chronic mineralocorticoid treatment, both of which 
which result in hypervolaemia and hypertension. The natriuretic response to small 
increments in BP is markedly enhanced by treatment with ouabain.
Increased concentrations of ouabain-like factor are observed in patients with 
asymptomatic left ventricular dysfunction due to dilated cardiomyopathy, suggesting 
that it may be an early marker of the disease (79).
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2.3.3 Renal kallikrein-kinin system
The main components of the renal kallikrein-kinin system are the enzyme 
kallikrein, the substrate kininogen, various effector hormones or kinins, metabolising 
enzymes (several kininases, the most relevant being kinases I and II and neutral 
endopeptidase) and an unknown number of activators and inhibitors of kallikrein and 
kinases (80). In the kidney, tissue kallikrein has been localised to the tubular cells of 
the distal nephron. Kininogen has also been localised to the distal nephron in man, 
suggesting an intrinsic renal kallikrein-kinin system, which may inhibit sodium and 
water reabsorption and promote renal vasodilatation (81). The renal kallikrein-kinin 
system may also interact with other natriuretic (e.g. renal DA and ANP) and 
antinatriuretic systems (e.g. RAS).
In healthy subjects, the fractional excretion of sodium and inorganic 
phosphorus, which reflects the total and proximal sodium reabsorption, shows 
significantly positive correlations for both urinary kallikrein and kinin excretion 
(82). In normal subjects but not in patients with hypertension, the activity of the 
renal kallikrein-kinin system is augmented following the intravenous infusion of 
0.9% saline, as evidenced by the increases in the plasma concentrations of 
prekallikrein as well as urinary kallikrein and kinin excretion and a decrease in 
urinary kinase excretion (82,83).
Epidemiological studies have shown an inverse relationship between BP and 
urinary kallikrein excretion (84). A large family pedigree study has shown that a 
dominant allele expressed as high urinary kallikrein excretion may be associated 
with a decreased risk of essential hypertension (85).
Song et al. (86) investigated the determinants of urinary kallikrein excretion 
in 204 normotensive subjects (119 Caucasians, 33 African-Americans, 52 Asians;
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109 men, 95 women) living in the U.S. Urinary kallikrein excretion in African- 
Americans was approximately 50% lower than Caucasians or Asians. In all ethnic 
groups, women excreted 50% more kallikrein than men. Those with a family history 
of hypertension were over-represented in the lower stratum of a bimodal distribution 
of kallikrein excretion. Potassium excretion was diminished in Africans, and in a 
multivariate analysis, potassium excretion was the strongest correlate of kallikrein 
excretion.
Urinary excretion of kallikrein is significantly lower in salt-sensitive than in 
salt-resistant hypertensive patients (87). Oral administration of glandular kallikrein 
(derived from porcine pancreas) reduces BP in salt-sensitive hypertensive patients 
and increases urinary sodium excretion in both salt-sensitive and salt-resistant 
hypertensive patients (88).
Urinary kallikrein excretion is lower in women with preeclampsia and mild 
to moderate hypertensive pregnant women compared with normotensive pregnant 
women (89).
Insulin-dependent diabetes mellitus without microalbuminuria is associated 
with decreased basal and ffusemide-stimulated kallirein excretion, which is directly 
related to blood glucose level (90). The decreased activity of renal kallikrein-kinin 
system might be involved in the increased tendency to sodium retention in diabetic 
patients.
Reduced urinary or renal kallikrein levels have been observed in genetically 
hypertensive rats (91). In a rat strain inbred for low urinary kallikrein excretion, BP 
is higher than controls (92). BP is increased after dietary salt loading in the low- 
kallikrein group but remains unchanged in controls. In rat, monoclonal antibodies to 
rat urinary kallikrein effectively blocks the generation of kinins in the nephron
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lumen, decreasing urinary kallikrein and kinin excretion by 74-85% and 76-79%, and 
inducing a 30% decrease in urine volume and a 20-40% decrease in urinary sodium 
excretion (93). Somatic gene delivery of human tissue kallikrein lowers the BP in 
spontaneously hypertensive rats (SHR) (94).
2.3.4 Prostaglandins
All the primary prostaglandins (PG) can be synthesised in the renal cortex
(95). They act predominantly at their site of production.
Prostaglandins exert direct or indirect effects on the nephron throughout its 
entire length. Two major roles of prostaglandins in blood volume homeostasis have 
been extensively studied. The first is the protective effects of prostaglandins as 
vasodilators in the glomerular microcirculation during states of sodium depletion
(96). The second role involves their effects on urinary sodium and water excretion, 
mediated either indirectly through vasodilatation or directly through tubular 
epithelial transport actions (97).
Studies on isolated renal microvessels have shown that both PGEg and PGI2 
attenuate angiotensin II (AH)-induced arteriolar vasoconstriction and PGIg 
antagonises All-induced efferent arteriolar vasoconstriction (98). PGE^ has been 
shown to counteract All-induced contraction of isolated glomeruli and glomerular 
mesangial cells in culture (96). Conversely, cyclo-oxygenase inhibition augments 
these contractile responses. A similar counter-regulatory role of prostaglandins with 
respect to renal nerve stimulation has been shown in micropuncture studies (99) and 
an interaction between vasopressin and prostaglandins was shown in studies using 
the isolated blood-perfused kidney (100).
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Intrarenal infusions of PGEj, prostacyclin, PGDg, and, less potently, PGEg  ^
increase the rate of sodium and water excretion (96,97).
To examine the mechanism of prostaglandin-induced natriuresis, two other 
experimental approaches have been tried. The effect of prostaglandin synthesis 
inhibition using indomethacin was studied in rats receiving a normal or high salt diet 
(101). Indomethacin administration increased fractional sodium reabsorption and the 
activity of the renal medullary Na\K^-ATPase. Addition of exogenous PGE2 to 
microsomal fractions from kidneys of normal rats was associated with suppression of 
the medullary Na^,K^-ATPase (101). These results suggest that the natriuresis 
associated with prostaglandin administration results from a direct inhibition of renal 
Na^K^-ATPase.
In healthy subjects, the natriuretic response to intravenous saline infusion is 
accompanied by increased urinary PGE excretion (102). However, indomethacin 
administration does not alter the urinary natriuretic response to intravenous saline 
infusion (103).
It has been pointed out that only in situations in which endogenous 
prostaglandin production is enhanced does prostaglandin activity becomes relevant 
to total sodium balance. Under these circumstances, inhibition of cyclo-oxygenase 
will result in retention of sodium and water.
Hence, the role of prostaglandins may be to maintain the internal milieu of 
the renal tissues during extreme changes in the environment. They can dampen the 
effects of other neurohormones (e.g. AH) to protect the specific nephron segment, 
which otherwise suffer injury (104). This may be the reason why the effects of the 
inhibition of prostaglandin synthesis vary considerably depending on the overall 
physiological state of the subject (105).
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2.3.5 Nitric oxide
Nitric oxide (NO) is synthesised from L-arginine by the enzymatic action of 
nitric oxide synthase (NOS). Three isoforms of NOS have been identified: brain 
bNOS, vascular endothelial eNOS and macrophage inducible iNOS. The vascular 
tone is partly controlled by NO generated from eNOS, activated by physical sheer 
stress (106). bNOS is more abundant and widely distributed than eNOS (107). The 
production of NO is determined by the type and quantity of NOS present and by 
availability of co-factors and substrates (106).
In the kidney, bNOS is found in the glomeruli and vasculature as well as the 
macula densa, collecting duct and inner medullary thin limb (108). eNOS is found in 
the arcuate and interlobular arteries, afferent arterioles and the glomerulus (109). 
Presumably, eNOS is present throughout the vascular endothelium of the renal 
circulation,
NO produced within the kidney plays a crucial role in sodium homeostasis 
and BP regulation by controlling the tone of glomerular arterioles and mesangium, 
pressure-natriuresis (Section 2.2), tubuloglomerular feedback, medullary circulation, 
renin release, and tubular function (110). In addition, NO may interact with other 
vasoactive and natriuretic/antinatriuretic systems.
In experimental animals, infusion of L-arginine increases renal blood flow 
and urinary excretions of sodium and water (111), Inhibition of NOS reduces renal 
blood flow by 25% and markedly reduces sodium excretion (112). The inhibition of 
NO synthesis markedly suppresses the slope of the arterial pressure-mediated 
response in sodium excretion. In support of the hypothesis that NO is involved in 
the mediation of the arterial pressure-natriuresis (Section 2.2), a direct relationship
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between changes in arterial pressure and the rates of urinary excretion of sodium as 
well as nitrate and nitrite (a marker for endogenous NO activity) is seen.
In humans, infusion of L-arginine has been shown to increase the excretion of 
NO and its second messenger, cGMP, but the effect of this on sodium excretion 
seems to depend upon the salt intake status (113). Thus, L-arginine enhances 
sodium reabsorption when subjects have a low salt intake, but inhibits it when salt 
intake is high.
NO-induced natriuresis occurs independently of changes in renal perfusion 
pressure, indicating a tubular effect of NO (114). In support of this hypothesis, in- 
vitro studies revealed that NO inhibits both Na^-K^-ATPase and Na^-H^-exchange 
activity in the proximal tubule. In the collecting duct, NO has been shown to 
decrease sodium flux with no effect on Na^-K^-ATPase activity.
On the other hand, inhibition of systemic NO synthesis by nitro L-arginine 
methylester (L-NAME) results in antinatriuresis and antidiuresis (115). These renal 
effects can be attributed to increases in sodium reabsorption both at proximal and 
distal nephron sites and decreases in renal diluting capacity. The direct association 
between the individual sodium-sensitivity and the pressor response to a NO synthase 
inhibitor, A^-monomethyl-L-arginine (L-NMMA) suggests that there is increased 
dependence of vascular tone on NO in normotensive subjects whose BP is more salt- 
sensitive (116).
In healthy subjects, hyperinsulinaemia is associated with a decrease in renal 
generation of NO (117). In contrast, mild ECF volume expansion increases urinary 
excretion of NO metabolites. This insulin-induced attenuation of renal NO synthesis 
may contribute to anti-natriuretic actions of insulin.
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In rats, it is possible to produce systemic hypertension by chronic blockade of 
NO synthesis using L-NAME. The hypertension is associated with marked renal 
vasoconstriction involving both preglomerular and efferent resistance vessels, as 
well as a fall in the glomerular capillary ultrafiltration coefficient (118). Glomerular 
BP appears to be elevated with moderate proteinuria.
Some animal models of genetic hypertension and certain forms of human 
hypertension are associated with a decrease in NO synthesis (119). Prolonged 
reduction of BP is seen in SHR after human eNOS gene therapy (120).
2.3.6 Adrenomedullin and related peptides
Adrenomedullin (ADM) shows structural homology with calcitonin-gene- 
related peptide (CGRP) and amylin (121). The ADM gene encodes ADM and the 
related pro adrenomedullin N-terminal 20-peptide (PAMP) and the two may act 
synergistically in ECF volume and BP homeostasis.
Adrenomedullin
Immunoreactive ADM has been found in multiple human tissues, including 
the adrenal medulla, heart, aorta, brain, lung, kidney, and gastrointestinal organs 
(122). Both vascular endothelial cells and smooth muscle cells sythesise ADM 
(123,124). ADM is detected in human urine, and urinary ADM levels are much 
higher than plasma levels, suggesting that the kidney may be one of the major tissues 
for ADM production (125). ADM acts on target cells through its unique receptors 
and CGRPj receptors, with cyclic adenosine monophosphate (cAMP) being the main 
second messenger (126).
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ADM is a potent and long-lasting vasodilator of the resistance and 
capacitance vessels in human forearm (127). Its vasodilator effects are mediated 
through a direct action on ADM receptors in vascular smooth muscle cells and an 
action on the endothelial cells to stimulate NO release (128). In experimental 
animals, ADM has renal vasodilator, natriuretic and diuretic effects (129).
Samson (130) has recently reviewed the role of ADM in fluid and electrolyte 
homeostasis. ADM stimulates NO production by endothelial cells, whereas PAMP 
acts presynaptically to inhibit adrenergic nerves that innervate blood vessels. Both 
peptides inhibit adrenocorticotropin release from the anterior pituitary gland and All- 
stimulated aldosterone secretion. In the brain, ADM inhibits water intake and salt 
appetite. The natriuretic and diuretic effects of ADM reflect its unique actions on 
renal blood flow and tubular function.
Compared with normal subjects, plasma ADM levels are 26% higher in 
patients with hypertension and 45% higher in hypertensives with renal failure (131). 
In the latter patients, plasma ADM is directly proportional to the creatinine levels, 
suggesting that the kidney has a major role in the clearance of ADM. In patients 
with renal failure, the fall in plasma ADM after haemodialysis indicates that its 
plasma concentration is influenced by the ECF volume status (132). In patients with 
hypertension, left ventricular hypertrophy is associated with higher plasma ADM 
(133). In congestive heart failure, plasma ADM increases progressively with its 
severity (134). Plasma ADM is increased in the early phase of acute myocardial 
infarction and is even higher in those complicated by congestive heart failure (135). 
Elevated plasma levels of adrenomedullin are an independent predictor of prognosis 
in predominantly mild to moderate heart failure treated by conventional therapy
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(136). Plasma ADM is also raised in patients with liver cirrhosis and chronic 
obstructive pulmonary disease (137).
In Dahl salt-sensitive rats, human adrenomedullin gene delivery lowers the 
BP and protects against salt-induced hypertension, cardiac hypertrophy, fibrosis and 
renal damage (138).
Calcitonin gene-related peptide
CGRP is synthesised and released from small, capsaicin-sensitive sensory 
nerves (139). This extensive network of sensory nerves is found in virtually all 
organs. CGRP has been shown to elicit potent vasodilation in the cerebral, coronary 
and peripheral vasculature.
In rat, intravenous infusion of CGRP results in a fall in BP with a marked 
increase in renal plasma flow and GFR (140). In healthy subjects, intravenous 
administration of CGRP lowers BP and increases the renal excretions of sodium and 
water (141,142).
In patients with severe hypertension, plasma CGRP-like immunoreactivity is 
lower than that of healthy subjects, even after treatment (143). In patients with 
moderate to severe pregnancy-induced hypertension, plasma CGRP levels are lower 
than those in healthy pregnant women (144). These findings suggest an involvement 
of the vascular afferent nerves in the aetiology of hypertension.
2.3.7 Vasoactive in testinal peptide
Vasoactive intestinal peptide (VIP) is found in the central and peripheral 
nervous systems and in some endocrine tissues, where it has both neurotransmitter 
and hormonal roles (145).
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In healthy subjects, intravenous infusion of VIP causes a fall in pulmonary, 
systemic and coronary vascular resistance and BP, a reflex sympatho-adrenal 
stimulation with increased heart rate and myocardial contractility and a direct 
positive inotropic effect (146,147).
In-vitro studies using human saphenous vein indicated that VIP can produce 
endothelium or NO-dependent dilatation of the capacitance vessels (148).
The renal effects of VIP depend on the doses used. In rats given lower doses, 
VIP only induces a small increase in fractional and absolute excretion of sodium 
(149). With higher doses, significant falls occur in mean arterial pressure (MAP) 
and GFR and absolute sodium excretion tends to fall.
2.3.8 Substance P
Substance P (SP), which is a member of the tachykinin family of peptides, is 
found mainly in the central nervous system and peripheral afferent nerve fibres. It 
acts through stimulation of the neurokinin receptors, having a particularly high 
affinity for the neurokinin-1 receptors (150).
In dogs, intravenous SP infusion produces a fall MAP and systemic vascular 
resistance (140). In regions with high SP concentrations such as the muscular layers 
of the fundus and ileum, regional blood flow increases. SP and CGRP coexist in 
central and peripheral nerve endings of sensory neurons. In the pithed rats, CGRP is 
10 times more potent than SP in producing vasodilatation, but CGRP has less than a 
third of the potency of SP in producng plasma extravasation (152).
In healthy subjects, SP infusion with plasma levels above the normal range 
produces lacrimation and sustained flushing, without significant changes in the pulse 
rate and BP (152). Brachial artery infusion of SP induces a dose-dependent
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vasodilatation in the forearm (154). Skin oedema in the infused forearm and 
systemic vasodilatation occur at higher doses. Vasodilatation due to CGRP is 
prolonged, with a half-life of biological effects of 18 minutes (155). Vasodilatation 
due to SP has a half-life of 15 seconds only, due to the rapid development of 
tachyphylaxis. Simultaneous arterial infusion of both peptides produces additive, and 
possibly synergistic, effects on forearm blood flow. The vasodilator actions of SP 
are mediated in part via NO (156).
In rats, infusion of SP into the abdominal aorta above the renal arteries 
produces a natriuresis and diuresis (157). Intravenous SP infusion increases the 
urinary flow rate, clearance of water and urinary excretion of sodium, potassium and 
phosphate (158). In dogs, renal arterial infusion of SP increases renal blood flow 
and urinary excretion of water, sodium and potassium, with a fall in MAP (159). 
However, with higher (hypotensive) doses, progressive less diuresis, natriuresis and 
kaliuresis are seen. Since the fractional excretion of sodium correlates with urinary 
free DA excretion, the renal effects of SP may be mediated by increases in renal DA 
activities (160).
In rabbit proximal renal tubules perfused in-vitro, SP produces a 50% 
reduction in the rate of fluid absorption (161). The sensitivity of proximal tubules to 
SP and the existence of SP-containing afferent fibres within the renal cortex suggest 
a role for SP in the control of proximal tubule reabsorption.
2.4 Antinatriuretic systems
Circulating or locally produced neurohormonal factors with antinatriuretic, 
vasoconstrictive actions are discussed in the section.
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2.4.1 Renin-angiotensin system
The RAS is a circulating neuroendocrine system (Figure 2b) in which the 
components produce the peptide hormone All in the circulation, which then acts on 
such target organs as blood vessels, adrenal glands, and kidneys to maintain BP, ECF 
volume and sodium homeostasis (162,163).
Renin
Angiotensin-converting
enzyme
Aminopeptidase A
Angiotensinases
Angiotensin II
Human angiotensinogen
Angiotensin I
Angiotensin III
Inactive peptide fragments
Figure 2b. The renin-angiotensin system.
Adapted from Gunning et al. (163).
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There are also complete RAS within a variety of tissues and organs serving 
paracrine, autocrine, and intracrine functions. Tissue RAS exerts long-term effects 
on the function and structure of the cardiovascular, renal and other systems.
The liver is the primary site of angiotensinogen protein and messenger RNA 
(mRNA) synthesis. Angiotensinogen mRNA is widely distributed. Circulating renin 
seems to be derived from the juxtaglomerular apparatus in the kidney (Table 2a).
Table 2a. Regulators of renin release from juxtaglomerular cells.
Mechanism Comments
Macula densa mechanism
Macula densa cells in i  salt intake -> distal tubule delivery of sodium
the distal tubule -> Î  renin release
which sense urinaiy High/medium sodium concentration at macula densa
NaCl concentrations renin release 
Low sodium concentration at macula densa 
T renin release
Baroreceptor mechanism
Juxtaglomerular cells T renal perfusion
act as their own t  stretch of juxtaglomerular cells
baroreceptor t  renin release
Neural control
Sympathetic nerves Renal nerve stimulation —> T renin release
predominantly innervate via p-adrenoreceptor
juxtaglomerular cells a-adrenergic receptor stimulation —> renin release
Endocrine/paracrine
T renin release PGE2, PGI2, DA
renin release AH (as negative feedback), endothelin, vasopressin 
(Vi receptor), adenosine (A  ^receptor), ANP, NO
Adapted from Gunning et al. (163).
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Renin cleaves off angiotensin I (AI) from angiotensinogen. An angiotensin- 
converting enzyme (ACE) splits AI into two fragments of which the larger represents 
the final hormone AIL
ACE (kinase II) exists as two isozymes. Somatic (endothelial) ACE is found 
in vascular endothelial cells, as well as in the renal proximal tubules. It plays a role 
in both the RAS (by converting AI to AH) and kallikrein-kinin system (by 
inactivating bradykinin). Circulating ACE is of endothelial cell origin. Pulmonary 
endothelium and peripheral tissues (especially the luminal surface of blood vessel 
walls) are the principal site of AI conversion to AH.
AH receptors are broadly divided into AT  ^ and AT 2 (164). All the well 
known physiological and pathophysiological effects of AH have been attributed to 
AT]. In the kidney, AT] receptors are located on endothelial, epithelial and vascular 
smooth muscle cells. AT^ has recently been shown to mediate antiproliferation and 
differentiation at least in some tissues and cells.
Through its direct action on smooth muscle cells, AH increases arteriolar 
resistance in renal, mesenteric, dermal, coronary, and cerebral vessels (165). AH 
exerts indirect pressor effects via the central and peripheral nervous systems. Its 
effects on the central nervous system include increased sympathetic discharge and 
decreased vagal tone (166). AH increases the vasoconstrictive response to renal 
nerve stimulation in dogs (167) and its inhibition attenuates the pressor response to 
NA in humans (168). The tissue RAS in the vasculature also contributes to the 
regulation of vascular tone.
AH stimulates aldosterone synthesis and secretion by zona glomerulosa cells 
of the adrenal cortex (169). In the cortical and medullary collecting duct and distal
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tubule, aldosterone increases net sodium reabsorption and diminishes sodium leak- 
back.
In conditions of decreased renal blood flow, GFR is preserved over a wide 
range of perfusion pressures. Such autoregulation of GFR is dependent on ATI, 
which preferentially vasoconstricts efferent arterioles while leaving afferent 
arteriolar resistance unaltered (170).
All stimulates proximal tubule sodium chloride and sodium bicarbonate 
absorption (171). All enhances proximal tubule sodium chloride transport indirectly 
by increasing presynaptic catecholamine release (172). Proximal sodium chloride 
and sodium bicarbonate absorption is in part mediated by All-induced decrease in 
peritubular capillary hydrostatic pressure and an increase in peritubular oncotic 
pressure. The effects of All on distal tubule transport of sodium and potassium are 
mediated through aldosterone release (169).
In healthy subjects, the natriuretic response to oral or intravenous salt loading 
is mediated partly by the suppression of the RAS, as reflected by a fall in FRA and 
plasma aldosterone concentrations (50). Thus, the natriuretic response to a saline 
infusion is greatly attenuated by the simultaneous infusion of aldosterone or All to 
maintain plasma aldosterone or All levels around basal values (173). Conversely, 
activation of the RAS contributes to the initial decline in renal sodium excretion seen 
after a sudden reduction in dietary sodium intake (174).
In experimental animals, intrarenal arterial infusion of ACE inhibitors or All 
antagonists increases renal blood flow and natriuresis (175). In both healthy subjects 
and patients with borderline hypertension, low doses ACE inhibitors enhance the 
natriuretic response to intravenous saline infusion (176,177).
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2.4.2 Sympathetic nervous system
By controlling cardiac output and the peripheral resistance, the SNS plays a 
dominant role in regulating the moment to moment cardiovascular homeostasis 
(178). Baroreceptors are located in the walls of the major arteries, including the 
carotid arteries and the aorta. When these stress receptors are stretched by high 
pressure, signals are transmitted to the brain stem, where they inhibit the sympathetic 
impulses to the heart and the vessels. This will allow the arterial pressure to fall 
towards normal. Conversely, when BP falls, decreased afferent impulses will 
diminish central inhibition, resulting in increased sympathetic outflow.
SNS-renal interactions
Stella & Zanchetti (179) and DiBona (180) have reviewed the ways in which 
the SNS can interact with the kidney. Like the heart, arteries and veins, the kidney is 
an important target organ for SNS activity. The kidney can influence not only the 
peripheral resistance by releasing vasoactive substances but also the body sodium 
and fluid composition by modulating sodium and water excretion. The main link 
between the SNS and the kidney is represented by the renal nerves, since changes in 
efferent renal nerve activity can elicit changes in renal functions, while afferent renal 
nerve activity driven by renal sensory receptors can interfere with the central and 
peripheral nervous system. Additional links are represented by circulating 
catecholamines acting on kidney function and by the actions of All on the SNS.
The hallmark of kidney circulation is autoregulation, by which blood flow is 
maintained constant despite changes in arterial perfusion pressure. The main 
extrinsic factor is the SNS, which can also influence the intrarenal distribution of 
blood flow (179).
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Renal SNS activity may alter urinary sodium and water excretions by at least 
two specific mechanisms: neural control of renin release from the juxtaglomerular 
cells (Table 2a) and renal excretory functions. Renal nerves control renin release by 
a direct action on the juxtaglomerular cells; this action is mediated via p,-adrenergic 
receptors (181). Circulating All and aldosterone are then increased and renal sodium 
excretion is reduced, a-adrenergic receptors located on the juxtaglomerular cells 
exert an inhibitory action on renin secretion (182). The stimulation of selected areas 
of the hypothalamus can produce either a decrease or increase in renin release (183), 
suggesting that renin secretion can be influenced by emotional stimuli and the central 
nervous system can influence renin release by modulating the efferent sympathetic 
discharge to the kidney.
Using a micropuncture technique, Bencsath et al. (184) first established that 
stimulation of renal nerves favours tubular reabsorption of sodium and water. This 
was later confirmed by Moss (185), who used the renal denervation technique. The 
antinatriuretic and antidiuretic effects of sympathetic nerve stimulation are caused by 
increased sodium and water reabsorption across the proximal tubule and seem to be 
unrelated to the systemic or intrarenal haemodynamic changes (186). These effects 
also extend to the thick ascending limb of the loop of Henle. The increase in sodium 
transport associated with renal nerve stimulation in the proximal tubule and in the 
loop of Henle is entirely mediated by a  i-adrenergic receptors and by activation of 
renal tubular Na\K^-ATPase (Section 3.3.1) and N a ^ e x c h a n g e  (187).
Upright posture is known to activate efferent renal nerve fibers as a part of 
widespread activation of the SNS. During the first few minutes of the manoeuvre, 
renin release increases and sodium and water excretion decreases (188). When the 
cardiopulmonary afferent fibers are activated by manoeuvres affecting the central
34
venous volume and atrial pressure in an opposite way to upright posture (e.g. head- 
out water immersion and lower body negative pressure), an increase in natriuresis 
and diuresis is seen (189,190).
Increased SNS activity during behavioural stress induces sodium and water 
retention. These excretory responses are mediated primarily via increased tubular 
reabsorption rather than decreased GFR (191). In young men with a family history 
of hypertension, psychological stress has also been shown to reduce urinary sodium 
and water excretion (192).
Plasma and urinarv free NA as indices of SNS activitv
Techniques to measure human SNS activity have recently been reviewed by 
Grassi & Esler (193). In the past, measurements of plasma free NA and 24-hour 
urinary free NA have been the most frequent method employed because they are the 
simplest and safest. Almost all the circulating NA is released from the sympathetic 
nerve endings, but a relatively small amount is produced by the adrenal medulla
(194). Only free catecholamines are considered to be active, since sulphoconjugation 
can rapidly inactivate excessive circulating free catecholamines to mitigate their 
actions and the conjugated fraction may act as a storage pool for free catecholamines
(195). The percentage of the free fraction with respect to the total amount of 
circulating NA is about 32% for NA (196). In the interpretation of results, it should 
be remembered that plasma NA levels may vary widely with several physiological 
and environmental factors (e.g. psychological stress, exercise and ortho stasis).
Studies in human subjects after tilting, exercise and stress suggested that 
urinary NA excretion reflects the overall SNS activity (197). NA excretion does not 
vary with urine volume but reflects the rate of infusion of NA into the plasma. Since
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urinary NA excretion falls distinctly at the stage of advanced renal failure and severe 
reduction in excretory kidney function (198), it cannot be reliably employed in this 
situation.
The effects of salt loading on SNS activitv
Contraction and expansion of the EOF volume in healthy subjects produce 
opposite changes in renal sodium excretion (see Section 7.4.4, Section 8.4.4, Section
9.4.3 and Section 10.4.3). These changes are mediated at least in part by increases 
and decreases in SNS activity, as reflected by the corresponding changes in plasma 
concentrations and urinary excretion of free NA.
Miller et al. (199) have shown in healthy subjects that plasma NA levels and 
urinary free NA excretion during sodium depleting with a low sodium diet and 
ffusemide ingestion are greater than those obtained during ECF volume expansion 
using intravenous saline infusions. Others have shown that a fall in plasma NA 
concentration and urinary free NA excretion accompanies the natriuretic response to 
oral salt loading and intravenous saline infusion (200-204). Conversely, an increase 
in SNS activity will help decrease renal sodium excretion during sodium restriction 
(205,206). Adrenergic blockade (by reducing tubular sodium reabsorption) impairs 
sodium conservation during sodium deprivation in man (207).
2.4.3 Neuropeptide Y
Neuropeptide Y (NPY) is a vasoconstrictor peptide and a co-transmitter with 
NA in sympathetic nerve endings throughout the central and peripheral nervous 
systems including the renal nerves. Plasma NPY concentrations are considered less 
sensitive than those of plasma NA as an index of SNS activity (208). At high
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concentrations, it has direct vasoconstrictor effect (209). In addition, it enhances the 
vascular effect of other vasoconstrictors, including NA and AIL
Bischoff & Michel (210) have recently reviewed the renal effects of NPY. 
The kidney expresses NPY receptors, among which Y,, Y  ^and Yj are involved in the 
regulation of renal function. Intrarenal or systemic administration of NPY causes 
potent renal vasoconstriction via Y^  receptors. GFR is altered only little if at all by 
NPY, indicating a greater effect on the vas efferens than the vas afferens. NPY can 
inhibit renin release via Y,-like receptors. NPY can stimulate the proximal tubular 
Na^,K^-ATPase via Yg receptors to produce antinatriuresis. NPY can antagonise the 
effects of vasopressin on isolated collecting ducts. It can act prejunctionally to 
inhibit NA release via Y  ^receptors. NPY antagonists enhance basal renal blood flow 
but do not alter basal natriuresis or diuresis, indicating that renovascular, but not 
tubular, NPY receptors may be tonically activated by endogenous NPY.
In renal proximal tubular cells, Holtback et al. (211) have shown that NPY 
determines the net effect of NA by its ability to attenuate the p- (inhibition of 
Na^,K^-ATPase) and enhance the a - (stimulation of Na^,K^-ATPase) adrenergic 
effects.
Increased circulating NPY levels are noted in patients with heart failure and 
acute myocardial infarction, reflecting changes in SNS activity and haemodynamics 
(212). In haemodialysis patients with fluid overload, the plasma concentrations of 
NPY correlate with the degree of fluid overload and arterial BP (213).
2.4.4 Vasopressin (antidiuretic hormone)
The primary physiological role of vasopressin is to maintain a normal plasma 
osmolality through its water-concentrating effects in the kidney. It also affects the
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ECF volume and BP by having vasoconstrictor and antinatriuretic effects in the 
kidney (214), by regulating the cardiovascular function (215) and by modulating 
central nervous system activity involved with ECF volume and BP homeostasis. In 
the presence of water deprivation, plasma hyperosmolality, hypotension or 
hypovolaemia, osmoreceptors in the hypothalamus, baroreceptors in the carotid 
arteries and stretch receptors in the left atrium are activated, stimulating the release 
of vasopressin from the posterior hypothalamus and enhancing thirst. On the other 
hand, hypo-osmolality inhibits both vasopressin release and thirst.
Vasopressin exerts its biologic actions by binding to specific receptors. Vj 
receptors are distributed throughout the kidney, in the glomerulus, the mesangial 
cells, the renal interstitial cells, and the myocytes of the renal vasculature (216). In 
the kidney, vasopressin acts on the receptors to enhance the permeability of the 
collecting duct to water, resulting in antidiuresis (217). At higher concentrations, 
vasopressin stimulates both the collecting duct and the thick ascending limb of the 
loop of Henle, resulting in increased electrolyte transport (218). The increased 
electrolyte transport by the thick ascending limb of Henle’s loop contributes to the 
formation of a maximally concentrated urine and the maintenance of ECF volume in 
conditions of large, acute ECF volume contraction. Part of the antinatriuretic effect 
of vasopressin is due to potentiation of the effect of aldosterone at the cortical 
collecting duct (218). Vasopressin also modulates sodium reabsorption through its 
vasoconstrictive effects (219). Vasopressin in physiological concentrations 
decreases vasa recta flow by stimulating, directly, V^  receptors, and, indirectly, via 
V2 receptors. The decrease in vasa recta flow is due to efferent arteriolar 
vasoconstriction.
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2.4.5 Endothelins
Three isoforms of human endothelin (ET) have been identified: ET-1, ET-2 
and ET-3 (220). ET-1 is the most potent vasoconstrictor and pressor peptide known. 
It is synthesisd in the endothelium and vascular smooth muscle cells. The ET^ 
receptor is highly selective for ET-1; the ETg receptor is equally sensitive for all 
three isoforms of ET. The ET^ receptor is present on vascular smooth muscle cells 
and mediates predominantly contraction by ET-1. The ETg receptor is present on the 
endothelium, where it mediates relaxation, and vascular smooth muscle cells, where 
it mediates vasoconstriction. The role of ET in cardiovascular and renal 
pathophysiology and the possible applications of ET antagonists have recently been 
reviewed (221,222).
The kidney is an important organ for ET synthesis and ET-1 is the most 
important. In the human kidney, ETg receptor predominates over the ET^ receptor. 
ET^ receptor is localised in the vasculature and ETg receptor in the renal tubules and 
medulla (223). ET-1 forms very strong ligand-receptor complexes that are rapidly 
internalised and inactivated, resulting in a very short half-life of circulating ET-1
(224). ET-1 exerts its actions in the kidney mainly as an autocrine/paracrine factor, 
which is also suggested by the fact that sites of ET synthesis and ET receptors are 
closely linked. Despite its short circulating half-life, the biological effects of ET-1 
are relatively prolonged. ET-1 at high concentrations has potent antinatriuretic and 
antidiuretic actions by inhibiting sodium and water reabsorption in the renal medulla
(225). Its other actions in the kidney include stimulation of renal cell growth (226), 
cell differentiation during organogenesis (227) and vasoconstriction (228). Big ET- 
1, its precursor, has suiprisingly potent natriuretic and diuretic activities mediated 
mainly by stimulation of NO production coupled to ETg receptor activation (229).
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Abnormalities of the ET system occur in a range of diseases associated with 
vasoconstriction, vasospasm and vascular hypertrophy and ET-1 may be causal, or at 
least contributory, in some of these pathophysiological processes (221,222). For 
example, hypertensive patients with renal disease have higher plasma ET levels than 
those without renal damage (230). Plasma ET levels are higher in patients with salt- 
sensitive essential hypertension (231) or obese patients with hypertension (232) than 
in normotensive controls. In heart failure, activation of the endothelin system and 
elevated circulating levels of both ET-1 and big ET-1 are observed (233). Studies in 
both humans and animal models of cardiovascular disease show that inhibition of the 
endothelin function is associated with improvement of haemodynamics (233).
Hypertension could be mediated by high ET levels in the circulation or the 
vessel wall or by alterations in response to ET at the receptor level (221,222). A 
decrease in the response of the ETg receptor (e.g. in the presence of dysfunctional 
endothelium) may attenuate the vasodilator response. Structural alterations of the 
vessel wall (e.g. vascular hypertrophy due to the mitogenic effects of ET) can play a 
role. ET may elevate BP by causing renal sodium and water retention. The actions 
of ET on the central and peripheral nervous systems can result in vasoconstriction 
through the release of other substances.
2.4.6 Renal serotonin system
Serotonin, or 5-hydroxytryptamine (5-HT), is a naturally occurring amine 
that can affect renal haemodynamics and the excretion of sodium and water. The 
kidney is rich in the enzymes required for the biosynthesis of serotonin as well as 
those necessary for its degradation (234). The essential amino acid L-tryptophan is 
first hydroxylated to 5-hydroxytryptophan (5-HTP) by the enzyme tryptophan-5-
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hydroxylase. 5-HTP is then decarboxylated by L-aromatic amino acid decarboxylase 
(also known as dopa decarboxylase) (L-AAAD) to serotonin. The latter is degraded 
primarily by type A monoamine oxidase (MAO-A) to 5-hydroxyindoleacetic acid (5- 
HIAA).
In man, parenteral administration in man of serotonin decreases the renal 
blood flow, GFR, urine output and sodium excretion (234). Infusion of serotonin 
renal pro-drugs reduces urinary sodium excretion and urine flow rate without 
significant alterations in renal plasma flow and GFR, which are suggestive of a 
tubular effect (235). Pretreatment with carbidopa, which blocks the formation of 
serotonin by inhibiting L-AAAD, substantially attenuates the increase in serotonin 
excretion and abolishes the antinatriuretic effect (236).
In healthy subjects, dietary salt restriction stimulates the renal serotonergic 
system as evidenced by a significant rise in the urinary excretion of serotonin and 5- 
HIAA (206). Sodium loading is expected to have the opposite effects.
Studies performed in isolated proximal convoluted tubule preparations have 
shown that 5-HTP and L-dopa use the same transporter in order to be taken up into 
the tubular cells and both 5-HTP and L-dopa exert a competitive type of inhibition 
upon their cellular uptake (237). The decreased formation of serotonin in the 
isolated proximal convoluted tubule induced by L-dopa reflects a reduction in the 
intracellular availability of 5-HTP. In rats, the infusion of L-dopa significantly 
decreases the antinatriuretic and antidiuretic effects of serotonin (238).
Serotonin and DA also share a common metabolic pathway involving the 
MAO-A. Inhibition of this enzyme increases renal interstitial fluid (RIF) serotonin, 
concomitant with decreases in arterial BP and GFR (239). However, DA can also be 
metabolised by type B monoamine oxidase (MAO-B) and catechol-0-
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methyltransferase (COMT) (see Section 3,2.4). Hence, available data suggest that 
serotonin may act as a counterregulatory paracrine substance to DA in the local 
regulation of sodium excretion (240).
2.5 The pathophysiology of salt sensitivity
There may be several mechanisms by 'which excessive dietary salt intake can 
elevate BP in susceptible subjects.
2.5.1 Increased blood volume and cardiac output
The principal mechanism for salt-induced hypertension is thought to be an 
expansion of the ECF volume and increased cardiac output (241). Such a tendency 
will normally be counteracted by a compensatory increase in natriuresis (Section 2.2) 
and changes in the activities of the natriuretic (Section 2.3) and antinatriuretic 
(Section 2.4) systems. However, in some individuals with defects in renal sodium 
excretion (e.g. due to dysregulation of the natriuretic or antinatriuretic systems) 
together with large sodium intakes exceeding excretory capacity, sodium and water 
retention and ECF volume expansion occur. Augmented venous return increases 
cardiac preload and consequently the cardiac output. The tendency for arterial BP to 
rise in response to the increase in cardiac output is offset because of activation of 
carotid and aortic baroreceptors and other receptors. The result, within a few 
seconds, is a strong decrease in sympathetic nerve signals to the entire circulatory 
system. However, this nervous feedback fades almost to insignificance (adapts) 
within days. The ECF volume and cardiac output begin to fall because of the
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adaptation of the nervous control mechanisms. In order to maintain arterial pressure 
in balance with physiological needs, peripheral vascular resistance increases.
Thus, although the hypertension begins as a result of volume loading and is 
maintained as long as the volume loading continues, the evidence of excess volume 
and excess cardiac output disappears in the later stages of the hypertension. 
Substituted in their place is a greatly increased peripheral vascular resistance. This 
conversion is due to whole-body regulation, which means simply that the body 
regulates its tissue blood flow (partly through changes in vascular resistance) to 
match the tissue needs.
2.5.2 The role o f blood vessel wall responsiveness
Vascular tone is the major determinant of arterial BP. Venous smooth 
muscle tone and venous blood volume determine the filling pressure of the heart and 
thereby influence cardiac output. Cardiac output and systemic vascular resistance 
determine arterial BP. Abnormalities of blood volume control have been implicated 
in hypertensive patients with increased blood volume and sodium sensitivity (242). 
The peripheral vessels themselves may also be important in determining the response 
to blood volume changes. Acute changes in blood volume are associated with a 
reduction in vascular resistance that offsets any increase in BP, whereas chronic 
changes in blood volume are associated with normalisation of cardiac output, but 
vascular tone is increased and this leads to elevated BP (243).
MacAllister & Vallance (243) have reviewed the contribution of the blood 
vessel wall during the systemic vascular adaptation to increases in blood volume. 
Mechanisms within the blood vessel wall enable the vessels to respond to local 
changes in BP and blood flow; these local mechanisms can influence the whole-body
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response to increases in blood volume. Blood vessels demonstrate both flow- 
dependent and pressure-dependent (myogenic) autoregulation. It is believed that NO 
mediated, flow-dependent dilatation predominates in acute volume loading, but that 
with chronic volume loading under certain conditions, this system may become 
down-regulated or ineffective and therefore the myogenic response predominates and 
BP rises. This will tend to make the cardiovascular system volume-dependent. 
Hence, systemic vessels, by sensing pressure and shear stress, are important in 
determining the overall BP responses to volume changes.
2.5.3 The natriuretic hormone hypothesis
Excess dietary salt intake may elevate BP through hormonal mediators. The 
most commonly postulated mediator is an inhibitor of Na^,K^-ATPase. This 
natriuretic hormone is thought to originate from the hypothalamus (Section 2.3.2). 
Chronic natriuretic hormone release may elevate BP through widespread inhibition 
of Na^,K^-ATPase in vascular smooth muscle, depolarising the cell membrane, and 
eventually increasing calcium influx (244). The resulting reduction in the sodium 
gradient across the cell membrane diminishes calcium efflux via the Na ,^Ca^  ^
exchange pump. Reduced efflux and increased influx elevate cytosolic calcium, 
promoting vascular smooth muscle contraction and elevated BP.
2.5.4 Elevated sympathetic nervous system activity
In salt-sensitive patients with essential hypertension (245), inappropriately 
high SNS activity during high salt intake may raise BP and cause sodium retention 
(Section 2.4.2). This may account for the inadequate decrease in vascular resistance, 
which in turn may be responsible for the rise in BP elicited by an increase in sodium
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intake (246,247). The pressor response to NA infusions during high salt intake is 
greater in salt-sensitive compared with salt-resistant normotensive (248) and 
hypertensive (249) subjects. An increased reactivity to the pressor actions of NA 
may contribute to the maintenance of hypertension in salt-sensitive subjects.
In salt-sensitive subjects, the mechanisms underlying enhanced SNS activity 
and responsiveness during high salt diet are uncertain. Gavras (250) speculated that 
salt-induced increases in SNS activity are due to salt-induced diminished affinity of 
a 2-adrenergic receptors in the central nervous system. Since a 2-adrenergic tone 
inhibits sympathetic outflow, this decrease in affinity will increase the systemic SNS 
activity. Trimarco et al. (251) have shown that high salt diet potentiates 
cardiopulmonary baroreceptor reflexes in salt-resistant but not in salt-sensitive 
hypertensive patients. The inadequate reduction in sympathetic discharge after salt 
loading may be secondary to a dysfunction of compensatory baroreceptor reflex 
mechanisms.
2.5.5 Alteration o f calcium and potassium metabolism
Excess dietary sodium may generate calcium and potassium deficiencies 
leading to altered hormone balances, vascular smooth muscle contraction and 
elevated BP (252).
Excess dietary salt intake enhances urinary calcium excretion. If this is 
prolonged, the calcium deficit generates defects in cellular calcium pump activity, 
thus increasing intracellular calcium and vascular constriction (253). The associated 
increases in circulating parathyroid hypertensive factor and 1,25-dihydroxyvitamin D 
levels may increase cellular calcium influx in vascular smooth muscle cells and 
stimulate BP rises (254).
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Krishna (255) has reviewed the aetiological role of potassium deficiency in 
hypertension. Epidemiological studies from different regions have shown an inverse 
relationship between potassium intake and prevalence of hypertension. Potassium 
supplementation in patients with hypertension lowers BP. Amelioration of diuretic- 
induced hypokalaemia with potassium supplementation enhances the BP response. 
Deficient potassium intake elevates BP in both normotensive and hypertensive 
subjects. Potassium depletion may be accompanied by sodium retention and calcium 
depletion.
Suter (256) has reviewed the possible mechanisms by which dietary 
potassium can lower BP. These include effects on natriuresis, barorefiex sensitivity, 
vasodilatory actions, and the central nervous system, as well as improvement of 
glucose tolerance and modulation of the RAS. Potassium deficiency due to high 
sodium intake (which increases urinary potassium loss) and poor intake may elevate 
BP.
2.5.6 Changes in membrane cation transport
Changes in membrane cation transport have been implicated as a possible 
mechanism underlying the haemodynamic and BP changes during high salt intake 
(257). The role of the Na^,K^-ATPase, N a \K \C r  cotransport, Na^,H^ antiport, 
erythrocyte Na^L"" countertransport have all been assessed. It remains unclear which 
membrane function is primarily affected by sodium loading, what mechanisms are 
responsible and whether altered membrane transport is secondary to another as yet 
undefined cellular disturbance evoked by sodium loading.
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2.5.7 Reduced insulin sensitivity
Recent evidence indicates that the cellular effects of insulin can underlie the 
increase in total body sodium and BP in salt-sensitive hypertensive subjects (258). 
Chronic infusion of insulin causes a sustained increase in BP in rats (259). Acute 
and chronic infusion of insulin may cause sodium retention (260), stimulate the SNS 
(261), alter the membrane cation transport (262) and stimulate hypertrophy of 
smooth muscle cells (263). High salt intake reduces insulin sensitivity in young 
normotensive salt-sensitive subjects with a genetic predisposition to developing 
hypertension but not in salt-resistant subjects (264). There is an association between 
hyperinsulinaemia and salt-sensitivity in blacks with normal BP or borderline 
hypertension (265).
2.5.8 Suppression o f nitric oxide synthesis
Previous studies showed that NO production in response to high salt intake 
may be impaired in patients with essential hypertension. Higashi et al. (266) showed 
that salt loading attenuates the conversion of L-arginine to NO in the endothelium of 
the renal vasculature in patients with salt-sensitive essential hypertension. Campese 
et al. (267) showed that high salt intake decreases plasma NO concentration in black 
hypertensive patients. Fujiwara et al. (268) showed that plasma NO level in these 
patients is decreased after salt loading and reversed after salt restriction. However, 
plasma NO and BP of normotensive subjects and patients with salt-resistant 
hypertension are unaffected by the change in salt intake (268).
The suppressant effect of high salt intake on NO synthesis could occur in 
susceptible subjects by several mechanisms, including altered transport of L-arginine 
through the endothelium membrane, decreased activity of the enzyme eNOS, and an
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increased breakdown or excretion of NO (268). Asymmetrical dimethyl-L-arginine 
(ADMA) is produced by endothelial cells and blood vessels (269) and is present in 
plasma and urine of humans (270), suggesting that ADMA may be an endogenous 
inhibitor of NOS in vivo. ADMA also inhibits L-arginine uptake into endothelial 
cells. Its plasma level is increased after high salt intake and decreased after salt 
restriction (268). Hence, a change in ADMA may be one mechanism for modulating 
NO synthesis during salt loading.
2.6 The clinical relevance and predictors of salt sensitivity
From both a clinical and public health perspective, the phenomenon of salt 
sensitivity in normotensive and hypertensive subjects is important. Normotensive 
salt sensitivity is possibly a common precursor of hypertension (271,272), but the 
phenomenon may be susceptible to dietary intervention, which may prevent or delay 
its progression to hypertension (vide infra). An association between salt sensitivity 
and a greater propensity to develop renal failure has been described in certain groups 
of hypertensive patients, such as blacks, the elderly and diabetic patients (273). Salt- 
sensitive hypertensive patients are more likely than salt-resistant subjects to have left 
ventricular hypertrophy, microalbuminuria, metabolic abnormalities and vascular 
endothelial damage that may predispose them to cardiovascular diseases (273,274). 
Salt restriction in hypertensive patients may lower BP (275) and augment the 
efficacy of antihypertensive drugs (276).
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2.6.1 Methods and criteria to diagnose salt sensitivity
One should realise that the changes in BP that occur with sodium loading 
follow a Gaussian distribution. Questions arise when one tries to define the 
boundaries of the 'salt-sensitive'. How large a rise in BP is necessary? How much 
sodium should be used to elicit a response? The lack of uniformity in the criteria and 
methods used to diagnose salt sensitivity is well illustrated in Table 2b. However, it 
is reasonable to regard a 10% change in MAP as significant.
Table 2b. Examples of methods and criteria to diagnose salt sensitivity.
Authors Protocol Subjects
Criteria
(AMAP)
Weinberger 
et al. (8)
0.9% saline infusion (2 litres/4 h), 
10 mmol sodium (1 day) plus 
ffusemide 40 mg (3 doses/8 h)
NT, HT lOmg Hg
<80 mmol sodium for 90 days NT >10%
Campese 
et al. (245)
10 mmol Na for 7 days,
100 mmol sodium for 7 days, 
200 mmol sodium for 7 days, 
random order
HT >10%
Sharma 
et al. (264)
220 mmol sodium for 7 days, 
20 mmol sodium for 7 days
NT >3 mmHg
Kawasaki 
et al. (277)
109 mmol sodium for 7 days, 
9 mmol sodium for 7 days, 
240 mmol sodium for 7 days
HT >10%
Sullivan 
et al. (278)
Ad libitum for 1 day,
10 mmol sodium for 4 days, 
ad libitum for 2 days,
200 mmol sodium for 4 days
HT >5%
MAP = mean arterial pressure. NT = normotensive, HT = hypertensive.
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2.6.2 Subject groups with a higher prevalence o f salt sensitivity
Weinberger et al. (8) studied the changes in MAP in normotensive and 
hypertensive subjects after ECF volume expansion and contraction. In both groups, 
salt-sensitive subjects were older and had lower baseline PRA than the salt-resistant 
subjects. Factors related to changes in MAP after changes in ECF volume included 
baseline BP and age. The hypertensive subjects were much more likely to be salt- 
sensitive than the normotensive subjects (51 vs 26%). Luft et al. (21) used an 
identical protocol to compare the changes in MAP in blacks and whites. They found 
that 32% of normal black subjects and 30% of normal whites were salt-sensitive. 
Conversely, 73% of hypertensive blacks were salt-sensitive compared with 55% of 
hypertensive whites. Salt-sensitive subjects in both the normotensive and 
hypertensive subject groups were older.
Skrabal et al. (248) studied the effects of salt restriction (reduced from 200 to 
50 mmol/day) over two weeks in 52 young healthy subjects. Twenty-two subjects 
(42%) showed a significant fall in ambulatory BP. Compared to 30 subjects without 
significant changes in BP, these 22 subjects showed a 2.5-fold higher incidence of a 
positive family history of hypertension and a significant higher baseline BP.
Salt sensitivity also appears to be more common in subjects with obesity, 
diabetes mellitus and renal failure (279,280).
2.6.3 Markers o f salt sensitivity
Various groups have attempted to identify markers of salt sensitivity, thus 
avoiding the inconvenience of studies involving salt loading and/or salt depletion 
over a period of several days.
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Salt-sensitive normotensive subjects display several features found in patients 
with hypertension, including increased vascular reactivity to pressor substances, 
increased forearm vascular resistance, decreased venous compliance, low PRA, 
decreased a 2/P2 adrenoreceptor ratio and insulin resistance (281).
Abnormal erythrocyte Na"^,Lr countertransport, a genetically determined 
trait, may serve as a marker of salt sensitivity (282). The haptoglobin phenotype Hp
I is associated with salt sensitivity, whereas the Hp 2 phenotype is associated with 
salt resistance (283).
Giner et al. (284) evaluated the association between genetic polymorphisms 
of the RAS and salt-sensitive hypertension. They reported that Spanish patients with
II and DI genotypes have significantly higher prevalence of salt sensitivity than DD 
hypertensives.
Adducin, an a/p heterodimeric protein found in the renal tubule is thought to 
regulate renal sodium transport through changes in the actin cytoskeleton. Cusi et al. 
(285) reported a significant linkage of the a-adducin locus in essential hypertension 
and greater sensitivity to changes in sodium balance in Caucasian subjects. An 
association between the a-adducin locus and essential hypertension is not seen in 
Japanese subjects (286).
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Chapter 3 Dopamine -  an important intrarenal natriuretic factor
Overall the past 30 years, the pioneer work of several workers has helped 
establish that DA is an important intrarenal natriuretic, vasodilatory substance in the 
body. Much of this work has been summarised elsewhere (10,240,287-302).
3.1 Evidence in support of renal DA being an important natriuretic factor
The idea that renal DA is important for the regulation of sodium homeostasis 
is based on the observations summarised here.
3.1.1 Dopamine in the urine is out o f proportion to other catecholamines
It has long been known that the amount of free DA excreted in human urine 
is 5-20 times greater than that of NA (303). In patients with impaired renal function, 
urinary free DA output declines with falling GFR (see Section 4.2), whereas free NA 
excretion falls only at the stage of advanced renal failure (198). These observations 
suggest that free DA in the urine is derived from the kidney.
The kidnev is the likelv source of urinarv free DA
Initially, the assumption was that the increased amount of DA in the urine 
reflects the filtered load of DA and is thus derived from the plasma. When a 
sensitive assay for plasma free DA became available. Da Prada & Zürcher (304) 
reported a mean level in man of 0.74 nmol/L. Assuming a GFR of 120 ml/min, this 
should result in a free DA excretion rate of 130 nmol/day. In fact, Crout (305) 
reported values of 650-2285 nmol/day. Subsequently, Ball et al. (306) determined
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the plasma and urine levels of free DA simultaneously in six healthy subjects. They 
calculated a urinary clearance rate of 1,996 ±185 ml/min (range 402-3,844 ml/min), 
which is greatly in excess of the GFR and, in most individuals, greater than the 
calculated renal plasma flow. Therefore, DA must be synthesised in the kidney with 
the bulk of urinary free DA originating from the kidney.
Two other hypotheses were put forward to explain the large amounts of free 
DA in the urine. Both are now considered very unlikely for the reasons summarised 
by Lee (288). Unger et al. (307) proposed that DA, derived from the adrenal gland, 
is rapidly conjugated as sulphate and glucuronide. The conjugated DA circulates to 
the kidney, where deconjugase enzymes act on the compound to release free DA, 
first into the renal tissue and then, after secretion, into the urine. However, Ball & 
Lee (15) showed that carbidopa greatly reduces urinary free DA output, suggesting 
that L-AAAD is necessary for the intrarenal production of DA and L-dopa from the 
plasma is the renal source of DA (see Section 3.1,10). Moreover, Ball et al. (306) 
showed in rats that both urinary free and conjugated DA increase in parallel after salt 
loading. If the 'deconjugation hypothesis' were correct, a rise in urine free DA 
should be accompanied by a corresponding decrease in its conjugates. Akpaffiong 
(308) showed that rats with their adrenal glands removed still exhibit a marked 
increase in urinary DA after oral salt loading. Studies using the renal pro-drugs, y- 
glutamyl-L-dopa (gludopa) and y-glutamyl-DA suggested that the former is a more 
effective source of urinary free DA (see Section 3.1.5).
DA-containing neuronal elements are present in animal kidneys (309). Since 
rapid, effective mechanisms exist for the re-uptake and inactivation of DA and other 
catecholamine neurotransmitters as soon as they are released into the synaptic cleft,
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it is doubtful if DA released from renal dopaminergic nerve endings can contribute in 
a material way to the excess of DA in the urine (288).
Sources and phvsiological significance of DA in human plasma and urine
In humans, DA in the plasma occurs mainly as DA sulphate, a biologically 
inactive metabolite, with the free (unconjugated) DA accounting for <1% of the total 
DA (310). Plasma free DA is mainly derived from the peripheral sympathetic nerve 
terminals and the released DA is converted to conjugated DA and to DA metabolites 
(311). Plasma DA sulphate originates from dietary intake as well as synthesis and 
the metabolism of endogenous DA, especially in the gastrointestinal tract (312). The 
former may reflect a gut-blood barrier to detoxify catecholamines derived from the 
diet and the latter a third catecholamine system, in which sulphoconjugation delimits 
the actions of DA as an autocrine-paracrine factor. Conjugated DA can also serve as 
a reservoir of active DA (195,313). It was suggested that free DA can be generated 
from this pool through deconjugation whenever a need for it arises (313).
Elchisak (314) reported that free DA accounts for 75% of the total DA in the 
kidney. This finding is consistent with the intrarenal synthesis of DA.
Free DA accounts for 16-20% of the total DA in the urine (315,316), but the 
measured proportion is higher if  the urine samples are acidified to a lower pH which 
may result in hydrolysis of conjugated DA (317). Other evidence supporting the 
kidney (proximal tubules) as the source of urinary free DA will be discussed later in 
this chapter.
Sulphated and non-sulphated conjugates of DA account for 80-84% of the 
total DA in the urine (315,316) and are derived from the filtrated load at the 
glomeruli (311).
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3.1.2 Dopamine receptors are present in the kidney
Cardiovascular and renal actions of DA are medicated through the interaction 
with specific DA receptors. Receptor-ligand binding, receptor autoradiography and, 
recently, molecular biology techniques have been used to examine the subtypes and 
distribution of DA receptors in the target organs (291,296). These peripheral DA 
receptors were traditionally divided into DAj and DA^ subtypes, whereas DA 
receptors in the brain were divided into D; and Dg subtypes. Advances in molecular 
biology have afforded the identification of at least five subtypes of DA receptors. 
These newly described receptors correspond pharmacologically and biochemically to 
the classic 'D^-like' (Dj and D5) and Dj-like' (D ,^ D3 and D4) receptors based on their 
ability to stimulate or inhibit adenyl cyclase, respectively. The pharmacological 
properties of DA, receptors approximate to those of D, and D5 receptors, whereas 
those of DA2 receptors approximate to those of D  ^receptors (Table 3a).
Within the kidney, the DA, receptors are present on the smooth muscle of the 
renal arteries, the juxtaglomerular apparatus and the renal tubules (Table 3a). The 
DA2 receptors are found in the intimai layer of the renal vasculature, glomeruli, 
sympathetic nerve terminals and the renal tubules (296). The tubular DA, receptors 
are present in higher density in the proximal tubules than the distal parts of the 
nephron, as well as the renal vasculature. DA, receptors and DA2 receptors are also 
located on both basolateral and brush border membranes of the proximal tubules.
The adrenal gland is another peripheral target of DA that is also linked to the 
ECF volume and BP homeostasis (302). In adrenal cortex, DA inhibits primarily 
aldosterone secretion, whereas in the adrenal medulla, it is involved in the regulation 
of catecholamine release from chromaffin cells.
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Table 3a. Peripheral DA receptors.
Subtype Location Response
DA, Blood vessels Vasodilation
('D,-like') Renal tubules Natriuresis, diuresis
Juxtaglomerular cells Renin release
DAz Postganglionic sympathetic nerves Vasodilation, bradycardia
(D^-like') Sympathetic ganglia Inhibition of transmission
Adrenal cortex (zona glomerulosa) Inhibition of aldosterone release
Adrenal medulla Inhibition of catecholamine release
Renal tubules ?
Adapted from Hussain & Lokhandwala (296).
3.1.3 Dopamine is a potent natriuretic agent
Our knowledge of this subject stems from the pioneer work of Leon 
Goldberg over a period of 25 years (16, 287). He and his colleagues first showed 
that DA is a potent natriuretic and diuretic agent in man (11). They also showed in 
dogs that intrarenal infusion of DA results in greater increases in renal blood flow, 
GFR and sodium excretion in the infused side compared with the non-infused kidney 
(318).
In the 1980s, it was uncertain whether DA’s natriuretic effect is secondary to 
an increase in renal blood flow and GFR (287) or a redistribution of intrarenal blood 
flow and/or a direct action on tubular sodium transport (319). Indirect evidence for a 
tubular site of action came from the studies of Wassermann et al. (320) who showed 
that the natriuretic effect of DA in the cat is independent of changes in renal blood 
flow and GFR.
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DA is a potent natriuretic agent even at so-called 'renal doses' (0.5-2.0 |ag/kg 
body weight/min) (321). In salt-repleted (i.e. usual salt intake prior to study with or 
without 0.9% saline infusion during the study) and hydrated (i.e. water to drink 
during the infusion) subjects, DA infusions produce dose-dependent increases in 
natriuresis and diuresis with increases in renal blood flow and the GFR (11,322-325). 
The renal actions of DA are well illustrated by the studies summarised in Table 3b.
Table 3b. Natriuretic and diuretic effects of DA in healthy subjects.
Authors DA dose 
(pg/kg/min) / 
study design
Main findings
McDonald 
et al., 1964 
(11)
Levinson 
et al., 1985 
(322)
Olsen 
et al., 1990 
(323)
2.6-7.1
i.e. the largest 
dose without 
f  MAP
0.03-3.0 vs 
5% dextrose 
for 2 h on 
4 occasions
3 for 3 h
Sodium excretion 171 571 pmol/min
Renal plasma flow 507 -> 798 ml/min 
GFR 109 -> 136 ml/min 
Cardiac output t ,  no changes in heart rate
Sodium excretion 188-390 vs 168 pmol/min 
Urine volume 3.8-5.6 vs 3.2 ml/min 
Heart rate 64 vs 61/min at dose of 3.0 pg/kg/min 
No changes in BP
Clearance of sodium 1.10 2.51 ml/min/1.73 m^
Fraction excretion of sodium 1.04 -> 2.13% 
Absolute distal reabsorption rate of sodium 42% T 
Proximal fractional reabsorption 13% 4- 
Fractional distal reabsorption of sodium
96.5 ^  94.5%
GFR 1 0 8 ^  118 ml/min
Clearance of lithium (an index of proximal tubular 
outflow of sodium and water)
32 -> 46 ml/min/1.73 m^
Urine volume 13 ^  16 ml/min
Effective renal plasma flow 498 -^711 ml/min
MAP 92 88 mmHg
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Studies employing different DA antagonists have helped characterise the 
specific intrarenal DA receptors mediating the actions of DA (324,325).
It is equally important to realise that the renal effeets of DA can be attenuated 
during sodium and water depletion. Bughi et al. (325) showed that the increase in 
renal blood flow in healthy subjects during DA infusions is attenuated by a low salt 
diet. Agnoli et al. (326) showed that DA 'loses' its vasodilatory, natriuretic effects in 
ECF volume depletion indueed by low dietary salt intake and diuretic treatment. It is 
likely that in these situations, the renal effects of DA are overcome by those of 
antinatriuretic and vasoconstrictor systems (Section 2.4). In contrast, prior ECF 
volume expansion by 0.9% saline infusion greatly enhances the natriuretie and 
diuretic actions of DA in pre-operative cardiae surgery patients (327).
At higher doses (2-5 pg/kg per min), DA also binds to p-adrenergic receptors 
(321). Above 5 pg/kg/min, a-adrenergic receptors are also activated. However, at 
low or higher doses, there is overlap in receptor activation, depending on the clinical 
state of the subject such as the BP and ECF volume status (328). Olsen et al. (329) 
suggested that in healthy salt-repleted, water-loaded subjects, the natriuretic effect of 
low doses of DA is primarily caused by attenuation of the inerease in distal sodium 
reabsorption normally seen after an increase in proximal tubular flow. Pressor doses 
of DA further increase sodium excretion, suggesting the presence of pressure- 
natriuresis at these high doses.
3.1.4 Other DAj agonists are also potent natriuretic agents
With the availability of highly selective DAj agonists, the role of renal DA in 
sodium homeostasis can be characterised better.
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Fenoldopam
Fenoldopam is a selective DA, receptor agonist without significant a- or p- 
adrenoceptor activity (330). In salt-repleted, hydrated healthy subjeets, fenoldopam 
increases renal blood flow, decreases renal vascular resistance and produces dose- 
related natriuresis and diuresis (Table 3c). It also produces peripheral vasodilation 
via stimulation of DA, receptors in blood vessels.
Table 3c. Renal and other effects of fenoldopam in healthy subjects.
Authors Dose Main findings
Stote
et al., 1983 
(331)
1 dose of 
25,50 or 
100 mg 
by mouth
After 100 mg, changes seen in hour 1, peak in hour 2 
firactional excretion of sodium 0.84 -> 1.64% 
urine volume 13 -> 21 ml/min 
renal plasma flow 671 1,012 ml/min 
free water clearance 10 —> 16 ml/min 
Smaller changes after 25 mg and 50 mg
Allison 
et al., 1987 
(332)
i.v. 0.025, 
0.05 or 0.1 
pg/kg/min 
for 2 hours
Dose-dependent increases: 
urine volume 14 17-25 ml/min 
renal plasma flow 609 748-1,047 ml/min 
GFR 110 —> 123 ml/min 
clearance of water 11 13-19 ml/min 
Fractional excretion of sodium (at 0.5 mg)
0.8 -» 3.0%
Dose-dependent f  in renal vascular resistance and 
DBF
Huges 
et al., 1988 
(333)
i.v. 0.05 
pg/kg/min
Sodium excretion 150 320 pmol/min 
Urine volume 13 —> 17 ml/min 
Renal plasma flow 344 481 ml/min 
Fractional excretion of sodium 1.3 -> 2.7% 
Filtration fraction 25 -> 16 ml/min 
Distal sodium load t  
Distal sodium reabsorption i- 
No changes in GFR, BP or heart rate
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In healthy subjects, infusions of fenoldopam 0.025-0.5 pg/kg/min produce 
small decreases in DBF. In hypertensive patients, fenoldopam 0.1-0.9 pg/kg/min 
decreases SBP (baseline >180 mmHg) by 18.5-28% and DBF (baseline >120 
mmHg) by 22-31.5% (330).
Dopexamine
Dopexamine, a synthetic DA analogue developed to improve myocardial and 
renal function in patients with low cardiac output states, has the renal effects of DA 
and haemodynamic effects of dobutamine. It predominantly stimulates DA, and P- 
adrenergic receptors (334). It has renal and vasodilatory effects (Table 3d). It has no 
a-adrenergic activity and has less agonist activity at DAj receptors.
Table 3d. Renal and other effects of dopexamine in healthy subjects.
Authors Dose Main findings
Mousdale 1 ,2 ,4 Dose-related T renal plasma flow, max 22%
et al., 1988 pg/kg/min t  SBP, max 15%
(335) for 30 min 'I DBF, max 38%
each Dose-related t  heart rate, max 65%
Olsen 1 pg/kg/min Sodium clearance 1.3 1.7 ml/min/1.73m^
et al., 1993 for 2 hours Fractional excretion of sodium 1 1.3%
(336) Urine flow 13 16 ml/min
Renal plasma flow 558 ->619 ml/min/1.73m^
30% t  cardiac output
SBP 121 -> 139 mmHg
Heart rate 52 62 beats/min
Peripheral resistance 21.6 ->■ 17.9 mmHg.min/L
No changes in DBF
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In pre-operative high-risk surgical patients, dopexamine can improve the 
cardiac output and allow greater inereases in oxygen delivery than dobutamine (337). 
It appears safe and effective in patients with low cardiac output syndrome after 
coronary artery bypass graft surgery (338). It produces beneficial renal and 
haemo dynamic effects in patients with severe congestive heart failure (339).
3.1.5 Dopamine pro-drugs are also potent natriuretic agents
Pro-drugs are pharmacologically inert. They must undergo biotransformation 
in the body before they can elicit a pharmacological effect (340). Such an approach 
is used with several objectives in mind: (a) to increase the efficacy of these drugs; (b) 
to target these drugs to a specific organ or site; (c) to decrease the toxicity of these 
drugs.
The DA pro-drugs include L-dopa, gludopa, ibopamine and docarpamine. 
The enzymes required for biotransformation are L-AAAD (see Section 3.1.10) for L- 
dopa, y-glutamyl transferase for gludopa, esterases for ibopamine and hydroxylases 
for docarpamine.
L-dopa
After ingestion or intravenous administration as an infusion, L-dopa is 
converted to free DA by L-AAAD in the kidney. DA can then act in a paracrine 
manner and induces renal vasodilatation and natriuresis (341-343). Hence, the renal 
effects of L-dopa in humans are very similar to those produced by DA infusion 
(Table 3e).
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Table 3e. Renal and other effects of L-dopa in healthy subjects.
References Dose Main findings
Brown & 
Dollery, 1981 
(341)
1 dose of 
250 mg by 
mouth
At baseline, positive correlation between plasma 
dopa and urine DA (r=0.85, p<0.01)
Plasma dopa Î  98-fold, urine DA T 93-fold, 
but plasma DA f  by 26-fold only, 
calculated clearance of plasma dopa by renal 
decarboxylation 114 ml/min
Shigetomi 
et al., 1991 
(342)
1 dose of 
500 mg by 
mouth
Sodium clearance 0.9 2.7 ml/min 
Plasma dopa (area under curve) T 792-fold 
Glomerular dopa load t  427-fold 
Urine free DA t  891-fold
Positive correlation between glomerular dopa load 
and urine free DA (r=0.59, p<0.02)
Positive correlation between urine sodium 
and urine DA excretion (r=0.52, p<0.02) 
SBP/DBP 4- 4.1/6.7 mmHg
Worth 
et al., 1988 
(343)
i.v. 7
|ag/kg/min 
for 2 hours
Sodium excretion 103 ->• 195 p,mol/min 
Urine volume 2.7 -> 5 ml/min (p>0.05)
Urine free DA 0.08 31.7 pmol/h
24% T effective renal plasma flow c.f. placebo
6% t  GFR (p>0.05) c.f. placebo
DBF 74.5 -» 69.5 mmHg
These studies provided further evidence that plasma dopa is the precursor of 
urinary free DA. At the baseline, there was a positive correlation between plasma 
dopa and free DA excretion (341). After the administration of L-dopa, plasma dopa 
and urinary free DA both increased by a similar proportion and the increase was 
much greater than that of plasma DA (341,342). There was a positive correlation 
between glomerular dopa load and urinary free DA (342). The inerease in plasma 
dopa, but not plasma DA, can account for the increase in urinary free DA (341,342).
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Gludopa
Wilk et al. (344) showed that gludopa is more renally specific DA pro-drug 
than L-dopa or y-glutamyl DA. In gludopa, glutamic acid is substituted on the y- 
nitrogen of L-dopa. It becomes a substrate, first for y-glutamyl transferase in the 
brush border of proximal tubular cells (345) to generate L-dopa, and then for L- 
AAAD in proximal tubular cells to generate DA.
In healthy subjects with adequate hydration, gludopa given as an intravenous 
infusion (12.5 or 25 |ag/kg/min) produces increases in urine sodium and free DA that 
outlast the time of infusion, presumably because of a prolonged conversion to DA in 
the kidney (Table 3f).
Table 3f. Renal and other effects of gludopa in healthy subjects.
Authors Dose Main findings
Worth 
et al., 1986 
(346)
12.5
pg/kg/min 
for 2 hours
Sodium excretion 80 ^  118 pmol/min 
Urine volume 3 -> 5 ml/min 
Effective renal plasma flow t  8% (p>0.05) 
GFR t  17% (p>0.05)
MacDonald 
et al., 1988 
(347)
25
pg/kg/min 
for 2 hours
Effects T with the duration of infusion 
Sodium excretion 190 -> 520 pmol/min 
GFR 95.6-> 112.5 mVmin 
Effective renal plasma flow 588 ^  738 ml/min 
Filtration fraction 0.17 -> 0.16%
Urine free DA f  several hundred-fold
Jeffrey 
et al., 1988 
(348)
25
pg/kg/min 
for 2 hours
Sodium excretion 120 -> 340 pmol/min 
(330-290 for 2 h after infusion)
Urine fi'ee DA Î  900-fold
(640 to 260-fold T for 2 h after infusion) 
Carbidopa inhibited DA excretion by 97% 
and abolished the natriuretic response
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In contrast, an equimolar dose of y-L-glutamyl-L-tyrosine (glutyrosine) (25 
pg/kg/min intravenously for two hours) does not produce a natriuresis (349), This is 
not surprising since tyrosine delivered to the kidney is not the substrate for renal DA 
synthesis. [As discussed in Section 3.2, the substrate for renal DA synthesis is L- 
dopa supplied to the proximal tubular cells.]
Ibopamine (di-isobutyryl-A-methyldopamine)
The need for parenteral administration limits DA’s application in clinical 
practice. Ibopamine, active after oral administration, has been introduced, mainly for 
the treatment of congestive heart failure (350). It is de-esterified in the gut and liver 
to release epinine (W-methyldopamine) into the circulation. Epinine stimulates DA, 
and DAj receptors and, to a lesser degree, p- and a-adrenoreceptors. It induces 
natriuresis with an increase in creatinine clearance in both healthy subjects and 
patients with renal impairment (351,352).
Ibopamine improves the symptoms of patients with congestive heart failure. 
The haemodynamie effects (increased cardiac index, increased stroke volume and 
decreased systemic vascular resistance) probably can be ascribed to the stimulation 
of DA, and DA2 receptors, whereas its neurohormonal effects (decreased plasma 
aldosterone and NA) are produced by DAg receptors (350). However, for some 
unexplained reasons, ibopamine seems to inerease the risk of death among those with 
moderate to severe heart failure (353). On the basis of these results, the indication 
for ibopamine in some countries was restricted to patients with mild heart failure.
Like DA, ibopamine has been used in the treatment of chronic renal failure 
(354). In DA-dependent patients, intravenous DA infusion can sometimes be 
switched to ibopamine (355).
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Docarpamine [N,(N-aeetyl-L-methionyl)-0,0-bis(ethoxycarbonyl) dopamine]
Docarpamine is well absorbed after oral administration (356,357). It is easily 
hydrolysed to the de-ethoxycarbonyl intermediate and then DA, mainly in the liver 
but also in the small intestinine. DA is released into the circulation.
Not surprisingly, docarpamine exhibits natriuretic, diuretic and positive 
inotropic effects in experimental animals after enteral administration (356,357). 
Increases in renal blood flow and GFR may also be seen.
Docarpamine has been used in patients with refractory ascites (358) and low 
cardiac output states (359). It has been used in post-cardiac surgery patients once 
their haemodynamics are stabilised and DA therapy can be weaned off (359,360). 
However, its use in cardiac patients may be limited by the risk of cardiac arrhythmias 
(359).
3.1.6 Positive correlation between urine sodium and urine free DA
If DA is an important intrarenal natriuretic hormone and dietary sodium is the 
major determinant of its intrarenal synthesis, there should be a positive correlation 
between urinary sodium and free DA outputs. Indeed, this is seen in some but not all 
ethnie groups (Table 3g).
In ethnic groups with, traditionally, a high salt diet (Caucasians, Japanese, 
Thais and Zimbabweans), there is a positive correlation between the 24-hour urinary 
sodium and free DA outputs. The x coefficient of the regression line is the highest 
among the Thais. The x coefficient or the 'slope' of the regression line is the factor 
by which urinary free DA output is elevated in proportion to an inerease in sodium 
output.
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Table 3g. Correlation between 24-hour urinary sodium and free DA outputs.
Authors Subjects Sodium
(mmol)
DA
(nmol)
X coef. r P
value
Critchley Caucasians (U.K.)
et al., 1989 
(361)
57 M, 26 F 
23 ± 0.7 y 
Zimbabweans
156 
± 6.5
1,480
±52
3.19 0.40 <0.001
21 M, 3 F 
24 ± 0.2 y 
Thais
163
±14
1,820 
± 112
5.1 0.64 <0.001
Patrick
51 M, 23 F 
22 ± 0.7 y
Caucasians (UK)
114 
± 6.5
1,510
±73
5.93 0.53 <0.001
et al., 1989 
(362)
40 M
26 (20-39) y
173
±8.5
1,572
±72
0.51 <0.001
Saito
et al., 1986 
(363)
Critchley
Japanese 
36 M 
20 ± 0.2 y
W. Africans (UK)
188 
± 13
1,815 
± 104
0.52 <0.01
et al., 1989 
(361)
16M, 9 F 
36 ±1.2 y 
Iranians
169 
± 12.2
1,780
±104
-0.08 0.01 NS
2 8 M, I l  F 
26 ± 1.6
169
± 8.8
1,830
±88
0.2 0.03 NS
In contrast, a significant renal sodium-DA relationship is not seen in West 
Afncans and Iranians, ethnic groups from areas with intense heat and, traditionally, a 
low salt diet (see Section 1.3 for possible explanation).
Unlike urban subjects in northern Venezuela who have a high salt intake, 
Piaroa Amazonie Indians do not use salt in their regular food intake. Romero- 
Vecchione et al. (364) reported that urinary excretion of sodium (210.7 ± 24.5 vs
6 6
12.6 ± 5.2 mmol/day) and DA (5,227 ± 387 vs 2,055 ± 262 nmol/day) differed 
markedly between these urban subjeets and the Piaroa Amazonie Indians. They 
eommented that indigenous tribes may require less renal DA synthesis to excrete the 
very small amounts of salt they consume in their regular diet.
In Japanese subjeets, the urinary excretion of water, sodium and free DA 
shows circadian variations with higher rates during daytime and lower rates at night 
(365). Urinary sodium and water correlate positively with urinary free DA. These 
results suggest that endogenous DA plays a role in the circadian variations of sodium 
and water metabolism.
A positive correlation between urinary sodium and free DA has also been 
reported in healthy Caucasian subjects under constant sodium intake (15), after 
changes in sodium intake (see Section 3.1.7) or after inhibition of DA synthesis with 
a subsequent fall in both urine sodium and free DA (15).
On changing from a supine to an upright posture, a decrease in natriuresis 
and diuresis is seen in healthy subjeets, possibly due to a decrease in renal DA 
synthesis but an increase in SNS and RAS activities (366). A positive correlation 
between the urinary excretion of sodium and free DA is seen in both supine and 
upright posture.
3.1.7 Oral salt loading increases urinary excretion o f both sodium and free DA
If intrarenal DA regulates the urinary excretion of sodium, the natriuretic 
response to oral salt loading should be accompanied by an increase in urinary free 
DA excretion. Indeed, this has been shown convincingly in humans (Table 3h and 
Table 3i) and experimental animals (Table 3j).
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Studies in humans
Table 3h. Increased urinary free DA excretion during the natriuretic response to 
oral sodium loading in healthy Caucasian subjects.
Authors Study design / 
daily Na intake
Main findings
Alexander 
et al., 1974 
(12)
Oates 
et al., 1979 
(13)
Casson 
et al., 1983 
(367)
Harvey 
et al., 1984 
(368)
Gill
et al., 1988 
(369)
Critchley 
et al., 1990
(370)
Rudberg 
et al., 1997
(371)
6 M, 1 F, 19-29 y* 
Na (9 mmol D l-8, 
259 mmol D9-18) 
fîusemide 40 mg/d 
on Dl-3
6 M*
Na (100 mmol 
Dl-3, 20 mmol 
D4-8, 220 mmol 
D9-13)
5M, 43 ± 2.7 y*
Na (40 mmol Dl-3 
220 mmol D4-12)
6M awaiting minor 
surgery, 45 ± 5 y* 
Na (20 mmol Dl-7 
220 mmol D8-14)
Sodium excretion 9 (mean of D6-8)
-> 259 (mean of D 15-18) mmol/d 
Free DA excretion 888 1,273 nmol/d
Free NA excretion 221 125 nmol/d
GFR 92 -> 105 ml/min
Sodium excretion Î  fi*om D5, max on D7 
Free DA excretion 1,200 (low Na)
-> max 1,800 nmol/d (D5)
Plasma free DA unchanged 
Free DA clearance in a pattern similar to 
fi’ee DA excretion 
PRA t  and i  with low and high Na intake
Sodium excretion 24 (D3) -> 92 (D4),
157 (D5) and 266 mmol/d (D6)
Free DA excretion 830 (D3) 855 (D4),
max 1,150 (D8) nmol/d 
PRA 4- with high Na intake
Sodium excretion 22 (D7)—> max 248 (DIO) 
Free DA excretion 820 (D7) -> 830 (D8), 
max 1,090 (D ll)nm ol/d 
PRA 'I with high Na intake
2M, 3F, 20-62 y* Free DA excretion 882 (D13-14)
Na (109 mmol Dl-7, 1,371 (D21-22) nmol/d
9 mmol D8-14, PRA and plasma aldosterone 4- with Na loading 
249 mmol D15-21) No changes in MAP, plasma/urine free NA
20 subjects Sodium excretion 142 257 mmol/d
200 mmol Na on D1 Free DA excretion 2,030 -> 2,740 nmol/d
16 subjects, 14-29 y* Sodium excretion 107 ->• 206 mmol/d 
Na (normal, then Free DA excretion 1,476 ->■ 1,750 nmol/d 
high on Dl-3) Aldosterone excretion 6.4 ->>4.1 nmol/12 h
Table 3h. (cont’d)
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Goldstein 
et al., 1989 
(372)
Gill
et al., 1991 
(373)
Wolfovitz 
et al., 1993 
(374)
10 subjects*
20-24 y 
Na (109 mmol 
Dl-7, 9 mmol 
D8-14, 249 mmol 
D15-21)
4 M, 6 F, 20-24 y* 
Na (9 mmol Dl-7, 
249 mmol D8-14)
6M, 6F, 24-55 y*
Na (40 mmol Dl-7 
unrestricted D8-14 
340 mmol D15-21) 
Sequence of diets 
randomised 
L-dopa infusion 
to T plasma dopa 
by about 10-fold
About 10 times as mueh free DA excreted 
as dopa throughout the study 
Free DA excretion 1,104 (Dl), 895 (D4) 
-^686  (D12), 816(D14),
1,313 (D19), 1,123 (D21) nmol/d 
Dopa excretion 15,2 (Dl), 14.2 (D4)
-> 9.2 (D12), 10.8 (D14)
->21.0 (D19), 18.1 (D21) lag/d 
Dopa clearance 4.6 (109 mmol Na),
3.9 (9 mmol Na), 7.8 (249 mmol Na) 
ml/min per 100 ml GFR 
Changes in dopa excretion parallel almost 
exactly changes in free DA excretion 
Plasma free NA 141 (D14) ->-91 (D21) pg/ml
Free DA excretion 912 (Dl), 838 (D7)
-> 1,332 (D12), 1,141 (D14) nmol/d 
Dopa excretion 65 (Dl), 51 (D7)
-> 103 (D12), 79(D14) nmol/d 
Free DA excretion T 60% and dopa excretion 
t  75% between D6-7 and D13-14 
Dopa clearance 4.15 -> 7.46 ml/min 
per 100 ml GFR 
Plasma free NA i  during the high Na intake 
Free NA excretion 105 (Dl), 107 (D7)
—>75 (D9), 96 (D14) nmol/d
Free DA excretion 1,483 (D7)
->> 1,872 (D21) nmol/d 
Dopa exeretion 115 (D7) 202 (D21)
-> 202 (D21) nmol/d 
No changes in BP, plasma dopa 
or renal plasma flow 
Strong positive correlations among urinary 
excretory rates of dopa, free DA and 
dihydroxyphenylacetie aeid (DOPAC) 
L-dopa infusion -> no changes in plasma DA, 
but TTT dopa and free DA excretion 
T rate of entry (spillover) of L-dopa into the 
circulation cannot explain T dopa and 
free DA excretion during Na loading
*A11 Caucasian subjects?
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From these studies of renal DA response to dietary salt loading, several
important observations should be highlighted:
(a). As already discussed in Seetion 3.1.1, if urinary free DA simply reflects the 
filtered load of DA and were derived from plasma free DA, a daily excretion 
rate of about 130 nmol is expected. The actual urinary free DA output is 6- 
15 times as much before salt loading. The figure is even higher (8-21 times 
as much) after salt loading. The calculated clearance values (indices of 
delivery of plasma free DA to the kidney) also far exeeed renal blood flow, 
indicating that free DA is formed within the kidney (13).
(b). The increase in urinary free DA excretion, in the absence of changes in 
plasma free DA after increased oral salt loading, implies that free DA is 
formed within the kidney in response to salt loading (13,373,374).
(c). Free DA excretion appears to lead, rather than follow, sodium excretion, 
suggesting renal DA needs to be mobilised first before a natriuretic response 
to oral salt loading is seen (13).
(d). The proportionate changes in dopa excretion during dietary manipulations 
parallel almost exactly the proportionate changes in free DA excretion. Both 
increase during salt loading and decrease during salt restriction. These 
results imply that: (i) increases in free DA excretion during salt loading can 
be accounted by increases in delivery of dopa to renal tubular fluid; (ii) 
urinary free DA is derived from circulating dopa (372-374).
(e). Under basal conditions, the strong positive correlations among urinary 
excretion rates of dopa, free DA and its metabolite, dihydroxyphenylacetie 
acid (DOPAC), are consistent with the renal synthesis and metabolism of DA 
after the uptake and decarboxylation of circulating dopa (374).
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(f). By administrating L-dopa to healthy subjects taking a low or high salt diet, 
Wolfovitz et al. (374) calculated that renal uptake and decarboxylation of 
circulating dopa accounted for virtually all the urinary excretion of free DA. 
They also suggested that dietary salt loading may enhance the sodium- 
coupled uptake of dopa from the plasma, thereby increasing the excretion 
rates of dopa and free DA.
Increases in urinary excretion of free DA during the acute natriuretic response 
to oral salt loading have also been reported in other ethnic groups (Table 3i).
Table 3i. Increased urinary free DA excretion during the natriuretic response to 
oral sodium loading in healthy Thai and black subjects.
Authors Study design / 
daily Na intake
Main findings
Critchley Thais, 20 subjects Sodium excretion 118 ->■ 223 mmol/d
et ah, 1990 Usual diet + 200 Free DA excretion 1,714 —> 2,314 nmol/d
(370) mmol Na on Dl
Sowers Blacks, 14 subjects Sodium excretion 40 -> 185 mmol/d
et al., 1988 44 ± 6 y Free DA excretion 1,521 -> 1,887 nmol/d
(375) Na (40 mmol Dl-14 Free NA excretion 943 ^ 1 2 4  nmol/d
180 mmol D15-28) No changes in urinary free DA/NA ratio 
No correlations between urinary free DA/NA 
ratio and sodium output 
Plasma aldosterone 0.58 ^  0.28 nmol/L 
No changes in PGEj excretion 
MAP 4 5-10 mmHg in all subjects when Na 
intake changed from normal to 40 mmol/d 
MAP t  6 ± 0.2 mmHg (7 ± 0.2%) when Na 
intake changed from 40 to 180 mmol/d
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Critchley et al. (370) also studied 13 Ghanaians (baseline 24-hour sodium 
output 141 + 4.2 mmol), 29 Iranians (160 ± 10.0 mmol) and 15 Thai vegetarians (60 
± 5 .4  mmol). Both the Ghanaians and Iranians showed no significant changes in 
urinary free DA output after salt loading (see Seetion 1.3 for the evolutionary benefit 
of their inability to mobilise renal DA). They proposed that the DA response among 
the Thai vegetarians with a very low salt intake may have become 'uncoupled' in 
order to conserve salt. Alternatively, there is a concealed positive DA response 
which is sluggish and delayed due to disuse.
It is worth noting that blacks are particularly salt-sensitive. Salt restriction or 
modest salt loading induces an obvious change in MAP (375). One possible reason 
for this is the lack of an efficient renal DA system among blacks. On salt loading, 
they either show no changes (370) or relatively small increases (375) in free DA 
excretion. The 'natriuretic index' (urinary free DA/NA ratio) does not change after 
salt loading and there is no correlation between this ratio and the sodium output.
However, Barendregt et al. (376,377) in the Netherlands reported that urinary 
free DA excretion in healthy Caucasian subjects is not affected by the changes in 
their sodium intake from 50 to 250 or from 50 to 150 and 300 mmol/day. Luippold 
et al. (378) in Geimany reported that urinary free DA excretion in healthy volunteers 
do not change during low sodium (<85 mmol/day), normal sodium (normal food ad 
libitum) and high sodium (normal food plus 1.7 mmol/kg/day) intake. However, the 
dietary intakes of other nutrients could not be entirely controlled (376-378).
Studies in experimental animals
An inerease in urinary free DA excretion during oral salt loading has also 
been shown in the rats (Table 3j).
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Table 3j. Increased urinary free DA excretion during the natriuretic response to 
oral sodium loading in rats.
Authors Study design Main findings
Ball
et al., 1978 
(306)
Wistar rats 
Low Na diet Dl-7 
+ NaCl, NaHCOa, 
KCl orNH^Cl 
on D5-7
Free DA excretion (nmol/d), D3 —> D6 
NaCl, 7.28 ^  14.24 
NaHCOg, 8.12 ^ 5 .5 9  
KCl, 6.7 -> 8.76 
NH.C1, 8.28 ^  12.76
Yamazaki 
et al., 1986 
(379)
Wistar rats 
Basal (0.26%) or 
high (3.14%) Na 
diet for 4 weeks
High vs basal Na diet, D28 
Free DA excretion 19.7 vs 9.1 nmol/d 
Free NA exeretion 12.8 vs 4.2 nmol/d 
Free adrenaline excretion 2.0 vs 0.7 nmol/d 
PRA 0.3 vs 3.8 ng/ml/h 
Renal free DA content 22.6 vs 15.5 ng/g 
No differences in renal NA content
Yoshimura 
et al., 1987 
(380)
Wistar rats 
Basal (0.26%) or 
high (3.14%) Na 
diet
Renal denervated vs sham-operated rats 
Basal Na diet -> higher sodium exeretion, 
lower free NA excretion, 
no differences in free DA/PGE excretion 
High Na diet higher sodium excretion, 
lower free NA/PGE excretion, 
no differences in free DA excretion 
Rats on high vs low Na diet 
Free DA excretion 44.0 vs 20.5 nmol/d 
PGE excretion 35.6 vs 12.4 ng/d 
No differenees in free NA excretion 
Bromocriptine ->> sodium excretion Î ,
PGE excretion t ,  free NA excretion 4- 
Carbidopa ^  free DA/PGE excretion 4, 
renal DA content 4,
no changes in sodium/free NA excretion 
and renal NA content
Grossman 
et al., 1990 
(381)
Dahl SS & SR rats 
Low (0.1%, w/w) 
or high (0.8%) 
Na diet
SS and SR did not differ in urinary responses 
Free DA and dopa excretion T 6-fold 
Renal denervation blunted the urinary free 
DA and dopa responses for 5 days 
Dopa spillover (from steady-state clearance of 
i.v. radioactive dopa) and free DA exeretion 
Î  to the same extent 
Radioactive dopa/DA ratio in arterial plasma 
300 times that in urine
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Table 3j. (cont’d)
Hayashi 
et al.,1991 
(382)
Jadhav 
et al., 1991 
(383)
Mühlbauer 
et al., 1993 
(384)
Wistar rats 
Low or high 
(0.9% saline) 
Na diet
Sprague-Dawley rats 
Drank 0.9% saline 
or water
Sprague-Dawley rats 
Controls ± carbidopa 
high Na ± carbidopa 
high Na + deoxy­
corticosterone ± 
carbidopa
Free DA excretion T in both innervated 
and denervated high salt group 
L-AAAD activity of proximal tubules t  
Denervation -> 44 renal NA content in all, 
slight 4 renal DA content in high-salt group
High salt group ->> urinary excretions of water, 
sodium, free DA and DOP AC T, ANP t  
No changes in free NA excretion 
No changes in renal DA/NA contents 
Transient T DA, receptor binding sites
Sodium excretion -> t  5-6 fold in high salt ± 
DOCA groups, 4 in high salt + DOCA + 
carbidopa group, no changes in eontrol + 
carbidopa group 
Free DA excretion -> 27% higher in high salt 
than in low salt group, 4 57-67% in all rats
Sharif 
et al., 1995 
(385)
Sprague-Dawley rats High salt vs normal salt diet ->
Ho
et al., 1994 
(386)
Wang 
et al., 1997 
(387)
0.33% (normal Na 
diet), 0% (low) or 
7.8% (high) NaCl 
for 4 weeks
Sprague-Dawley rats 
Tap water, then 
18 g/lNaCl to -> 
drink
Sprague-Dawley rats 
Normal (0.28% NaCl) 
or high (4% NaCl) 
Na diet 
Response to gludopa
i.v. infusion
free DA excretion t ,  plasma aldosterone 4, 
no changes in free NA or DA/NA ratio 
Plasma aldosterone f  in low salt diet 
Diuresis during high salt diet 4 by carbidopa 
or SCH 23390, but not domperidone 
Cortical/medullary DA, and DAg sites 4 by 
low salt diet and cortical DA, binding sites 
4 by high salt diet
Sodium excretion -> peak T on D2 
Free DA excretion ->* peak t  on D4 (49%) 
STI (sodium transport inhibitor) excretion 
->• peak t  on D5 (6.7-fold)
STI excretion parallels sodium excretion, 
but free DA excretion lags behind
High salt diet natriuresis and free DA 
excretion f ,  but 4 renal interstitial fluid 
(RIF) DA
Gludopa —> natriuresis with T t  free DA 
excretion than RIF DA 
Prior bilateral renal denervation did not 
affect basal DA excretion/RIF DA or 
gludopa induced natriuresis
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Table 3j. (cont'd)
Ho Sprague-Dawley rats High salt diet -> natriuresis, 4 OLS (ouabain-
et al., 1997 Low Na/high Na like substance/Na^,KVATPase inhibition
(388) ± earbidopa ^  Carbidopa 4 natriuresis during high salt,
but not normal salt diet 
Carbidopa f  OLS during low salt diet
Several important observations from these studies should be highlighted:
(a). In rats initially maintained on a low salt diet and then given equimolar dietary 
supplements of NaCl, NaHCOg, KCl or NH4CI (306), urinary free DA 
excretion increased in rats given NaCl, KCl and NH4CI, but decreased in rats 
given NaHCOj. These findings argue against a simple effect of ECF volume 
expansion by sodium ion and suggest that the renal DA response is not 
specific to the sodium ion. However, since free DA beeomes unstable in 
alkaline urine, the fall in urinary free DA after NaHCOj may well be an in- 
vitro phenomenon.
(b). Renal DA content was higher in rats maintained on a salt diet than in rats on 
a normal sodium diet (379). This observation is compatible with increased 
DA synthesis within the kidney during salt loading. Failure of suppression of 
SNS activity during salt loading contributed to the increase in BP, which 
could be prevented by ganglionic blockade using hexaméthonium.
(c). Renal denervation has no effects on the increase in urinary free DA excretion 
in response to oral salt loading (380,382). However, urinary excretion of NA 
is decreased (380). In addition, salt loading is assoeiated with an increase in 
L-AAAD activity in the proximal convoluted tubules. These results suggest
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that the increase in urine free DA exeretion during high salt intake is mainly 
caused by the enhancement of extra-neuronal DA production by the kidney.
(d). The increases in urinary free DA excretion associated with salt loading ean be 
accounted for by the increased spillover of dopa into the bloodstream (381). 
Renal nerves may eontribute to the early DA excretory responses since renal 
denervation can delay the urinary DA and natriuretic responses. There is 
substantial intrarenal conversion of dopa to DA since the ratio of radioactive 
dopa to radioactive DA is much more higher in arterial plasma than in urine.
(e). Quantitative autoradio graphie studies have shown that chronic salt loading is 
associated with a deerease in the number of DA, receptors in the renal cortex 
(385). This finding is compatible with the observations that a high salt diet 
increases the production of renal DA and that this then causes the observed 
down-regulation of the eortical DA, receptors.
(f). Using a novel in-situ interstitial microdialysis technique, Wang et al. (387) 
have characterised the intrai'enal DA production and distribution in response 
to chronic salt loading. DA produced in the kidney is released preferentially 
into the tubule lumen, rather than peritubular spaee, and exerts a direct 
tubular effect on the control of sodium excretion.
3.1.8 Urinary free DA excretion decreases during salt restriction
In contrast to oral salt loading, a fall in urinary free DA and sodium output is 
seen in humans during salt restrietion (372,373,389,390). Urinary free DA excretion 
remains lower than the baseline during the salt restriction period (373,390).
Piaroa Amazonie Indians living in the Amazons Forrest have a very low 
sodium intake (12.6 mmol/day) compared with urban subjects (210.7 mmol/day) in
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northern Venezuela (Section 3.1.6). Consistent with a role for renal DA in sodium 
homeostasis is the presence of a much lower free DA output (2,055 vs 5,227 
nmol/day).
3.1.9 Intravenous saline infusion increases the urinary excretion o f both sodium 
and free DA
Intravenous saline infusion increases the urinary excretion of both sodium 
and free DA. This has been demonstrated both in humans (Table 3k and Table 31) 
and experimental animals (Table 3m and Table 3n).
Studies in humans
Table 3k. Inereased urinary free DA excretion during the natriuretic response to 
acute saline infusion in healthy Caucasian subjects.
Authors Study design / 
0.9% NaCl i.v.
Main findings
Alexander 
et al., 1974 
(12)
Castellano 
et al., 1986
(391)
Jeffrey 
et al., 1989
(392)
7F, 19-23 y*
59 mmol Na Dl-3 
5% dextrose —> 
NaCl 900/min
4 M ,4F, 19-57 y* 
120 mmol N aD  1-5 
2 L/2h
9M , 20-38 y*
20 ml/kg/h for 3h 
(at 2-5 h) 
Carbidopa 100 mg 
or placebo at 0 
and 5 h 
Hydrated
Sodium excretion 6.4 -> 21.5 mmol/h 
Free DA excretion 42.4 -> 54.9 nmol/h 
No changes in free NA + adrenaline excretion, 
GFR or renal blood flow
Free DA excretion 128 ^  150 nmol/mol cr 
Free NA exeretion 17 ^  14 nmol/mol cr
Sodium excretion t  5-fold, peak in 5-6 h, 
26% of total Na excreted during study 
Free DA excretion f  26% in the 5-6 h 
and lasted until the end of study (10-11 h) 
PRA 4, plasma All 4, plasma ANP T 
Carbidopa 44 free DA excretion without 
effect on sodium excretion
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Table 3k. (cont’d)
Stenvinkel 
et al., 1991 
(393)
Stenvinkel 
et al., 1992 
(394)
Stokes 
et al., 1993 
(395)
Stenvinkel 
et al., 1997
(396)
Stokes 
et al., 1997
(397)
9 M, 31-40 y* 
25 ml/kg for 2 h 
Hydrated
4M , 6F, 21-49y* 
0.9% NaCl vs 
5% dextrose 
25 ml/kg for 2 h 
Hydrated
8 M, 4 F*
100 mmol Na 
2 L/3 h plus 
carbidopa 100 mg, 
indomethacin 50 mg 
or placebo 
Urine collections 
(90 min) x 5 
(Ul-5) starting at 
-90 min (Ul)
Sodium excretion T 46%
Free DA excretion î  12.8% in 2nd and 3rd h, 
16.2% in 4th h, 9.5% in 5th h 
PRA i ,  plasma ANP t ,  GFR 4- 
No changes in renal plasma flow
Fractional excretion of sodium progressively 
t  from 1st h, max 85.7% (4th h)
Free DA excretion t  16% (2nd h),
16.5% (3rd h) and 15.6% (4th h)
Free NA excretion 4 21.4% (4th h)
Plasma ANP T 59% (2nd h) and 27% (4th h) 
PRA 4, GFR 4 in 1st and 2nd h 
5% dextrose fractional excretion of sodium 
and free DA excretion did not change, 
free NA excretion f  33.3% (4th h), plasma 
ANP f  44.3% (2nd h), PRA transiently 4
27% of 300 mmol Na excreted in U l,
65.7% by U2 and 111% by U3 
Urinary free DA/NA ratio 9.2 ^  34.1 
Plasma ANP T up to 86.3% (U4)
No ehanges in PGE^ and kallikrein excretion 
Carbidopa -> 44 sodium excretion in 2 of 6 
subjects, urinary DA/NA ratio 4 1.6 (Ul),
1.1 (U2), 0.9 (U3) and 3.4 (U4) 
Indomethacin -> 3 of 6 subjects with 44 
sodium excretion, urinary DA/NA ratio 
15.3-19 (Ul-3), PGE2 excretion 4 (Ul)
15 subjects, 34 ±1 y* Free DA excretion f  14% 
12.5 mg/kg/h for 2 h
1 4M ,6F ,  28 ± 3 y* 
100 mmol Na diet 
2 L/3 h plus 
Carbidopa 100 mg, 
indomethacin 50 mg 
or placebo 
Hydrated 
(1st eollection) 
Hydrated
Sodium excretion f ,  urinary DA/NA ratio T, 
plasma albumin 4, plasma ANP t ,
PRA 4, plasma aldosterone 4, 
no changes in urinary PGE^
Carbidopa -> urinary DA/NA ratio 44, 
no effects on other parameters 
Indomethacin -> natriuresis 4 ,t distal sodium 
reabsorption, PGEg 4 transiently, 
no effects on other parameters
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Table 3k. (cont’d)
Stokes 6 M,4 F, mean 27 y* Saline infusion -> natriuresis, urine free DA
et al., 1997 100 mmol Na diet (at pH 2-2.5) f  in Ul-4, but no signifieant
(398) 2L/3 h or 200 ml/3h changes overall, free DA (57 ± 23%) and
4% dextrose- conjugated DA (1,622 ± 497%) T Ul-5,
0.18% saline no changes in free/conjugated NA,
plus carbidopa free DA/NA ratio 6.1 (Ul) and 8.2 (U5),
100 mg or placebo conjugated DA/NA ratio 6.1 (Ul), 58.3 (U5),
Urine collections free DA (at pH 1-1.5) T 225 ± 97% Ul-5,
(90 min) x 5 4 plasma albumin, PRA, aldosterone,
(Ul-5) starting at Carbidopa -> p=NS for 4 natriuresis U3-4,
-90 min (Ul) and 4 cumulative sodium excretion (6.3%),
Hydrated free DA excretion 4 Ul-5, no changes in
Free DA measured in conjugated DA, free DA/NA ratio 76-98%
aliquots and , (Ul-4) and 210% (U5), conjugated
analysed under pH DA/NA ratio 88-122% (Ul-5)
1-1.5 and 2-2.5
*A11 Caucasian subjects?
Hydrated = water was given at regular intervals to ensure adequate urine flow rates.
Several important observations from these studies should be highlighted:
(a). After intravenous saline infusion, the magnitude of increases in urinary free 
DA excretion is considerably small (up to 34%) compared to the changes in 
sodium excretion (up to 5-fold).
(b). In the study of Jeffrey et al. (392), free DA excretion increased after saline 
infusion and remained elevated at the end of the study, at a time when more 
than 70% of the sodium load remained to be excreted. In the studies of 
Stenvinket et al. (393,394), free DA excretion increased during the second 
hour of infusion and remained elevated for two hours post-infusion. It is 
conceivable that renal DA assumes greater significance during the later stages 
of the natriuretic response.
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(c). The preliminary observations made by Stokes et al. (395) suggest that some 
subjects can be identified as having renal DA- or prostaglandin-dependent 
mechanisms in the early phase of natriuretic response to saline infusion.
(d). Stokes et al. (397,398) subsequently showed that the natriuretic response to 
saline infusion is associated with an increase in the 'natriuretic index' (urinary 
free DA/NA ratio). Although there was an increase in free DA excretion 
during the infusion (398), the change did not reach statistical significance by 
repeated measures of analysis of variance. Carbidopa failed to attenuate the 
natriuretic response despite a fall in urinary free DA excretion (in contrast to 
the studies summarised in Table 3m on page 80 and Section 3.1.10).
(e). Stokes et al. (398) showed that conversion of conjugated DA to free DA can 
occur in-vitro if urine aliquots are acidified to a pH of 1.0-1.5 instead of 2.0- 
2.5. To prevent unwanted cardiovascular and renal effeets, excessive DA 
may be conjugated (Section 3.1.1 and Section 3.2.4) as soon as it is formed. 
Thus, there is a surge in excretion of conjugated DA after saline infusion.
Increased urinary free DA excretion is also seen in healthy Japanese subjects 
during the natriuretic response to intravenous saline infusion (Table 31). However, 
Barendregt et al. in the Netherlands (376,377) could not confirm an increase in free 
DA excretion during the natriuretic response to saline infusion in Caucasian subjects. 
During the low sodium intake period (50 mmol/day), a sodium load (38 mmol) was 
given as 500 ml glucose 2.5%/NaCl 0.45% over two hours. During the high sodium 
intake period (250 mmol/day), a sodium load (154 mmol) was given as 1,000 ml of 
0.9% NaCl over two hours. On both diets, the saline infusions enhaneed sodium 
excretion but did not increase free DA excretion.
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Table 31. Increased urinary free DA excretion during the natriuretic response to 
acute saline infusion in healthy Japanese subjeets.
References Study design / 
0.9% NaCl i.v.
Main findings
Kawabe 
et al., 1991 
(399)
4 M, 3 F, 49 ± 3 y 
100 mmol Na Dl-10 
500 ml/h for 3 h 
Hydrated
Sodium excretion T 151%
Free DA excretion T 34%
PRA and plasma aldosterone 4 
Plasma ANP t ,  GFR t
No changes in plasma/urine free NA/adrenaline
Kawabe 
et al., 1992 
(400)
5M, 3F, 46 + 3 y 
100 mmol Na Dl-10 
500 ml/h for 3 h 
Hydrated
Sodium excretion f  47%
Free DA excretion Î  64%
PRA and plasma aldosterone 4 
Plasma ANP t ,  GFR Î
Studies in experimental animals
Table 3m. Increased urinary free DA exeretion during the natriuretic response to 
acute saline infusion in anaesthetised dogs.
Referenees Study design / 
0.9% NaCl i.v.
Main findings
Faucheux 
et al., 1977 
(401)
1 ml/kg/min for 20 
min, then 0.5, 
25% albumin 6.5 
ml/kg over 
20 min or 
no treatment
Saline -> sodium exeretion f  840%, 
fraetional sodium exeretion t  811%, 
urine volumef 270%, free DA T 811%, 
fraetional clearance of DA t  138%,
% t  DA excretion related to fraetional 
sodium exeretion (r=0.41, p<0.05), 
plasma free NA + adrenaline 4 53.8%, 
free NA + adrenaline excretion 4 60.9%, 
no changes in plasma DA or GFR, 
renal plasma flow T 19%
Albumin —> plasma NA + adrenaline 4 51.2%, 
free NA + adrenaline excretion 4 58.2%, 
renal plasma flow T 20%, no changes in urine 
sodium/free DA, plasma DA or GFR
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Table 3m. (cont’d)
Cuche 
et al., 1983 
(402)
Sowers 
et al., 1984 
(403)
Hypotonie (0.45% 
NaCl or dextrose 
2.5%) 2 for 45 min 
-> 1 ml/kg/min 
Isotonie saline 1 for 
45 min —> 0.5 
ml/kg/min 
Hypertonie (1.8% 
NaCl or Na SOJ 
0.5 for 45 min -> 
0.25 ml/kg/min
30 ml/kg/h X 2 h 
with or without 
earbidopa
MeClanahan 
et al., 1985 
(404)
30 ml/kg/h X 2 h 
with or without 
earbidopa
Comparable plasma protein and 
f  GFR/renal plasma flow 
Plasma sodium/osmolality 4- in hypotonie,
T in hypertonie, no ehanges in isotonie 
Fraetional exeretion of sodium t  30-fold 
in hypotonie, 7-fold in isotonie and 
16-fold in hypertonie groups 
Free DA exeretion î  53.4% in isotonie group, 
f  31.3% in hypertonie group, 
no ehange in hypotonie group 
Free NA exeretion i  52.9% in hypotonie, 
no ehanges in isotonie or hypertonie groups
Sodium exeretion T 415% (during infusion) 
and 289% (post infusion)
Free DA exeretion t  267% (during infusion) 
and 106% (post infusion)
Correlation between urinary sodium and 
free DA during infusion (r=0.72, p<0.025) 
Urine volume T 253% (during infusion) 
and 107% (post infusion)
Free NA exeretion 4- 72.3% (during infusion) 
and 57.2% (post infusion)
No ehanges in MAP, GFR or renal plasma flow 
Carbidopa no inereases in free DA and 
sodium exeretion during saline infusion
Sodium exeretion T during (1st h 190%,
2nd h 621%) and post (279%) infusion 
Free DA exeretion t  during (1st h 24.2%,
2nd h 227%) infusion 
Correlation between urinary sodium and 
free DA during infusion (r=0.72, p<0.025) 
Urine volume Î  during (2nd h 346%) and 
after (146%) infusion 
Free NA exeretion i  during (1st h 40.6%,
2nd h 73%) and post (57.2%) infrision 
PRA and plasma aldosterone 4- 
No ehanges in MAP, GFR or renal plasma flow 
Carbidopa -> sodium exeretion 4' 40% (in 
2nd h of infusion e.f. eontrol), sodium load 
exereted during infusion i  35%, 
free DA exeretion i- during infusion 
(57% in 1st and 86% in 2nd h)
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Table 3m. (cont’d)
Boren 5% of body weight Sodium excretion T 933%, clearance of
et al., 1980 over 30 min sodium t  1,003%, free DA excretion f  56%
(405) DA clearance Î  53.6%,
fractional clearance of DA t  27.1%
No changes in renal blood flow, GFR, plasma 
DA, plasma/urinary NA or filtered DA
Several important observations are summarised here:
(a). During the natriuretic response to saline infusion, the SNS activity (urinary 
free NA and adrenaline output) decreased quite rapidly, whereas the renal DA 
response was more sluggish (401). Both the renal and fractional clearance of 
free DA increased in the absence of changes in plasma DA, suggesting that 
the increase in urine DA after salt loading is of renal origin. The positive 
correlation between increases in urine free DA and the fractional excretion of 
sodium suggests that renal DA regulates sodium excretion. An increase in 
urinary DA excretion occurred after saline infusion but not after albumin 
infusion despite a similar reduction in NA and adrenaline excretion. This 
observation argues in favour of a specific effect of sodium or sodium chloride 
on intrarenal DA synthesis and against a 'spillover' of DA from SNS neurons.
(b). Cuche et al. (402) could show a dissociation between urinary sodium and free 
DA excretion using hypotonic saline infusion. This finding does not provide 
support for a physiological role of renal DA during ECF volume expansion.
(c). Carbidopa eliminates the increase in urinary free DA excretion and markedly 
attenuates the natriuretic response to saline infusion (403,404). It appears 
that renal production of DA is an important mechanism mediating the 
natriuretic response to acute ECF volume expansion with saline infusion.
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Table 3n. Increased urinary free DA excretion during the natriuretic response to 
acute saline infusion in anaesthetised rats.
Authors Study design / 
0.9% NaCl i.v.
Main findings
Hansell 
et al., 1988 
(406)
Hegde 
et al., 1989 
(407)
Chen
et al., 1991 
(408)
Bass
et al., 1991 
(409)
Sprague-Dawley rats 
Ringer solution 2ml/ 
0.1 kg over 1 h 
(2% ofBWperh)  
with or without 
haloperidol
Sprague-Dawley rats 
20.4 ml over 1 h 
with or without 
SCH-23390
Sprague-Dawley rats 
Volume expansion, 
modest (9 ml 
= 2.5% BW), 
moderate (18 ml = 
= 5% BW) or 
severe (36 ml 
= 5% BW) 
over 1 h
Sprague-Dawley rats 
Volume expansion, 
small (2 + 0.1%
T BW) or large
Sodium exeretion T 17-fold 
Free DA exeretion T 37.9%
DOPAC exeretion t  29.9%
Plasma ANP T
Urine volume t  123%, GFR T 19.8%
No changes in free NA exeretion or BP 
Haloperidol -> greater T in plasma ANP and 
free DA/DOPAC exeretion,
•l natriuretic/diuretic responses by 45%
Sodium exeretion t  during (max 60-fold) and 
after (38 -> 18-fold) infusion 
Urine volume t  during (max 20-fold) and 
after (11 ^  4-fold) infusion 
Free DA excretion T during (max 4.7-fold) 
and after (6.2 ^  3.5-fold) infusion 
SCH-23390 4- the natriuresis/diuresis
Modest sodium excretion f  31-fold,
free DA excretion T 26%, urine volume 
f  14-fold, correlation in urine sodium/
DA pre/during infrision (r=0.63, p<0.05) 
Moderate -> sodium excretion t  60-fold, 
free DA excretion T 48%, urine volume 
T 23-fold, correlation in urine sodium/
DA pre/during infusion (r=0.82, p<0.01) 
Large sodium excretion t  123-fold, 
free DA excretion Î  57%, urine volume 
Î  23-fold, correlation in urine sodium/
DA pre/during infusion (r=0.82, p<0.01)
Small sodium excretion 1 155% (69% 
after SCH 23390), urine volume T 59%, 
free DA excretion T 25%
Large —> sodium excretion t  735%, urine
(17.9 ± 0.6% T BW) volume Î  1,026%, no changes in free DA
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Table 3n. (cont’d)
Hegde 
et al., 1992 
(410)
Hansell 
et al., 1996 
(411)
Reddy 
et al., 1998 
(412)
Sprague-Dawley rats 
20.4 ml (6% of BW) 
over 1 h 
With or without 
intact vagi or 
renal nerves 
± SCH 23390
Rats with intact vagi vs vagotomised rats 
similar T in sodium excretion/urine volume, 
free DA exeretion T in rats with intact vagi, 
SCH 23390 4- natriui'esis/diuresis in rats 
with intact vagi 
Rats with innervated vs denervated kidneys 
denervated kidney showed similar sodium 
excretion/urine volume and similar f  urine 
free DA but greater T in sodium excretion/ 
urine volume after infusion 
SCH 23390 4- natriuresis and diuresis in 
denervated kidneys
Sprague-Dawley rats Urine sodium t  >13-fold and free DA Î  42%
± adrenalectomy 
NaCl (5% of BW)
Wistar rats 
Normalor high 
salt diet +
ANP infusion, 
saline infusion 
(8 ml/h), both 
or none
(> 14-fold and 36% in adrenalectomised rats) 
Plasma dopa, adrenal > systemic before (62%) 
and after (42%) infusion in both groups 
Dopa excretion was similar in both groups
Sodium excretion Î  by high salt diet 
Fractional excretion of sodium f  by both ANP 
infusion and saline infusion 
Synergistic effect of ANP/saline infusion on 
sodium excretion during normal salt intake 
Free DA excretion f  with a high salt diet 
Free DA excretion T further after saline 
infusion during a normal or high salt diet 
Free DA excretion T even further after saline 
and ANP infusion during a normal or high 
salt diet
Benserazide to inhibit DA formation fi'ee 
DA and sodium excretion
Several important observations from studies in rats are highlighted here:
(a). The natriuretic and diuretic responses to acute ECF volume expansion with 
saline infusion are accompanied by increased free DA excretion and are 
markedly attenuated by DA receptor blockade with haloperidol or SCH- 
23390 (406,407). These findings provide strong support for a role of renal
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DA in mediating the natriuretic and diuretic responses to acute ECF volume 
expansion.
(b). Chen & Lokhandwala (408) showed that the relative contribution of renal DA 
to acute ECF volume expansion-induced natriuresis is related to some extent 
to the degree of volume expansion. With modest to moderate increments in 
the ECF volume (2.5 to 5% body weight), the kidney can adjust the renal 
production of DA, as evidenced in the finding that moderate ECF volume 
expansion produces fiirther increase in free DA excretion in comparison with 
modest expansion (48 vs 26%). However, with further increase in the degree 
of ECF volume expansion (10% body weight), the kidney is unable to 
produce more DA. Under this condition, other factors probably play a more 
important role in the natriuretic response.
(c). Bass & Murphy (409) showed that renal DA contributes to the natriuresis 
produced by small (2% of body weight), but not large (18% of body weight), 
increases in ECF volume induced by saline infusion. Under the former but 
not the latter condition, a concomitant increase in free DA excretion is seen 
and the natriuresis is attenuated by DA^ antagonist. Hedge & Lokhandwala 
(410) also showed that the effects of DA receptor blockade on natriuresis 
produced by saline infusion is dependent on the degree of hypervolaemia. 
The renal DA system appears to be relatively more important in promoting 
natriuresis at the lower (physiological) range of hypervolaemia, whereas in 
the higher range, other factors probably have a greater impact.
(d). Hedge & Lokhandwala (410) tried to identify the mechanism whereby an 
intravenous sodium load and/or ECF volume expansion stimulate the renal 
production of DA. Unlike rats with intact vagi, bilaterally vagotomised rats
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did not show an increase in urinary DA excretion after saline infusion. DA, 
receptor blockade also attenuated the natriuretic and diuretics responses in 
rats with intact vagi, but failed to do so in vagotomised rats. The results 
suggest that in rats renal DA contributes to the natriuretic and diuretic 
responses to ECF volume expansion through a reflex involving the vagus 
nerve. Vagal afferents originating in the cardiopulmonary region may relay 
to the central nervous system information regarding the ECF volume status. 
However, even without the contribution from renal DA, vagotomised rats 
were equally capable of handling a salt load. It has been speculated that 
activation of vagal afferents during ECF volume expansion leads to the 
release of a humoral substance which in turn mediates the increase in 
endogenous DA production. Alternatively, a decrease in the circulating level 
of a substance having a tonic inhibitory effect on DA synthesis could be 
responsible.
(e). During 0.9% saline infusion, urinary sodium and free DA excretion increased 
similarly in both intact and adrenalectomised rats. Hansell et al. (411) 
therefore concluded that the adrenal glands are only minor suppliers of 
plasma L-dopa and minor sources of urinary free DA.
(f). Reddy et al. (412) compared the renal mechanisms of natriuresis in acutely 
and chronically ECF volume-expanded rats. Circulating ANP did not play a 
significant role in the natriuresis of chronic salt loading. The synergism 
between ECF volume expansion and ANP did not reside in changes of 
proximal tubular sodium transport but was a property of more distal nephron 
segments where both ANP and DA, induced by chronic salt loading, may 
share a common intracellular pathway to inhibit tubular sodium reabsoprtion.
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3.1.10 Studies using inhibitors o f L-AAAD
The DA-synthesising enzyme L-AAAD has been identified in proximal 
tubule cells of the kidney by immunohistochemistry (413,414), biochemical (382)
and in-situ hybridization (415) methods.
Studies using inhibitors of L-AAAD have provided further evidence that 
intrarenal DA plays an important role in regulating renal excretion of sodium:
(a). Ball & Lee (15) studied the effect of interference with renal DA synthesis on 
urinary sodium excretion in healthy subjects receiving their usual diets. They 
found that carbidopa causes a fall not only in urinary free DA excretion but 
also in urinary sodium excretion.
(b). Carbidopa markedly reduces the urinary free DA output and attenuates the 
natriuretic response to salt loading (Section 3.1.7 and Section 3.1.9). 
However, because of the abundance and redundancy of compensatory 
systems determining sodium balance, the effects of inhibition of endogenous 
DA synthesis (and of any other systems) may be transient and small.
(c). Some healthy subjects in the early phase of natriuresis after an intravenous 
saline load can be identified as having a DA-dependent mechanism for 
sodium excretion. Carbidopa reduces the renal excretion of both free DA and 
sodium in such subjects (Section 3.1.9).
(d). Bertorello et al. (414) reported that the proximal tubules from rats maintained 
on a high sodium diet (8.25 mmol/day) for 10 days showed the expected 
decrease in Na^-K^-ATPase activity compared to rats maintained on a normal 
salt diet. This difference was abolished by pretreatment with the L-AAAD 
inhibitor, benserazide.
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(e). Protein ingestion leads to increased urinary excretion of free DA (22-50%), 
sodium (36-125%) and water (24-31%) in healthy subjects aged 20-43 years
(416,417). Suppression of DA excretion by carbidopa markedly attenuates 
the natriuretic and diuretic responses to protein ingestion. The concordant 
responses of both DA and sodium to protein ingestion (416,417) and to 
carbidopa (416,417) and the correlation between urinary sodium and DA 
(416) support a role for DA in the regulation of sodium excretion.
(f). Carbidopa inhibits the increase in free DA excretion and abolishes the renal 
actions of gludopa in healthy subjects (Section 3.1.5).
3.1.11 Studies using DA receptor antagonists
Pharmacological evidence supporting the importance of renal DA in sodium
homeostasis is provided by studies involving the use of non-selective DA antagonists
(metoclopramide, haloperidol and cA-flupenthixol), selective DA, antagonists (SCH-
23390 and (+)-sulpiride) and selective DA^ antagonist (domperidone).
(a). Infusion of SCH-23390 into the renal artery of uninephrectomized dogs (418) 
and rats (419) produces a dose-dependent reduction in urine volume, urinary 
sodium excretion and fractional excretion of sodium. Rebound natriuresis 
and diuresis occur after the drug is stopped (418).
(b). In healthy subjects, metoclopramide attenuates the natriuretic response to 
ECF volume expansion produced by saline infusion (17,420).
(c). In rats, prior treatment with haloperidol (406,421), SCH-23390 
(407,409,410) or c/^-flupenthixol (422) attenuates the natriuretic response to 
ECF volume expansion produced by saline infusion.
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(d). In healthy subjects, (+)-sulpiride attenuates the natriuresis and the acute fall 
in PRA seen with gludopa (347). Domperidone inhibits the fall in PRA but 
does not affect the natriuretic response to gludopa infusion (346).
Hansell & Fasching (421) emphasised that the effect of DA blockade on 
natriuresis is dependent on the degree of hypervolaemia, with the renal DA system 
being relatively more important in promoting natriuresis at the lower range of 
hypervolaemia. This may be the reason why metoclopramide has no effects in rats 
on the natriuretic response to saline infusion equal to 10% rise in body weight (423).
However, Bradley et al. (424) were unable to block the natriuretic response to 
saline infusion in dogs using either SCH-23390 or domperidone.
3.1.12 Evidence from studies involving water immersion
Head-out water immersion (WI) produces a prompt cephalad redistribution of 
circulating blood volume. The increase in central blood volume produces natriuresis 
and diuresis. This physiological manipulation provides a model to investigate the 
mechanisms governing volume homeostasis during acute hypervolaemia.
In healthy subjects submitted to WI, the natriuresis and diuresis is 
accompanied by an increase in plasma ANP and endogenous inhibitor N a\R L 
ATPase and a decrease in SNS activity, PRA and plasma aldosterone (425,426). The 
natriuresis associated with a normal sodium intake (100 mmol/day) is significantly 
greater than that of a low sodium intake (20 mmol/day) (425).
The natriuresis and diuresis produced by WI can be blunted by DA blockade 
with metoclopramide (427,428) or domperidone (428). This finding suggests that 
the DA system contributes to the natriuretic response produced by WI.
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3.1.13 Evidence from in-vitro studies
Rat kidney slices can synthesise DA when incubated with its precursor, L- 
dopa, or the DA pro-drug, gludopa. This has been shown by histofluorescence (429) 
and biochemical studies (430-432). The DA formed is histologically extraneuronal, 
intracellular and localised in segments SI and S2 of proximal tubules in innervated 
as well as in denervated kidneys (429), However, DA fluorescence is not seen in the 
presence of a L-AAAD inhibitor (benserazide) or in the absence of sodium (429), 
suggesting that the synthesis of DA by kidney tubules is dependent on the presence 
of both L-AAAD and sodium.
In isolated rat kidney preparations, perfusion with L-dopa or gludopa results 
in an increased release of free DA into both the urine and the perfusate (431). Both 
L-dopa and gludopa also induce a concentration-dependent renal vasodilation, which 
can be abolished by the DA, antagonist, SCH-23390.
Renal tubular Na'^jK^-ATPase, which regulates sodium transport, is inhibited 
by DA (18,414,432-435). The inhibitory effect of DA on proximal tubule Na^,KA 
ATPase activity is enhanced by a high salt diet (414) or when the intracellular 
sodium concentration is increased (432). In rats, uninephretomy results in increased 
renal DA activity and DA-sensitive enhanced natriuresis (435). Apart from in the 
proximal tubule, DA inhibits Na^,K^-ATPase activity in the cells of the distal 
nephron (434). The inhibition of sodium transport in renal proximal tubules by DA 
is also exerted via the Na^-H^ exchanger at the luminal or brush border membrane 
(see Section 3.2).
In-vitro studies have also helped to identify the putative DA, receptor- 
mediated signal transduction pathways (see Section 3.2). This action is mediated via 
DA, receptors.
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3.2 The formation, actions and inactivation of intrarenal DA
3.2.1 The formation o f DA at the proximal tubule
The synthesis of DA at the proximal tubule is summarised in Figure 3 a.
Luminal side Basolateral side
L-dopa
Na"
DA
DAi receptor 
 >
L-dopa
>  Na"
L-AAAD
DA >  DA
DAi receptor 
<--------
Figure 3 a. A schematic representation depicting the formation and actions of DA
at the level of the proximal tubule.
As discussed in the text, filtered L-dopa present in the tubular lumen 
can be taken up by the proximal tubule and converted into DA. This 
DA can exit the cells and acts as an autocrine or paracrine factor. The 
stimulation of DAi receptors in the renal tubules will produce a 
natriuresis; the stimulation of DAi receptors in the renal vasculature 
will produce vasodilation and increase the GFR.
Adapted from Lokhandwala & Amenta (291).
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L-dopa from the plasma is filtered at the glomerulus
The proximal tubule cells lack tyrosine hydroxylase, the rate-limiting enzyme 
for catecholamine synthesis in neuronal tissue which is responsible for hydroxylating 
tyrosine to L-dopa (436). L-dopa necessary for DA production must, therefore, be 
supplied to the proximal tubular cells from the glomerular filtrate (or the blood from 
the peritubular space).
L-dopa is taken up into the proximal tubular cells bv active transport
Using microperfusion and capillary perfusion techniques, Chan (437) has 
shown in the rat that L-dopa is absorbed from the proximal renal tubule very avidly. 
This process is not affected by L-AAAD inhibitors, suggesting that it does not 
depend on intratubular decarboxylation mechanisms. Cyanide can block this uptake 
process, suggesting that this is an energy-dependent process.
L-dopa transporters are located both in the apical and basolateral membranes 
(291). L-dopa enters proximal tubule cells via a sodium cotransporter (Figure 3a).
The active transport of L-dopa is stimulated bv the sodium ion
As with most transport systems for amino acids, the transport of L-dopa 
across the apical and basolateral membranes of the proximal tubular cells is sodium- 
dependent and stimulated by sodium ions (438).
L-dopa inside the proximal tubular cells is converted bv L-AAAD to free DA
Once within the proximal tubular cells, the L-dopa will be exposed to the 
high concentrations of L-AAAD that exist there and will be rapidly converted to DA.
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Baines & Chan (439) injected L-dopa into the proximal tubule or peritubular 
space of innervated and denervated rat kidneys. They reported a rapid conversion of 
L-dopa to urinary free DA. There were no important differences between the 
innervated and denervated kidneys. They estimated that at least 30% of urinary free 
DA is derived from circulating L-dopa. When L-tyrosine was injected into the 
proximal tubule, they found very little conversion to urinary free DA even in the 
innervated kidney.
Rat kidney slices can synthesise DA when incubated with its precursor, L- 
dopa (Section 3.1.13). The synthesis of DA by kidney tubules is dependent on the 
presence of both L-AAAD and sodium. The latter may facilitate the uptake of L- 
dopa into proximal tubular cells (Section 3.2.2).
In the isolated rat kidney perfused with L-dopa, increased release of free DA 
into urine and perfusate is seen (Section 3.1.13).
cGMP may be involved in the regulation of DA synthesis, probably through 
the control of the entry of L-dopa and sodium into the proximal tubular cells 
(440,441). In rat kidney slices incubated with exogenous L-dopa, the addition of 
cGMP phosphodiesterase inhibitors (which prevent the degradation of cGMP) to the 
incubation medium decreases DA synthesis.
DA so formed is transported out of proximal tubular cells before it can effect a 
natriuresis and vasodilation
In order to be active, DA formed in proximal tubular cells has to leave the 
compartment where the synthesis has occurred, since the DA receptors are believed 
to be located on the external surface of the cell membrane. The outflow of newly 
formed DA in both dog and rat kidney slices loaded with exogenous L-dopa follows
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Michaelis-Menten kinetics with a saturable component and a non-saturable one, the 
latter assuming importance only at higher concentrations of DA (442).
A substantial fraction of DA formed in the proximal tubule will be secreted 
into the luminal space where it may act, via the DA, receptors, as a paracrine or 
autocrine mediator of renal haemodynamic and/or tubular function (443). DA may 
also be secreted into the peritubular space. From the peritubular space, DA can be 
transported via the capillary network and act as a paracrine factor on the basolateral 
membrane of tubular cells.
In the proximal tubule, where the most significant amount of natriuresis is 
induced, DA exerts its action via inhibition of the two principal sodium transporters: 
the basolateral Na'^-KLATPase (Section 3.1.13) and apical Na^-H^ exchanger (444).
The outward transfer of DA in renal tissues seems to involve the activation of 
a carrier-mediated process (442) and probably involves changes in the activity of the 
Na^H^ exchanger (445). While the flux of sodium ions across tubular epithelial 
cells is largely dependent on Na^-K'^-ATPase activity, the Na^-H^ exchanger on the 
luminal membrane plays a major role in the transport of sodium ions into these cells. 
This luminal Na^-H^ exchanger is thought to be responsible for the bulk of active 
sodium reabsorption in the proximal tubule. In rat kidney slices loaded with L-dopa, 
inhibition of the Na^-K^-ATPase results in a considerable reduction in the outflow of 
newly formed DA, whereas activation of the Na^-H^-exchanger facilitates the 
outflow of DA (445).
Under certain conditions (e.g. positive sodium balance and ECF volume 
expansion), renal DAg receptors may enhance the ability of DA, receptors to inhibit 
sodium transport both in the renal proximal tubule and in more distal nephron 
segment by synergistic effects on signal transducers (297).
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3.2.2 The regulation o f renal DA synthesis
Sodium intake is the most important factor regulating renal DA synthesis.
The extracellular sodium
The active reabsorption of L-dopa and other amino acids from the proximal 
tubule is a carrier-mediated process stimulated by sodium ions (438). This may be 
one of the mechanisms whereby oral (Section 3.1.7) and intravenous (Section 3.1.9) 
sodium loading and hence the local sodium concentration in the kidney can stimulate 
the renal production of free DA.
As already discussed in Sections 3.1.7 and Section 3.1.9, salt loading results 
in an increased delivery of L-dopa to sites of uptake by proximal tubular cells and 
hence an increase in free DA synthesis.
Production of free DA by renal tissues under in-vitro conditions also appears 
to be dependent on the sodium chloride concentration in the medium (431,446).
The transtubular reabsorption of sodium
If tubular sodium regulates intrarenal DA synthesis, inhibition of sodium 
reabsorption should reduce free DA production from L-dopa by the proximal tubule. 
In fact, ANP has been reported to produce a marked reduction in the synthesis of DA 
by rat kidney slices loaded with L-dopa (441). This natriuretic agent inhibits tubular 
sodium reabsorption following the activation of specific receptors. These receptors 
are coupled to guanylate cyclase, the activation of which results in an increase in 
either tissue cGMP levels or its urinary excretion (447). In rat kidney slices 
incubated with L-dopa, the addition of cGMP phosphodiesterase inhibitors or a 
cGMP derivative decreases DA synthesis (440,441). These data suggest that
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increased intrarenal accumulation of endogenous cGMP modulates tubular sodium 
reabsorption and may restrict the uptake of L-dopa by tubular epithelial cells.
Ouabain is an inhibitor of Na^-K^-ATPase, which control the net transtubular 
transport of sodium in proximal renal tubules. In rat kidney slices incubated with L- 
dopa, ouabain produces a concentration-dependent inhibition of the formation of DA 
(446), suggesting that the tubular transport of L-dopa is sodium-dependent.
The intrarenal production of DA is dependent on the integrity of the tubular 
transport of sodium, namely on the association between the actin cytoskeleton and 
Na^-K^-ATPase in tubular epithelial cells. Damage of the actin cytoskeleton leads to 
a modification in the localisation of Na'^-K'^-ATPase in the cell wall which ultimately 
results in a decrease in the tubular reabsorption of sodium (448). In rat kidney slices 
loaded with L-dopa, cytoskeleton disrupter compounds inhibit the formation of DA 
(449).
Protein intake and feeding
In healthy subjects, protein ingestion leads to an increase in urinary free DA 
excretion and natriuresis, both of which are markedly attenuated by carbidopa
(416,417). A protein meal provides an amino acid load including tyrosine, which is 
converted to dopa via tyrosine hydroxylase predominantly in peripheral tissues that 
contain catecholamine-synthesising cells such as sympathetic nerve terminals and 
chromaffin-containing tissues. Urinary DA is then produced by the action of L- 
AAAD on dopa.
Rats fed a high protein meal also show an increase in sodium and free DA 
excretion (450,451). Another study, however, has shown that feeding, but not salt 
loading, is the dominant factor controlling urinary free DA excretion in rats (452).
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Potassium intake
In normotensive elderly subjects, potassium chloride (40 mmol/day) given 
intravenously increases the urinary excretions of sodium, DA and potassium (453). 
Spironolactone given orally (75 mg/day) increases sodium excretion but decreases 
the excretion of potassium and DA. In rats maintained on a low salt diet, free DA 
excretion increases after dietary supplements of potassium chloride (306).
Calcium intake
Dazai et al. (454) studied the effects of oral calcium supplementation (1 g/day 
for one week) on renal DA activity in patients with mild to moderate hypertension. 
Urinary excretion of free DA, sodium clearance and fractional clearance of sodium 
were increased. Sodium clearance and fractional excretion of sodium showed 
significant correlations with urinary free DA. These results suggest that oral calcium 
supplements induce natriuresis partly through augmentation of renal DA activity.
Phosphate intake
Bemdt et al. (455) showed in rats that increasing dietary phosphate intake 
augments the urinary excretions of free DA and its metabolite DOPAC. They also 
showed that this increase in free DA excretion occurred whether or not the renal 
nerves were present (456).
3.2.3 Cellular signalling processes coupled to DAj receptors
The messenger systems coupled to renal DA, receptors are outlined in Figure
3b.
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DAi receptor
Gs
Adenylate cyclase Phospholipase-C
Membrane lipids IP3
PLA2
cAMP DAG
Arachidonic acid
Cyt P450
Protein kinase CProtein kinase A
20-HETE
Na^-K^-ATPaseInhibition
Brush border side Basolateral side
Natriuresis
Figure 3b. A schematic presentation of DA, receptors and associated cellular 
signalling systems in the nephron that mediate the inhibition of 
sodium-transport proteins and thereby increase in natriuresis.
The two signalling pathways, adenylate cyclase and phospholipase C, 
are linked to DA, receptors through the coupling of G proteins.
IP3, inositol triphosphate; DAG, diacylglycerol; PLAj, phospholipase 
Aj, Cyt P450, cytochrome 450 monoxygenase; Pi, phosphorylation; 
20-HETE, a metabolite of arachidonic acid.
Adapted from Hussain & Lokhandwala (296).
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In the renal proximal tubular cells, DA, receptors are coupled to both 
adenylate cyclase (457) and phospholipase-C (458). Activation of adenylate cyclase 
following stimulation of DA, receptors is followed by inhibition of the Na^-H^ 
exchanger located in the brush border membrane, whereas activation of 
phospholipase-C upon stimulation of DA, receptors is followed by an inhibition of 
Na^,K^“ATPase located in the basolateral membrane presumably via protein kinase C 
mediated phosphorylation (296). Therefore, it is likely that both pathways act 
synergistically to produce DA-mediated inhibition of tubular sodium reabsorption.
Decreased sodium reabsorption in the proximal convoluted tubule tends to be 
compensated for by increased sodium reabsorption in the downstream segments, and 
the final regulation of the amount excreted in the urine takes place in the collecting 
duct. In the rat cortical collecting duct and in Madin-Darby canine kidney cells (a 
cell line derived from the dog distal nephron), both DA and fenoldopam inhibit 
Na^,K^-ATPase activity (434). That this action of DA is mediated via the DA, 
receptors is further supported by several other studies. This action is completely 
abolished by the selective DA, antagonist, SCH-23390. The effect of DA or 
fenoldopam on Na\K^-ATPase is closely paralleled (in a reciprocal fashion) by their 
stimulation of adenylate cyclase. A role for adenylate cyclase stimulation and the 
consequent increase in cAMP in Na^,K^-ATPase inhibition is also supported by the 
finding that phosphodiesterase inhibitors inhibit the pump to a degree similar to that 
from DA stimulation.
Direct evidence that DA, receptor activation causes inhibition of Na' j^K -^ 
ATPase via stimulation of protein kinase C is provided by the work of Kansra et al. 
(459). DA and fenoldopam produce concentration-dependent increases in protein 
kinase C activity, which is blocked by SCH-23390. A high salt intake also increases
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phospholipase C activity in rat renal cortex tissue (459), and this increase is reduced 
by SCH-23390.
3.2.4 The inactivation o f renal DA
DA is metabolised by degradation (Figure 3c) or conjugation (see page 101).
DA
MAO COMT
DOPAC 3-MT
COMT MAO
HVA
Figure 3c. Major pathways for renal DA metabolism.
Renal DA can be metabolised both by deamination via monoamine 
oxidase (MAO) and by méthylation via catechol-O-methyl-transferase 
(COMT). The common end-metabolite is homovanillic acid (HVA), 
the predominant DA metabolite in the urine. Thus, the physiological 
significance of renal DA ultimately depends on its capacity to be 
regulated.
DOPAC, dihydroxyphenylacetic acid; 3-MT, 3-methoxytyramine. 
Adapted from Eklof et al. (460).
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The MAO activity in renal tissue is high (461). The COMT activity in renal 
tissue is also very high (462). These enzymes may participate in the regulation of 
renal DA availability. In rats, nitecapone, an inhibitor of peripheral COMT, induces 
a dramatic natriuresis, which is associated with inhibition of Na'^-K'^-ATPase activity 
in both the proximal convoluted and proximal straight tubules (463). Both effects 
are completely abolished by SCH-23390. Nitecapone and gludopa have an additive 
effect on the natriuretic response. Other nitrocatechol COMT inhibitors (entacapone 
and tolcapone) also markedly increase urinary sodium excretion (464). In opposum 
kidney cells, all three nitrocatechol derivatives increase cAMP accumulation and 
reduce Na^-K^-ATPase and Na^-H'" exchanger activities, this being prevented by 
SCH-23390 (464). Others have shown that inhibition of COMT results in increased 
RIF DA, urinary DA and absolute excretion of sodium (239). Combined inhibition 
of COMT and MAO increased RIF DA, urinary DA and urinary 5-HT (Section 
2.4.6), which is accompanied by increases in urine flow rate and, absolute and 
fractional excretion of sodium. COMT plays an important role in determining renal 
DA availability and hence the natriuretic effects of the renal DA system.
To prevent any unwanted effects, the excess DA from intrarenal synthesis 
may also be inactivated by conjugation with sulphate (see Section 3.1.1) or 
glucuronic acid (465).
3.3 Interactions of renal DA with other neurohormonal systems
The natriuretic and vasodilatory effects of renal DA are in part related to its 
interactions with other vasoactive systems.
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3.3.1 Bi-directional regulation o f tubular sodium reabsorption
The natriuretic (Section 2.3) and antinatriuretic (Section 2.4) neurohormones 
appear to regulate sodium excretion through a common pathway that involves 
reversible activation or deactivation of renal tubular Na'^,K'^-ATPase (463). Aperia et 
al. (18) reported in 1987 that DA inhibits the activity of proximal tubular Na^,K^ 
ATPase. Since then, this enzyme as a target for the bi-directional regulation of 
sodium transport, has been extensively studied. Other agents with a well established 
natriuretic effect, such as ANP (466), PGEj (467) and nitric oxide (468), also inhibit 
the activity of Na"^,K^-ATPase. Agents with an antinatriuretic effect, such as NA 
(469,470), AH (471), aldosterone (472), serotonin (473), insulin (474) and 
neuropeptide Y (469), stimulate the activity of this key enzyme.
3.3.2 The natriuretic agents 
Atrial natriuretic peptide
In rats, the natriuretic and diuretic effects of ANP are attenuated or blocked 
by DA antagonists (475,476) or carbidopa (476). During ANP infusion, there are no 
changes in the urinary excretion of free DA. The response to carbidopa suggests 
that, at least, background levels of endogenous DA are necessary for the full effects 
of administered ANP. Other workers reported that carbidopa or benserazide 
attenuates the natriuretic effect of ANP in ECF volume-expanded rats (477). The 
natriuretic response to ANP is restored by small doses of DA, which do not in 
themselves have a natriuretic action.
The situation is less clear in man. Wilkins et al. (478) reported that carbidopa 
partially blocks the natriuretic effect of ANP in normal subjects. However, Lewis et 
al. (479) were unable to confirm this finding. Moreover, the studies by Freestone et
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al. (480) using (+)-sulpiride and Allen et al. (481) using domperidone suggested that 
neither DA, nor DAg activation is involved in the natriuretic effect of ANP,
Studies trying to determine whether DA infusions affect ANP synthesis or 
release yielded conflicting results. Neither the studies of Shenker et al. (482) in 
healthy subjects nor Tulassay et al. (483) in premature infants showed any effects of 
DA infusions on ANP levels. However, Fontana et al. (484) could demonstrate a 
differential effect of DA infusions on plasma ANP levels in healthy subjects (an 
increase) and patients with congestive heart failure (a decrease). Hirata et al. (485) 
have shown that the effects of ANP and DA on GFR and natriuresis are additive in 
healthy subjects and in patients with essential hypertension. In contrast with DA, 
ANP increases efferent arteriolar resistance and urinary cGMP excretion, suggesting 
that the renal effects of ANP are different from those of DA.
Brismar et al. (486) recently summarised the mechanisms by which renal DA 
and ANP interact to regulate sodium excretion. They suggested that the renal tubular 
DA] receptors are, under basal conditions, mainly located intracellularly. ANP and 
its second messenger, cGMP, cause a rapid translocation of DA, receptors to the 
plasma membrane.
Renal prostaglandins
Gullner et al. (487) studied the effect of inhibition of prostaglandin synthesis 
on urinary free DA excretion in six healthy women. Indomethacin (2 mg/kg/day) for 
seven days produced a transient decrease in urinary sodium excretion, averaging 80 
mmol over three days. Urinary free DA excretion during the control period was not 
different from that during indomethacin treatment.
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Intravenous frusemide is a known stimulus for both DA and prostaglandin 
production. Jeffrey et al. (488) reported that a single dose of indomethacin 100 mg 
had no effect on the urinary DA response to frusemide in healthy males.
Yeyati et al. (489) reported that intravenous DA (6 pg/kg/min) produces renal 
vasodilation and natriuresis in healthy subjects. These effects could be reversed by 
intravenous indomethacin (2 mg/kg), suggesting that the renal effects of DA may 
depend on normal prostaglandin production. Horton et al. (490) reported that DA 
infusion (1 pg/kg/min) increases the renal blood flow and renal production of PGIj in 
healthy subjects. These renal effects could be blocked by both metoclopramide and 
cyclo-oxygenase inhibitors. However, the increase in GFR and natriuresis after 
fenoldopam infusion (Section 3.1.4) could not be blocked by cyclo-oxygenase 
inhibitors. In contrast, Jeffrey et al. (491) reported that healthy subjects given 
gludopa showed no consistent increases in urinary PGE^ output. However, urinary 
PGE2 measurements are notoriously unreliable (RL Jones, personal communication). 
Prior treatment with a single dose of indomethacin 100 mg did not alter the 
natriuresis produced by gludopa.
Yoshimura et al. (380) studied the role of renal nerves and DA on urinary 
excretion of PGE in rats with or without salt loading. In rats with renal denervation, 
urinary excretion of PGE decreased during salt loading, but urinary excretion of PGE 
and sodium was enhanced by bromocriptine, a DAj agonist. Urinary excretion of 
PGE and free DA was suppressed by carbidopa, a L-AAAD inhibitor. These 
observations suggest that renal adrenergic nerves and tubular DA in the kidney play 
an important role regarding the release of PGE, particularly during salt loading.
In isolated rat glomeruli and cultured rat mesangial cells, Barnett et al. (492) 
found that DA does not affect the rate of mesangial cell production of PGE2. Huo &
105
Healy (493) reported that rat inner medullary collecting duct cells express DAg 
receptors. When these cells are incubated with DA, there is increased production of 
PGE2. This increase can be blocked by domperidone, a DAg antagonist.
Renal kallikrein-kinin system
Little is known about the interaction between intrarenal DA and the renal 
kallikrein-kinin system. Shimamoto et al. (494) have shown an augmented response 
of urinary kallikrein-kinin and PGE2 to DA infusion in Japanese subjects with a 
family history of hypertension. Similar findings have been reported in patients with 
essential hypertension (495).
Nitric oxide
Haynes et al. (496) studied the physiological role of NO in regulation of renal 
function in humans. L-NMMA, an inhibitor of NO synthase, significantly reduced 
GFR, urine flow rate, sodium and free water excretion. Urinary excretion of nitrate 
(an index of NO release) and free DA also decreased.
Venkatakrishnan et al. (497) investigated the effect of locally generated NO 
on renal function and its potential influence on the renal responses to DA, receptor 
agonists. The intrarenal infusion of a NO synthase inhibitor, L-NAME, in rats 
produced significant decreases in urine volume, urinary sodium excretion, GFR and 
fractional sodium excretion. The natriuresis and diuresis produced by intravenous 
infusion of fenoldopam or DA were associated with increases in urinary nitrate 
excretion. These renal effects and increases in nitrate excretion due to DA, receptor 
stimulation were attenuated by L-NAME.
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These results indicate that intrarenal NO plays an important role in regulating 
renal sodium excretion (Section 2.3.5) and that an intact renal NO system is required 
for the full expression of the natriuretic and diuretic responses seen during DAj 
receptor activation.
3.3.3 The antinatriuretic agents 
Renin-angiotensin system
With its p,-adrenoreceptor or a-adrenoceptor agonist effects, DA in higher 
doses is expected to stimulate renin release (290). Furthermore, by interacting with 
the vascular DAj receptors, DA can vasodilate afferent arterioles, stimulate the renal 
baroreceptors and release renin. In contrast to fenoldopam, gludopa, which increases 
DA synthesis within the kidney, lowers PRA (290). These observations suggest that 
intrarenally generated DA, but not exogenous DA, can inhibit renin release from the 
juxtaglomerular apparatus.
Eadington et al. (498) have shown that infusion of All in sub-pressor doses in 
man reduces urinary free DA output. This reduction in DA output may contribute to 
the antinatriuresis, since the prior administration of carbidopa does not affect the 
antinatriuretic effect of AH.
Systemic and/or locally produced AH stimulates salt and water reabsorption 
in the renal proximal tubule. DA may serve as a counterregulatory hormone to A ll’s 
acute actions on the renal proximal tubule, Cheng et al. (499) tried to find out if DA 
modulates AT, receptor expression in cultured proximal tubule cells expressing DAj 
receptors. They concluded that DA, acting through DAj receptors, decreases ATj 
receptor expression in the proximal tubule, an effect likely to be mediated by 
increased intracellular cAMP levels. Local production of DA leads to decreased AT,
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receptor expression, suggesting DA may reset the sensitivity of the proximal tubule 
to AIL
Pharmacological, functional and clinical evidence indicates a role for DA in 
the activity of the adrenal cortex, primarily by regulating aldosterone secretion (500). 
In fact, DA and DAg agonists inhibit aldosterone secretion from the adrenal cortex. 
These effects are abolished by DA receptor antagonists such as metoclopramide and 
sulpiride. Metoclopramide increases plasma aldosterone levels.
In patients with mild to moderate hypertension, bromocriptine administered 
at a single dose of 2.5 mg reduced the SBP and DBP by 4.5% and 2.2%, respectively 
(501). At the same time, a 41.5% reduction in PRA and a 8.2% reduction in plasma 
aldosterone were seen. All these actions of bromocriptine could be blocked by 
metoclopramide.
Sympathetic nervous svstem
The role for endogenous DA in modulating SNS activity has been reviewed
(502.503). DAj receptor stimulation-induced vasodilation may activate the SNS and 
RAS. Activation of DAj receptors, which are found prejunctionally on sympathetic 
nerve endings and on chromafin cells, causes an inhibition of NA release from 
sympathetic nerve terminals and adrenaline release from the adrenal medulla. An 
inhibitory effect of the non-selective DA agonist ibopamine on the rise in plasma NA 
levels during exercise is found in normal man and in patients with severe congestive 
heart failure.
Infusions of DA 1 pg/kg/min, but not 3 pg/kg/min, were found to reduce the 
rise in plasma NA levels associated with cold pressor test or exercise in normal man
(503.504). This effect was abolished by pretreatment with domperidone. With the
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lower dose DA infusion, the inhibitory effects of presynaptic DA^ receptor or 
adrenoceptor stimulation on plasma NA concentration predominate. With the higher 
dose DA infusion, the inhibitory effects may be counteracted by enhanced synthesis 
and release of NA.
Mannelli et al. (505) studied the effects of presynaptic DA^ receptor blockade 
on the sympathetic-adrenal response to graded exercise in healthy subjects. Graded 
exercise caused significant increases in SBP, MAP, plasma NA plasma adrenaline 
and PRA. Pretreatment with domperidone caused a greater increase in plasma NA at 
the end of exercise and an overall increase in plasma adrenaline. These results may 
suggest that endogenous DA, by activating DAj receptors, limits catecholamine 
release during sympathetic-adrenal stimulation induced by exercise.
In patients with essential hypertension, dihydroergotoxine, a DAj receptor 
agonist, has been shown to reduce SBP and DBP, heart rate and plasma NA levels 
(506). The fall in BP correlates significantly with the decrease in plasma NA levels.
In rabbits, arterial NA concentration and total and renal NA spillover rates 
are markedly decreased in a dose-related manner by gludopa infusions (507).
In isolated proximal renal tubular cells, stimulation of Ps-adrenergic receptors 
decreases the number of high-affmity L-dopa uptake sites resulting in reduction of 
the uptake of L-dopa and the production of DA (508).
109
Chapter 4 Pathophysiological significance of renal DA in common diseases
Since renal DA may play an important role in ECF volume and BP 
homeostasis in man, any dysregulation of this endogenous natriuretic factor may 
contribute to sodium and fluid retention and their consequences such as hypertension 
and the exacerbation of cardiac failure.
4.1 Hypertension
As summarised in Chapter 3, the physiological effects of endogenous DA are 
'protective' against sodium retention and hypertension. Abnormalities in the renal 
DA system may lead to salt-sensitive hypertension.
4.1.1 Human essential hypertension
There are reports of a deficiency in the intrarenal synthesis of DA in various 
forms of human hypertension. This subject has recently been reviewed by Hussain 
& Lokhandwala (296), O’Connell & Aheme (297), Soares-da-Silva et al. (298) 
Murphy (301) and Amenta et al. (302).
Urinarv free DA outnut is reduced in established hvpertension but mav be increased 
in the earlv phases of hvpertension
Suppressed urinary free DA excretion has been reported in: (a) Caucasian 
patients with essential hypertension compared with normotensive subjects (509-511); 
(b) Japanese patients with salt-sensitive hypertension compared with normotensive 
subjects and patients with salt-resistant hypertension (512); and (c) Japanese patients
no
with low-renin hypertension compared with healthy subjects and patients with 
normal-renin hypertension (513). For example, Kjeldsen et al. (509) in Norway 
reported that 24-hour urine free DA output was 7.4% lower in hypertensive patients 
(aged 5 0 + 1  years, BP 169 ± 3 /  113 + 1 mmHg) compared with normotensive 
subjects of similar age. In Japanese patients with low-renin hypertension, the 
depressed intrarenal DA synthesis is often associated with increased renal vascular 
resistance, decreased renal plasma flow and expansion of ECF volume (514).
In contrast to the findings in older patients (aged 41.6 + 2.2 years) with mild 
to moderate hypertension (513), young Japanese patients (aged 18-27 years, SBP 
>150 mmHg or DBP >90 mmHg) had higher urinary free DA (1,920 + 80 vs 1,520 ± 
130 nmol/day, p<0.001) and NA (216 ± 11 vs 179 ± 12 nmol/day, p<0.05) outputs 
compared with age-matched normotensive subjects (515).
By measuring DA and its metabolites in plasma (DA sulphate) and urine 
(homovanillic acid) as well as its response to an intravenous injection of frusemide 
40 mg, Kuchel (516) recognised two distinct patterns in Caucasian patients with 
essential hypertension: a hyperdopaminergic state in borderline (labile) hypertension 
(BP <140/90 mmHg following four days of bed rest without medications) and a renal 
DA deficiency in stable hypertension (BP >140/90 mmHg). The borderline essential 
hypertension patients were 10-15 year's younger than the stable hypertension group. 
Approximately 20% of borderline hypertensive patients became stable hypertensives 
within 12 years. Re-investigation of these patients indicated that their renal DA 
indices changed from those typical of borderline hypertension to those typical of 
stable hypertension. It was hypothesised that the increased intrarenal DA synthesis 
in borderline hypertension may represent an early antihypertensive compensatory 
mechanism.
I l l
limura et al. (517) reported that normotensive Japanese subjects with a family 
history of hypertension have a lower urinary free DA excretion compared to those 
without a family history. The study was performed in young healthy subjects (aged 
20-30 years) after a standard diet (120 mmol sodium and 75 mmol potassium) for 
three days. On day 4, the 1-hour urinary free DA output was 18.5% lower in the 
subjects with a family history. This observation suggests that renal DA activity is 
already suppressed at the prehypertensive stage and the renal 'defect' is genetic, since 
it precedes the onset of hypertension.
In other studies, the 24-hour urinary free DA output in normotensive subjects 
with a family history of hypertension (363) or patients with borderline hypertension 
(365) was found to be similar to that of normotensive subjects without such a family 
history. However, unlike normotensive Japanese subjects without a family history of 
hypertension (aged 20.2 ± 0.2 years, DA output 1,815 ± 104 nmol/day), those with a 
positive family history (aged 19.7 ± 0.2 years, DA output 1,881 ± 118 nmol/day) did 
not show a positive correlation between their 24-hour urinary sodium and free DA 
outputs (Table 3g), suggesting that their renal DA system is altered even in the 
prehypertensive stage.
Absence of a renal DA response to salt loading
Unlike healthy subjects (see Table 3h), patients with essential hypertension 
generally do no show an increase in urinary free DA excretion following oral sodium 
loading. For example, Harvey et al. (368) in the U.K. studied eight hypertensive 
patients (aged 42 + 5 years, BP 162 + 9 / 103 ± 4 mmHg) over two weeks during 
which oral sodium intake was increased from 20 to 220 mmol/day. A paradoxical
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fall in urine free DA output followed by a return to baseline values was seen. These 
hypertensives tended to retain more sodium and have a greater increase in BP.
Others reported that urinary free DA output does not change after salt loading 
in salt-sensitive patients with hypertension, but an increase in urine DA is still seen 
in non salt-sensitive patients (369,373,512). Gill et al. (369) in the U.S. classified 19 
patients with normal-renin essential hypertension as salt-sensitive (7 whites and 1 
black, aged 61 ± 2.8 years) or salt-resistant (9 whites and 2 blacks, aged 41 ± 3.5 
years), depending whether their MAP did or did not increase by >8% when salt 
intake was increased. The responses of the two subsets and five normal subjects to 
sodium intakes of 9, 109 and 249 mmol/day each given for seven days were as 
follows. The salt-sensitive patients retained more sodium than normal subjects did 
(427 ± 33 vs 256 ± 44 mmol, p<0.01); plasma or urinary free NA did not decrease 
and urinary free DA did not increase after salt loading. The salt-resistant patients 
excreted sodium normally; their plasma and urinary NA was decreased when they 
were given a high salt intake; urinary DA did not change after salt loading. Shikuma 
et al. (512) in Japan classified 18 patients with mild hypertension as salt-sensitive 
(n=10, aged 53.5 ± 6.3 years) and salt-resistant (n=8, aged 60 ± 5.3 years), 
depending whether their MAP increased by >10% when salt intake was increased 
from 34-51 mmol/day for seven days to 341-376 mmol/day for seven days. The 
mean increase in MAP after salt loading was 16% in the salt-sensitive patients and 
2% in the salt-resistant patients. Urinary free NA decreased in both groups. Urinary 
excretion of free DA increased in the salt-resistant patients, but did not change in the 
salt-sensitive patients.
Unlike the situation with dietary salt loading, an increase in urinary free DA 
after an intravenous 0.9% saline infusion is seen in Japanese patients with essential
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hypertension (399,400) and Caucasian patients with borderline (391,518,519) or 
stable (391) hypertension. Kawabe et al. (399) in Japan studied 12 patients (aged 52 
± 2 years, DBP >95 mmHg) 10 days after a regular diet (100 mmol of sodium and 60 
mmol of potassium per day). The increase in urinary DA output after an intravenous 
0.9% saline infusion (1,500 ml over three hours) was similar to that of age-matched 
controls (Table 3k). Castellano et al. (391) in Italy studied nine patients (aged 23-58 
years) with borderline hypertension (WHO criteria) and 11 patients with established 
hypertension (aged 30-55 years) after a standard diet (120 mmol of sodium and 80 
mmol of potassium per day) for five days. Urine analysis was performed on two 
separate days: under basal conditions and after a saline infusion (2,000 ml over two 
hours). The mean increase in urinary free DA output was 14% in patients with 
borderline hypertension and 29% in patients with established hypertension; these 
changes were not statistically different from those seen in normal subjects (Table 
3k). The decrease in urinary free NA output was significantly less in patients with 
stable hypertension (6% vs 23% for patients with borderline hypertension and 18% 
for normal subjects, p<0.05). Borghi et al. (519) in Italy studied 16 patients with 
borderline hypertension (aged 23 + 1 years, DBP >90 and <90 mmHg on two of 
three occasions) after a constant daily sodium intake of 100 mmol for seven days. 
They all had a normal PRA (according to a standard nomogram relating upright PRA 
to 24-hour urinary sodium excretion). An intravenous 0.9% saline infusion (0.4 
ml/min/kg for 45 minutes, followed by 0.15 ml/min/kg for 75 minutes) resulted in a 
110% increase in urinary free DA output.
Unlike healthy Caucasian subjects without a family history of hypertension, 
those with a family history tend to show reduced natriuretic and renal DA responses 
to intravenous 0.9% saline infusion. This was seen after these subjects were on a
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low (20 mmol/day) or medium (170 mmol/day) sodium diet for the previous week 
(520). No differences were seen between those with and without a family history of 
hypertension following a high (340 mmol/day) sodium diet.
Decreased renal decarboxvlation of L-dona
The work of Gill et al. (369,373) helped define the nature of the defect in DA 
mobilisation in Caucasian patients with normal-renin essential hypertension. Sixteen 
patients were on a constant diet containing 9 mmol/day of sodium for seven days, 
followed by the same diet but containing 249 mmol/day of sodium for seven days. 
Salt-sensitivity was defined as an increase in MAP of 8 mmHg between the diets; on 
this basis, nine patients were salt-sensitive and seven, salt-resistant. The rate of 
urinary excretion of dopa was significantly higher in the salt-sensitive patients than 
in the salt-resistant patients throughout the study. When dietary salt intake was 
increased to 249 mmol/day, urinary dopa excretion increased more in salt-sensitive 
patients than salt-resistant patients. At the end of the high salt diet, DA excretion 
was significantly attenuated in the salt-sensitive patients, despite higher rates of dopa 
excretion. Thus, the urinary ratio of free DA to dopa was decreased in salt-sensitive 
patients, regardless of salt intake. These results suggest that salt-sensitive patients 
have decreased renal uptake or decarboxylation of dopa and this deficiency is 
associated with enhanced delivery of dopa to renal uptake sites during dietary salt 
loading. A higher rate of urinary excretion of dopa and a low urinary free DA/dopa 
ratio appear to be markers of salt-sensitive hypertension in humans.
Aoki et al. (521) studied the conversion of L-dopa to DA in the kidneys in 
normotensive and hypertensive Japanese subjects. Plasma dopa concentrations, 
creatinine clearance and urinary sodium and free DA outputs were measured before
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and after the single oral administration of L-dopa 400 mg in the two groups of 
subjects while on a constant diet. Dopa administration caused increases in plasma 
dopa concentrations, urinary free DA output and the fractional excretion of sodium. 
No significant differences were found in the plasma dopa concentration and the 
product of plasma dopa x creatinine clearance (which reflects the dopa delivery at 
the renal proximal tubule) between the normotensive subjects and the patients with 
normal-renin or low-renin hypertension. However, the ratio of urinary free DA to 
the product of plasma dopa x creatinine clearance (which indicates the conversion of 
dopa to DA in the kidney) was lower in the patients with essential hypertension 
(especially those with low-renin hypertension) than that in the normotensive 
subjects. These results suggest that a reduced intrarenal conversion of dopa to DA 
may contribute to the attenuated natriuresis as well as renal DA activity in low-renin 
hypertension.
Impaired intrarenal conversion of dopa to DA is also seen in Caucasian 
patients with stable essential hypertension. After the administration of a single dose 
of dopa (500 mg orally), hypertensive patients showed a greater reduction in BP, a 
lower creatinine clearance, a higher fractional excretion of sodium and a lower PRA 
than healthy subjects (522). The hypertensive patients also had higher plasma dopa 
concentrations, ratios of plasma dopa to DA and urine DA metabolite output. 
Despite an augmented glomerular load of dopa, the excretion rates of free DA and its 
metabolites remained comparable to those in the control subjects. These 
observations suggest that in patients with hypertension, less exogenous dopa is 
decarboxylated to DA and DA is metabolised more rapidly.
limura et al. (517) in Japan studied 20 young healthy subjects with (n=10, 
aged 23.0 ± 0.5 years) or without (n=10, aged 23.5 ± 0.9 years) a family history of
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hypertension. After three days on a standard diet with 120 mmol/day of sodium and 
75 mmol/day of potassium, renal clearance was measured during 1-hour clearance 
periods before and after a DA inftision (3 pg/kg/min). Blood samples were taken at 
the midpoint of the 1-hour renal clearance urine collection periods. The following 
parameters were determined: renal plasma flow, MAP, plasma dopa, urinary free 
DA, creatinine clearance and fractional excretion of sodium. Compared to subjects 
without a family history, those with a family history had a significantly larger urine 
volume (132%), urinary sodium excretion (106%) and fractional excretion of sodium 
(168%) in response to the DA infusion. No significant differences were found in the 
product of plasma dopa x renal blood flow and the product of plasma dopa x 
creatinine clearance (which reflect the dopa deliveiy at the renal proximal tubule). 
However, the ratio of urinary free DA to the product of plasma dopa x creatinine 
clearance (which indicates the conversion of dopa to DA in the kidney) was lower in 
those with a family history. These findings suggest that a reduction in the intrarenal 
conversion of L-dopa to DA already exists in the prehypertensive stage.
Consistent with a renal defect in the conversion of L-dopa to DA is the 
finding by Clark et al. (510) that Caucasian patients with essential hypertension have 
a decreased urinary free DA excretion in response to an increase in dietary precursors 
for DA supplied by a protein load (see Section 3.2.2). They studied six hypertensive 
men (aged 48-67 years, BP 140-180/90-100 mmHg) and seven healthy men (aged 
44-68 years) after two different meals: 60 g protein and a non-caloric electrolyte- 
equivalent broth. In the normotensive subjects, there was a 23% increase in urinary 
free DA output after protein feeding. In hypertensive subjects, there was no change 
in urinary free DA. In the normotensive subjects, there was a 74% increase in 
sodium excretion after the protein meal, but no significant change was seen in
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hypertensive subjects. There were no differences in renal plasma flow, GFR and 
plasma dopa between the groups before and after the protein meal.
However, features of accelerated, rather than diminished, renal DA synthesis 
are seen when patients with borderline hypertension are given L-dopa. This has been 
demonstrated by Shigetomi et al. (523) in Canada. Ten patients aged 24-51 years 
with borderline hypertension (BP returned to normal after four days of bed rest) and 
10 healthy subjects aged 19-29 years were studied while receiving a diet containing 
150 mmol sodium, 100 mmol potassium and 60 g protein per day. Basal and L- 
dopa-induced (500 mg orally) changes in BP and pulse rate as well as in 3-hourly 
plasma and urine samples were measured. They found that hypertensive patients, 
compared with controls,: (a) showed a greater dopa-induced decrease of SBP; (b) had 
an accelerated plasma DA sulphate and urinary DOPAC excretion (see Section 3.2.4) 
in response to dopa; and (c) eliminated comparable quantities of DA in urine despite 
a lower rise in the glomerular dopa load. Furthermore, dopa-induced natriuresis was 
greater in the borderline hypertensive patients. Urinary sodium excretion after dopa 
administration in the control subjects was significantly correlated with urinary free 
DA excretion (r=0.52, p<0.02). Such a correlation was not seen in the hypertensive 
patients and the dopa-induced hypematriuresis exceeded the urinary DA increase.
In patients with hypertension, the impairment of intrarenal conversion of L- 
dopa to DA may be due to a defect in L-AAAD (510,516), the enzyme that catalyses 
this conversion, or a decrease in the renal tubular uptake of L-dopa (369,373).
Up-reeulation of DA receptors and/or a change in receptor affmitv
Several observations provide support for the hypothesis of an up-regulation 
of the DA receptors and/or a change in the receptor affinity in patients with essential
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hypertension, secondary to decreased endogenous intrarenal DA production (524). 
First, the natriuretic response to DA infusion (2-3 pg/kg/min) is significantly greater 
in both Caucasian and Japanese patients with essential hypertension than in 
normotensive subjects (513,524-527). DA infusions generally lower the MAP and 
increase the heart rate in hypertensive patients but not in normotenisve controls 
(525,526). DA infusions also produce greater increases in GFR in hypertensive 
patients (525,526). Secondly, the increase in urinary cAMP output (which correlates 
with sodium excretion) in response to tubular DA receptor stimulation by DA 
infusion is more pronounced in Caucasian patients with hypertension than in healthy 
subjects (524). Thirdly, a greater increase in the urinary excretion of kallikrein and 
PGE2 is seen in Japanese patients with hypertension compared with healthy subjects 
(527). Fourthly, the antinatriuretic response to injected metoclopramide is greater in 
Japanese patients with low-renin hypertension, when compared with normal-renin 
hypertensive patients and normotensive subjects (513).
Japanese patients with low-renin hypertension show greater increases in 
urinary excretion of sodium (525,527), kallikrein and PGE^ (527) to DA infusions, 
when compared with patients with normal-renin hypertension and healthy subjects. 
After the oral administration of L-dopa, BP falls but sodium excretion and GFR 
increase in both normotensive and hypertensive subjects; these responses are greater 
in borderline hypertensive patients than healthy subjects (523) and in salt-sensitive 
hypertensive patients compared to salt-resistant patients (528).
Augmented responses to a DA infusion (3 pg/kg/min) are also seen in 
healthy Japanese subjects with a family history of hypertension when compared to 
subjects without a history (494,517,527). Both the natriuretic response and the 
increase in urinary kallikrein activity are greater.
119
A recent study by O’Connell et al. (529) also provides support for the theory 
that DAj (Drlike) receptor up-regulation occurs in patients with essential 
hypertension. The up-regulation of DA, receptor function takes place in the distal 
tubules and not in the proximal tubules. Such an up-regulation of the DAj receptor 
in the distal tubules offsets the defect in the proximal tubules, leading to natriuresis 
and diuresis in response to fenoldopam.
A defect in the coupling of the DA  ^ receptor and its messenger system, 
adenylyl cyclase (Section 3.2.3) has recently reported in the primary cultured cells of 
hypertensive human proximal tubules (530). This defect is receptor-specific. A DAj 
receptor/adenylyl cyclase defect in human proximal tubular cells is similar to the 
defects found in the proximal tubules of some animal models of genetic hypertension 
(see Section 3.1.4).
4,1.2 Hypertension associated with obesity
Salt sensitivity in obese subjects may be due to the combined effects of 
hyperinsulinaemia, hyperaldosteronism, increased SNS activity and impaired renal 
DA activity (531,532).
In obese Japanese patients with essential hypertension, the body mass index 
(BMI) correlates positively with the MAP, plasma volume, ECF volume and total 
exchangeable sodium, and negatively with plasma NA concentration and PRA (532). 
The fi*actional excretion of sodium, which reflects renal tubular reabsorption of 
sodium, is significantly lower in obese patients than in normal weight patients with 
essential hypertension. The hypotensive effect of salt restriction and the natriuretic 
response to DA infusions are more pronounced in overweight than in normal weight 
patients. Urinary firee DA excretion correlates positively with the BMI in normal
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weight patients. In contrast, there is a negative correlation between BMI and urinary 
free DA excretion in overweight patients. In obese patients with essential 
hypertension, sodium retention and ECF volume expansion may be due to attenuated 
renal DA activity.
4.1.3 Association o f dopamine receptor gene polymorphism with hypertension
The human DA D1 receptor (DRDl) gene has been localised to chromosome 
5 at q35.1 (533). A polymorphism, A-48G, has been identified at —48 bp of the 5' 
untranslated region (534). Sato et al. (535) performed an association study in 131 
patients with essential hypertension and 136 age-matched normotensive controls. 
Polymerase chain reaction was used to amplify the A-48G polymorphic site in the 
DRDl gene, and restriction analysis of the polymerase chain reaction product was 
used to score the A and G alleles. G allele was observed more frequently in patients 
with hypertension (16% vs 8%, p=0.01). DBP was higher in the A/G  patients than in 
the A/A patients (115 ± 15 vs 106 ±11 mmHg, p<0.01). The A-48G polymorphism 
in the 5" untranslated region of the DRDl gene was associated with essential 
hypertension in Japanese subjects.
My colleagues have studied the association between DA D2 receptor (DRD2) 
gene Taq\ polymorphism, BP and obesity in Hong Kong Chinese (536). They 
recruited 209 non-diabetic hypertensive and 174 gender-matched normotensive 
subjects. The hypertensives had increased BP (149 ±18 /8 9  ±11 vs 113 + 9 /6 6  + 
9 mmHg, p<0.001), increased dyslipidaemia, and a greater degree of obesity (BMI 
25.8 ± 3.8 vs 23.3 ±3.6 kg/m^, p<0.001). The A1 and A2 alleles of the DD2R gene 
Taql polymorphism were identified using a polymerase chain reaction-based 
restriction fragment length polymorphism protocol. The A1 allele frequency was
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decreased in the hypertensives compared with controls (42 vs 52%, p=0.006). In the 
combined population, SBP, DBP and MAP were 6, 5 and 6 mmHg lower, 
respectively, in subjects with A lA l genotype relative to the A2A2 genotype 
(p<0.05), whereas skinfold thickness was increased at the iliac (p<0.001) and triceps 
(p<0.03) sites.
4.1.4 Rat models o f hypertension
Studies using Dahl salt-sensitive rats and SHR also provide evidence for a 
defect in the renal DA system having an aetiological role in salt-sensitive 
hypertension (296).
Dahl salt-sensitive rats excrete sodium poorly in response to a sodium load. 
The kidney DA content is decreased in salt-sensitive rats fed a high salt diet (537). 
Urinary DA excretion does not increase in salt-sensitive rats subjected to acute ECF 
volume expansion (538). Urinary DA and cAMP excretions are reduced in salt- 
sensitive rats compared with Wistar rats fed a normal salt diet (514).
A defect in the DAj receptor has also been reported in the proximal tubules of 
Dalt salt-sensitive rats. In normotensive rats, when endogenous DA is allowed to 
accumulate through the use of a DA |3-hydroxylase inhibitor, which inhibits DA 
conversion to NA, down-regulation of proximal tubular DAj receptors and complete 
ablation of DA  ^ receptor mediated stimulation of adenylyl cyclase activity occurs 
(538,539). The DAj receptors in salt-sensitive rats are resistant to such effects. A 
high salt intake for 10 days down-regulates Na^-K^ -ATPase activity in the proximal 
tubules of salt-resistant rats and this is reversed by the L-AAAD inhibitor, 
benserazide (540). In contrast, a high salt intake does not affect Na^-K^-ATPase 
activity in salt-sensitive rats apparently because of a defective DA, receptor mediated
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cellular signaling mechanism. DAj agonists are unable to stimulate adenylyl cyclase 
in the proximal tubules from salt-sensitive rats, whereas direct stimulation of the 
enzyme by forskolin has the same effects in salt-sensitive and salt-resistant rats 
(541).
In SHR, DA production and excretion is normal or even increased (542). In 
spite of normal DA receptor density, DA and fenoldopam-mediated natriuretic 
responses are diminished under normal conditions, as well as during acute ECF 
volume expansion (543,544).
DAi agonists stimulate adenylyl cyclase activity to a lesser extent in the 
proximal tubules of SHR compared with normotensive Wistar rats (545). Further 
studies revealed that the defect resides in the coupling of the receptor with adenylyl 
cyclase. The defect is nephron segment-specific (only in the proximal part) and 
organ-specific (only in the kidney) (26). The stimulation of another signaling 
system, phospholipase C (Section 3.2.3), by DA  ^agonists is also reduced in SHR.
Thus, in SHR, in spite of normal renal production of DA and DA receptor 
density, there is defective transduction of the DA  ^ receptor signal in the proximal 
tubules, resulting in decreased inhibition of sodium transport (Na^-K^-ATPase and 
Na^-H^-exchanger activity) by DA.
In obese hypertensive rats, reduction in DA; receptom numbers and a defect 
in receptor-G protein coupling may account for the inability of DA to activate DA, 
receptor-coupled signal transduction pathway and cause inhibition of Na^-K^- 
ATPase (546).
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4.1.5 The role o f DA receptors in the pathogenesis o f hypertension
Albrecht et al. (547) studied the role of the DAj^ receptor in the pathogenesis 
of genetic hypertension in the F2 generation from female Wistar-Kyoto rat and male 
spontaneously hypertensive rat crosses. A DA; agonist inhibited Na^-H^-exchanger 
activity in brush border membrane samples from normotensive F2s but not 
hypertensive F2s. A DA; agonist, when infused into the renal artery, increased 
sodium excretion in normotensive F2s but was inactive in hypertensive F2s, SBP 
was higher in the homozygous and heterozygous rats compared to normal controls. 
Moreover, the rats lacking one or both DAj^ alleles developed diastolic 
hypertension. The co-segregation with hypertension of impaired DA; receptor 
regulation of renal sodium transport and the development of elevated SBP and DBP 
in rats lacking one or both DA;^ alleles suggests a causal relationship of the DA,a 
receptor gene with hypertension.
Asico et al. (548) studied the cardiovascular consequences of the disruption 
of the D3 receptors (a member of the family of DAj receptors) expressed in renal 
proximal tubules and juxtaglomerular cells. Mice lacking the D3 receptors (mutant 
mice) were generated by target mutagenesis. Both the SBP and DBP was higher in 
heterozygous and homozygous than in wild-type mice. Saline infusions increased 
urine flow rate and sodium excretion to a similar extent in wide-type and 
heterozygous mice, but these responses were attenuated in homozygous mice. PRA 
was much higher in homozygous than in wild-type mice; values for the heterozygous 
mice were intermediate. Blockade of AT; receptors decreased SBP for a longer 
duration in mutant than in wide-type mice. Thus, disruption of the D3 receptor 
increases renal renin production and produces renal sodium retention and renin- 
dependent hypertension.
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4.2 Chronic renal diseases
In chronic renal diseases, sodium retention and hypertension are common and 
may be due to abnormalities in intrarenal DA synthesis. Pestana et al. (549) have 
recently reviewed renal dopaminergic mechanisms in renal parenchymal diseases 
and hypertension.
Chronic renal parenchymal diseases are accompanied by a progressive loss of 
tubular units endowed with the ability to synthesise DA from L-dopa. Therefore, 
large reductions in the urinary excretion of free DA are seen in patients with chronic 
renal failure (550-553). There is a strong, negative correlation between the urinary 
excretion of free DA and the GFR (551-553). Urine free DA excretion is similar in 
patients with glomerular or tubulo-interstitial diseases (551). Urinary free DA 
excretion increases markedly in renal failure patients following renal transplantation 
(552). The recovery of renal function in renal transplant recipients is accompanied 
by an enhanced ability to synthesise DA and inactive it to DOPAC and HVA (554). 
Casson et al. (367) noted that patients with chronic renal diseases and varying 
degrees of renal impairment do not show the expected increase in urinary free DA 
excretion after oral salt loading. Smit et al. (555) reported that the response to DA 
infusions (0.25-8 pg/kg/min) is blunted in patients with renal failure (GFR 34-85 
ml/min).
Pestana et al. (553) showed that the reduced urinary free DA output in renal 
failure is not attributable to the enhanced metabolism of renal DA. The daily urinary 
outputs of L-dopa, free DA and its metabolites, DOPAC and HVA, in conditions of 
controlled sodium, potassium and phosphate intakes were compared in two groups of 
patients (average GFR in group 1 and group 2 is 39 and 139 ml/min/1.73 m^). Group 
1 showed a 60% reduction in the urinary excretion of L-dopa, DA and DOPAC and a
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40% reduction in HMA excretion. A positive linear relationship was seen in the two 
groups between the GFR and daily urinary outputs of L-dopa, DA, DOPAC and 
HVA. The urinary DA:L-dopa and DOPAC:DA ratios were similar in both groups. 
Hence, the reduced urinary free DA output in renal failure is attributable to decreased 
intrarenal DA synthesis.
Kuchel & Shigetomi (556) suggested that in patients with hypertension and 
moderate chronic renal failure, renal DA deficiency may have a potential role in 
perpetuating renal failure via glomerular hypertension.
The beneficial effects of dopaminergic drugs in the long-term treatment of 
patients with progressive renal failure have been confirmed (354).
In autosomal dominant polycystic kidney disease (ADPKD), hypertension is 
often observed before the loss of renal function. The role of intrarenal DA in relation 
to sodium homeostasis was studied by Barendregt et al. (557). ADPKD patients 
with borderline hypertension and near normal renal function and matched healthy 
subjects were studied at three levels of daily sodium intake: 150, 50 and 450 mmol. 
At all levels of sodium intake, cumulative sodium balance was similar, but daily 
urinary outputs of DA and dopa were higher in ADPKD patients. Renal vascular 
resistance, filtration fraction and BP were also higher in ADPKD patients. During 
the 450 mmol sodium intake period, the effects of a L-dopa inftasion (7 pg/kg/min) 
were studied. The L-dopa infusion appeared to 'normalise' the patients’ renal 
haemodynamics resulting in a stimulation of natriuresis similar to that of the 
controls. These results suggest that: (a) increased intrarenal DA production, as a 
mechanism to maintain sodium homeostasis, occurs in borderline hypertensive 
APPKD patients; and (b) DA agonists, by 'normalising' renal haemodynamics, may 
be beneficial to these patients.
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In patients with IgA nephropathy and near normal renal function, the changes 
in 24-hour mean BP when going from low to high sodium intake (from 20 to 350 
mmol/day) correlated negatively with the daily excretion of DA (r=0.77, p<0.01) 
(558). The urinary excretion of L-dopa and DA in salt-sensitive patients was lower 
than in salt-resistant patients , irrespective of their daily sodium intake. The rise in 
urinary DA output during salt loading (from 20 to 350 mmol/day) was greater in salt- 
sensitive patients than in salt-resistant patients (21.2 ± 2.5% vs 6.3 ± 1.4% increase, 
p<0.05).
Cyclosporin A is a potent immunosuppressant used for organ and tissue 
transplantation to prevent graft rejection and graft-versus-host disease. This drug is 
markedly nephrotoxic and may cause hypertension. Administration of cyclosporin A 
to rats produces an increase in BP, a reduction in urinary excretion of sodium, free 
DA, DOPAC and HVA (559). These reductions appear to result from a fall in the 
amount of L-dopa made available to the kidney and do not involve changes in 
tubular L-AAAD and DA metabolism.
4.3 Congestive heart failure
As cardiac performance declines in patients with congestive heart failure, 
various neurohormonal systems are progressively stimulated in an attempt to 
maintain sufficient blood flow to peripheral organs (560). This may result in further 
progression of the heart failure with sodium and water retention (561). The inability 
to excrete ingested sodium is a well recognised feature of congestive heart failure 
(562).
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When the daily sodium intake in patients with mild, asymptomatic heart 
failure is increased from 100 to 250 mmol, both the left ventricular end-diastolic and 
end-systolic volume increases, whereas the ejection fraction and stroke volume fail 
to increase and the total peripheral resistance fails to decrease (563). These patients 
also have a higher cumulative sodium balance than healthy subjects.
An interesting finding of Lang & Kaufinann (564) on the urinary excretion of 
DA in patients with New York Heart Association (NYHA) classes II, III and IV heart 
failure suggests the possibility of a compensatory role of DA in mild heart failure, 
the efficiency of which may be reduced in severe cases. The mean urinary excretion 
of DA was increased to 12,407, 9,142 and 6,530 nmol/day in class II, III and IV 
patients, respectively. It returned to the normal range of 2,612-5,224 nmol/day when 
the heart failure was treated adequately. Similar results have been reported by 
Asakura et al. (565) in classes III and IV patients (free DA excretion falling from 
15,855 to 3,454 nmol/day following treatment). They also found a marked increase 
in urinary free DA within 24 hours after the onset of the symptoms of heait failure.
Hayashi et al. (566) studied the urinary free DA excretion, the delivery of L- 
dopa to the renal proximal tubules (plasma L-dopa x creatinine clearance) and the 
intrarenal conversion of L-dopa to DA (the ratio of urinary free DA to the product of 
plasma dopa x creatinine clearance in 30 patients with congestive heart failure and 12 
normal controls. With increases in NYHA functional class, urinary free DA, plasma 
L-dopa, delivery of L-dopa and intrarenal DA production fell progressively. Urinary 
sodium excretion (r=0.46, p<0.05) and creatinine clearance (r=0.54, p<0.01) 
correlated positively with urinary free DA. Linear correlations were seen between 
left ventricular ejection fraction and urinary free DA (r=0.57, p<0.01), plasma NA 
(r=0.50, p<0.01) or plasma L-dopa (r=0.42, p<0.05). These results suggest that in
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patients with heart failure, both the delivery of L-dopa to the proximal tubules and its 
conversion to DA within the kidney are suppressed.
Ferreira et al. (567) studied post-acute myocardial infarction patients with or 
without asymptomatic left ventricular systolic dysfunction (ejection fraction <40%). 
Patients with left ventricular systolic dysfunction had lower urinary excretion of L- 
dopa (66,8 ± 10.1 vs 115.3 ± 21.9 nmol/day, p=0.04). Urinary free DA was similar 
in the two groups (1,124 ± 172 vs 1,049 ±146 nmol/day), resulting in higher urinary 
DA/L-dopa ratios in patients with left ventricular systolic dysfunction (20.4 ± 3.0 vs 
9.9 ± 0.8, p<0.001). Ejection fraction was negatively correlated with urinary DA/L- 
dopa ratios. Renal DA synthesis is well preserved in patients with asymptomatic left 
ventricular systolic dysfunction, despite reduced urinary excretion of its precursor. 
This suggests that renal uptake and/or decarboxylation of L-dopa is enhanced in this 
condition, as a compensatory mechanism, contributing to preservation of urinary 
sodium excretion.
There are good theoretical reasons for the use of dopaminergic drugs in the 
treatment of congestive heart failure (Section 3.1.3, Section 3.1.4 and Section 3.1.5). 
Although the prognoses of these patients have not been shown to improve after the 
long-term use of ibopamine (Section 3.1.5), these drugs are still very valuable in the 
acute management of heart failure because of their beneficial effects on renal and 
systemic haemodynamics and sodium and water excretion. In particular, low-dose 
DA may have a renal-protective effect during vigorous diuretic therapy for 
congestive heart failure associated with mild or moderate renal insufficiency (568). 
As already mentioned earlier (Section 3.1.3), low-dose DA is not always natriuretic, 
depending whether the antinatriuretic systems are 'overactive' after the development 
of hypovolaemia. That may be the reason why DA infusions are not particularly
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useful in elderly heart failure patients already receiving high dose loop diuretics 
(569).
4.4 Diabetes mellitus
Diabetes mellitus and hypertension often coexist. In our surveys of adults 
attending specialist clinics at the Prince of Wales Hospital, about half of Chinese 
diabetic patients (predominantly NIDDM) have hypertension (570,571). In contrast 
to western countries where coronary artery disease is the main cause of mortality in 
diabetic patients, renal failure and strokes are the leading causes of death in Hong 
Kong Chinese diabetics (572).
Diabetes mellitus is characterised by a tendency to sodium retention. An 
increase in total exchangeable sodium has been shown in both normotensive and 
hypertensive diabetic patients (573,574). The natriuretic response to salt loading is 
impaired in diabetic patients (575,576). Diabetic patients, particularly those with 
nephropathy, are often salt-sensitive (279,576). Diabetic patients with hypertension 
respond well to moderate restrictions of salt intake (576,577). Cardiovascular 
pressor responsiveness to NA and AH may be exaggerated in diabetic patients (578). 
Thus, the hypertension accompanying diabetes mellitus involves abnormalities in at 
least two major BP-regulating systems: the body sodium-fluid volume state and 
cardiovascular reactivity.
Since IDDM patients given an intravenous saline infusion have a higher GFR 
but a lower sodium excretion than healthy controls, enhanced tubular reabsorption of 
sodium rather than impaired filtration is suspected (575). It was subsequently 
confirmed that some IDDM patients have increased sodium reabsorption at the
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proximal renal tubule (579), which is also the site of action of intrarenal DA and may 
reflect a deficiency of DA synthesis and action. The renal sodium-DA relationship 
in diabetic patients has since been extensively investigated.
NIDDM patients
Murabayashi et al. (580) in Japan studied the urinary excretion of free DA in 
21 NIDDM patients (aged 54.8 ±1.9 years) and six normal subjects (aged 48.8 ± 4.8 
years) after receiving a standard diet (150 mmol sodium and 50 mmol potassium per 
day). Diabetic patients with a poor control (2 hour postprandial blood glucose >13.8 
mmol/L), obesity (BMI >27 kg/m^) or hypoalbuminaemia (serum albumin <30 g/L) 
were excluded. Twelve diabetic patients had nephropathy (albumin excretion >200 
mg/day). SBP was higher in diabetics with nephropathy (155.0 ± 2.4 mmHg) than in 
diabetics without nephropathy (117.6 ± 9.4 mmHg) and healthy subjects (122.0 ±1.0 
mmHg). Urinary free DA output was lower in diabetics with nephropathy (342 ±58 
nmol/day) than in diabetics without nephropathy (859 ± 108 nmol/day) and in 
healthy subjects (1,173 ± 101 nmol/day). Multiple regression analysis revealed that 
the 24-hour urinary excretion of DA correlated significantly with the creatinine 
clearance as well as the SBP and DBP. The results indicate that renal DA synthesis 
may decrease as diabetic nephropathy progresses.
My colleagues (581) at the Chinese University of Hong Kong studied the 
relationships between plasma ANP, urinary DA, BP and albuminuria in 165 Chinese 
patients with NIDDM treated by diet or oral hypoglycaemic drugs. In group 1, 88 
patients had normoalbuminuria (urinary albumin excretion <30 mg/day). In group 2, 
48 patients had microalbuminuria (30-300 mg/day). In group 3, 29 patients had 
macroalbuminuria (>300 mg/day). Supine BP was higher in patients with abnormal
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albuminuria (140.9 ± 2.9 mmHg in group 1, 158.1 ± 3.8 mmHg in group 2, 166.7 ±
4.4 mmHg in group 3, p<0.001). The 24-hour urinary sodium output was similar in 
the three groups. Mean plasma ANP concentrations increased with increasing 
proteinuria (33.3 pg/ml in group 1, 39.1 pg/ml in group 2 ,5 0  pg/ml in group 3, 
p<0.01). Mean 24-hour urinary free DA output was inversely related to proteinuria 
(1,292 nmol in group 1, 1,142 nmol in group 2, 983 nmol in group 3, p<0.05). In 
patients with albuminuria >30 mg/day, plasma ANP was negatively correlated with 
urinary DA output (r=-0.25, p<0.02). It was hypothesised that, in patients with 
NIDDM, defective DA mobilisation in the renal tubules may cause impaired 
natriuresis with increased BP and a compensatory rise in plasma ANP.
Segers et al. (582) in Belgium studied the renal sodium-DA relationship in 72 
NIDDM patients without proteinuria (aged 55 ± 1.4 years, HbAn, 10.0 ± 0.2%, BMI 
30.0 ± 0.6 kg/m^). All had a GFR >90 ml/min. Basal urinary free DA excretion 
during a 200 mmol sodium diet was reduced in the diabetic males (non-insulin 
treated 992 ± 26, insulin treated 866 ± 24 nmol/g creatinine) and females (non­
insulin treated 1,328 ± 27, insulin treated 1,070 ± 22 nmol/g creatinine) compared 
with the normal ranges for males (1,196 ± 28 nmol/g creatinine) and females (1,438 
± 26 nmol/g creatinine). No correlation was present between urinary free DA and 
the BMI, age, duration of diabetes, HbAjc or the presence or absence of hypertension. 
As in healthy controls, a significant correlation between urinary free DA and 
fractional excretion of sodium was seen in the non-insulin treated patients (r=0.30, 
p<0.04) but not in diabetics treated by insulin. In diabetic patients, an intravenous 
infusion of 0.9% saline (120 ml over 5 minutes, then 600 ml over one hour) induced 
a progressive natriuresis that was comparable to that of the healthy subjects. In 
healthy subjects, urinary free DA excretion increased up to 136 ± 12%. However, in
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the NIDDM patients, no increase in urinary free DA was seen. The insulin treated 
patients actually showed a reduction in urinary free DA 30 minutes after the saline 
infusion. DA infusion (3 pg/kg/min) for one hour induced an increase in sodium 
excretion that was less pronounced in the diabetic patients than in the controls. The 
natriuretic response was the lowest among the insulin-treated patients. These results 
suggest that NIDDM patients display a derangement of their renal DA system, which 
is accentuated by insulin treatment.
Shigetomi et al. (583) in Japan studied the cardiovascular and renal DA 
responses to the ingestion of 100 g protein in NIDDM patients. Both patients and 
healthy controls showed an increase in GFR, but the expected increase in fractional 
excretion of sodium was seen only in the controls. Since the increase in urinary L- 
dopa was blunted in the patients, the impaired natriuretic response to protein feeding 
may result from a decreased intrarenal DA synthesis.
IDDM patients
In their study of 48 IDDM patients (aged 25-38 years), Patrick et al. (362) in 
the U.K. found no evidence of a defect in the mobilisation of renal DA prior to the 
development of hypertension or overt nephropathy. All 48 patients had a creatinine 
clearance >80 ml/min, but 11 had microalbuminuria (albumin/creatinine ratio >3 
g/mol). The 24-hour urinary sodium output in diabetic patients with (albumin 
excretion 44-248 mg/day) or without (3-22 mg/day) microalbuminuria did not differ 
from the 40 healthy controls (165 ± 16 and 160 ± 10 vs 173 ± 9 mmol, p=NS). Their 
24-hour urinary free DA output was also similar (1,450 ± 89 and 1,632 ± 72 vs 1,572 
± 72 nnmol, p=NS). Moreover, both diabetic patients and healthy subjects showed a
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significant correlation between urinary free DA and sodium (r=0.80, p<0.01 and
1- 0.44, p<0.01 vs r=0.51, p<0.001; p=NS for within group comparison).
Madacsy et al. (584) in Hungary reported that IDDM children with (albumin 
excretion 101-288 mg/day) or without (<29 mg/day) incipient nephropathy had 
lower mean urinary excretion of free DA (165.2 and 430.3 nmol/day) and sodium 
(98.4 and 206.2 mmol/day) than age-matched healthy controls (478.6 nmol/day and
198.1 mmol/day). BP was higher in the children with incipient nephropathy than in 
controls. These results suggest that a decrease in endogenous DA can play a role in 
sodium retention which may in turn lead to the development of hypertension in 
children with incipient diabetic nephropathy.
Segers et al. (585) in Belgium also found that the 24-hour urinary free DA 
output was lower in IDDM patients compared with controls. A significant 
correlation between urinary free DA and sodium excretion was present in 
normoalbuminuric patients and in controls, but not in patients with 
microalbuminuria. Patients with a relatively short duration of diabetes (<15 years) 
had a comparable DA infusion-induced increase in fractional excretion of sodium as 
normal controls. However, patients with a longer duration of diabetes (>15 years) or 
microalbuminuria displayed no significant changes in sodium output during DA 
infusion.
Rudberg et al. (371) in Sweden studied the renal DA response to a high salt 
diet (usual intake with additional 103 mmol/day for three days) in 16 IDDM 
adolescents with normal BP and albumin excretion rates. The average increase in 
sodium excretion tended to be lower than in healthy controls, implying a sluggish 
response and a degree of sodium retention. A 4.4% increase in SBP was seen in the 
patients, but not in the controls. Furthermore, free DA excretion rose significantly in
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the control subjects (Table 3h), but not in the IDDM patients. Thus, a positive 
correlation between the changes in DA and sodium output was found in the controls, 
but not in the patients. This suggests an impairment in the renal DA system in 
IDDM patients despite the absence of nephropathy or hypertension.
Stenvinkel et al. (393) in Sweden studied the renal DA response to a 2 hour 
0.9% NaCl infusion (25 ml/kg) in eight men (aged 2 7 + 1  years) with uncomplicated 
IDDM. The maximum increase in sodium excretion was reduced in the patients 
compared with healthy controls (47.6 vs 92.2%). The fractional proximal tubular 
sodium reabsorption decreased in the controls but not in the patients. Fractional 
distal tubular reabsorption decreased similarly in both groups. Urinary free DA 
excretion increased by about 15% in the controls (Table 3h) but did not change in the 
patients. The mean urinary DA excretion above baseline was greater in the controls 
(8.4 + 2.1 nmol/h) than in the patients (-2.2 ± 2.1 nmol/h). Plasma ANP also 
increased in the controls but not in the patients. These results suggest that IDDM 
patients have a blunted natriuresis in response to ECF volume expansion with saline 
infusion. This abnormality seems mainly to be due to impaired inlribition of 
proximal tubular sodium reabsorption, which may be the result of defective 
intrarenal DA mobilisation.
Since ACE inhibitors can facilitate renal sodium excretion and All infusions 
may reduce urinary free DA excretion in IDDM patients, Stenvinkel et al. (394) in 
Sweden studied the effects of ramipril on the natriuretic and renal DA responses to a
2-hour 0.9% NaCl infusion (12.5/kg/h) in nine patients (aged 28 + 3 years, HbAj .^ 8.4 
± 0.7%, BP 127 ± 4/84 ± 3 mmHg) with early nephropathy (249 ± 56 mg/day) and 
15 healthy controls (Table 3h). The diabetic patients had a higher basal renal 
perfusion pressure than the controls. Following two days of ramipril treatment, a
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decrease in basal renal perfusion pressure was seen. ACE inhibition was claimed to 
improve natriuretic responses due to a normalisation in proximal tubular sodium 
handling. A blunted increase in urinary free DA excretion was seen in IDDM, which 
tended to normalise following ACE inhibition. These results suggest that IDDM 
patients with early nephropathy display abnormalities in renal haemodynamics, 
natriuresis and urinary DA mobilisation in response to a sodium load, which can be 
reversed by short-term inhibition of ACE (394).
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Chapter 5 Renal sodium-DA relationships in normotensive and hypertensive 
Chinese
5.1 Background of the study and main objectives
If DA is an important intrarenal natriuretic hormone and dietary sodium is the 
major determinant of its intrarenal synthesis, there should be a positive correlation 
between 24-hour urinary sodium and free DA output (Section 3.1.6). Indeed, this 
has been reported in Caucasians, Japanese, Thais and Zimbabweans (Table 3g).
A direct relationship between 24-hour urinary sodium and free DA outputs is 
not seen in West Africans and Iranians, ethnic groups from regions with intense heat 
and, previously, a salt-scarce environment (Section 3.1.6). The evolutionary benefit 
of diminished salt excretion from an inability to mobilise renal DA is obvious 
(Section 1.3). However, the genes that previously protected against salt depletion are 
a disadvantage in modem times when salt is readily available. Individuals with an 
inability to mobilise renal DA in response to increases in salt intake (Section 3.1.7) 
will be prone to salt retention and even hypertension (Section 2.5).
Chinese have been living in a salt-abundant environment for centuries and 
subjects living in Hong Kong have a higher salt intake now than in previous times 
(Section 1.6). It is interesting and important to find out whether they have an 
efficient renal DA system. Hypertensive subjects and their first-degree relatives are 
more likely to be salt-sensitive (Section 2.6), possibly due to a deficient renal DA 
system (Section 4.1.1). Whether this is also the case in Chinese was not known.
In the two cross-sectional studies now described, my main objective was to 
determine if there is a positive correlation between 24-hour urinary sodium and free 
DA outputs in normotensive Chinese subjects with or without a family history of
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hypertension and patients with essential hypertension. These studies were performed 
during 1989-1991 and 1996-1998. There was a need for the second study because of 
the changes in classification of hypertension (586) and the recommended choice of 
BP measurement device (Section 5.2.2) since the first study. Also, our assay could 
now measure urinary DA and kallikrein simultaneously (Section 5.2.4). The greater 
number of subjects recruited in the second study also enabled me to investigate the 
interrelationships between urinary cations and free DA and kallikrein outputs in both 
normotensive subjects and patients with hypertension.
5.2 Subjects and methods
These cross-sectional studies had been approved by the Clinical Research 
Ethics Committee of the Chinese University of Hong Kong.
5.2.1 Subjects
All the healthy subjects and patients with hypertension were recruited during 
the cooler months of 1989-1991 and 1996-1998. The hot summers were avoided 
because of the problem of increased sodium loss from sweating and uncertain effects 
of high environmental temperature on the stability of catecholamines during urine 
collections (587). Informed consent was obtained from the participants after the 
nature and purpose of the study were explained.
Studv one. As part of my study of the association between BP and sodium 
and potassium intakes (29), 96 healthy Chinese subjects aged 20-65 years were 
randomly recruited mainly from the community, but also from the staff of the Prince 
of Wales Hospital and medical students. They all had BP below 140/90 mmHg. In
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addition, 24 patients with essential hypertension but no other diseases were recruited 
from our medical clinics at the Prince of Wales Hospital. They were either untreated 
or had been off antihypertensive drugs for at least two weeks. They all had SBP 
>160 mmHg and/or DBP >95 mmHg. Their renal function tests, fasting blood 
glucose and urinalysis were all normal.
Studv two. As part of our studies of the metabolic syndrome (588), 85 
healthy Chinese subjects aged 26-60 years were recruited at random mainly from the 
staff of the Prince of Wales Hospital and their friends. Their BP was all <120/80 
mmHg. Their renal function tests, fasting blood glucose and lipid profiles were all 
normal. In addition, 47 patients with essential hypertension but no other diseases 
were recruited from our medical clinics. They were either untreated or had been off 
treatment for at least four weeks. They all had BP above 140/90 mmHg. Their renal 
function tests, fasting blood glucose and lipid profiles were all normal.
5.2.2 BP measurement
All these participants attended our Clinical Pharmacology Studies Unit at the 
Prince of Wales Hospital as out-patients for BP measurements.
Studv one. Sitting (after 5 minutes) BP was measured on three occasions by 
a research nurse, using a Hawksley random-zero sphygmomanometer. [This device 
was originally chosen with the view to reduce the bias of multiple readings per 
person (589). It is now known to underestimate systolic readings by 2.0-3.7 mmHg 
(590).] An average of the three readings was taken as the subject’s BP. Phase V 
DBP was used. In six of the patients with hypertension recruited in 1991, BP was 
measured by a semi-automatic sphygmomanometer (Dinamap), which had become 
the standard equipment for hypertension-related studies in our Department.
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Studv two. Sitting (after 5 minutes) BP was measured at one-minute interval 
by a Dinamap. An average of three readings was taken as the subject’s BP.
5.2.3 Urine collections and measurment o f urinary cations and creatinine
All the participants were asked to provide one 24-hour urine collection while 
on their usual diets, but alcohol and medications were avoided. Clear instructions on 
the need and the method for complete collection were given.
In studv one, urine was collected into 2-litre plastic bottles containing 100 ml 
of 0.5 M HCl to ensure a pH of <3 and the stability of DA. In studv two, urine was 
collected into 2.5-litre plastic bottles containing 40 ml of 2 g/L boric acid. All the 
bottles were returned on the same day of completion of the collection. Aliquots were 
taken and stored deep frosen at -20‘’C until analysis.
Urinary sodium and potassium were measured by indirect ion-selective 
electrodes and creatinine by Jaffe reaction on a Beckman Astra-8 Chemistry 
Analyser (Beckman Instruments, USA).
The 24-hour urinary output was calculated for sodium, potassium, creatinine 
and free DA. In studv two, urinary kallikrein was also measured. Creatinine output 
was used as an index of under-or over-collection. In studv one, seven subjects with 
values outside the reference range quoted by our laboratory (7.1-17.7 mmol/day in 
men and 5.3-15.5 mmol/day in women) were excluded. In studv two, subjects with 
values outside the reference range were asked to repeat the collection.
5.2.4 Measurement o f urinary free catecholamines
Urinary free catecholamines were measured in batches by high performance 
liquid chromatography (HPLC) with electrochemical detection. The methodology
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used and the performance of the assays have been described in detail elsewhere 
(30,587,591). The principles of the methods are briefly summarised here.
The method used until 1995 (HCl used as preservative for urine collection!
With the help of Wong (587) and Ho (591), an ion-pair reversed phase HPLC 
method was developed.
The extraction of urinary free catecholamines was based on the method of 
Davidson & Fitzpatrick (592). However, after the adsorption of free catecholamines 
onto the alumina in 3 M Tris buffer, the alumina was washed with 0.1 M Tris buffer 
instead of 0.1 M barbitone buffer. The adsorbed free catecholamines were eluted 
with 0.1 M HCl instead of 0.5 M HCl.
The separation and quantification of free catecholamines by HPLC was based 
on the method of Weicker et al. (593). Due to the use of a different type of column 
(stationary phase) in our HPLC system, the acetate-citric buffer mobile phase was 
modified. Methanol 14% was used instead of methanol 5%, and the flow rate was 
increased from 1.0 to 2.0 mPminute. A 3 M Tris buffer was used to maintain an 
optimal pH condition of 8.6 during the adsorption process. The main objective was 
to maintain a total elution time of 15 minutes for all catecholamines. Furthermore, 
the eluted catecholamines were further washed with ethyl acetate to remove electro­
active species from the eluant. Electrochemical detector with the applied potential 
set at +0.6 V was used for the quantification of catecholamines.
The 'optimal’ preservative (acid) for urine collection, storage conditions and 
pretreatment method before HPLC measurement were systematically studied. It has 
been a common pratice to use acids as preservatives for urine collections to prevent 
catecholamine degradation. However, higher concentrations of inorganic acids may
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hydrolyse conjugates of catecholamines, resulting in falsely high free catecholamine 
concentrations (594). To study the effects of duration of storage of acidificed human 
urine, a final acid concentration of 0.025 M HCl was used. This concentration was 
selected based on the collection of 24-hour urine samples into 2-litre containers with 
100 ml of 0.5 M HCl. In previous experiments by our group, 0.5 M HCl solution 
had not been shown to increase free catecholamines after a short period. As more 
urine was collected in the bottle, the acid solution will be diluted further. The lower 
acid concentration would not be sufficient to cause hydrolysis of the conjugated 
catecholamines. Urine samples acidified with 0.025 M HCl were kept at 30°C to 
simulate collection conditions by out-patients. There were no significant changes in 
the urinary free catecholamines over 48 hours. The same samples were also stored 
frosen at -20°C to simulate practical situations of storing batches of samples before 
analysis. Although small changes in free DA concentrations were detected after one 
month, the range of changes were within ± 5 % of the fresh samples. This 
magnitude of variation was within the inter-batch precision limits. However, both 
noradrenaline and adrenaline changed significantly by about 10% after one month. 
The effects of storage at -70°C need to be determined.
Therefore, for the collection of 24-hour urine, 100 ml of 0.5 M HCl solution 
was added to each 2-litre plastic container. The urine samples were kept at 4°C if the 
analyses could be done within three days. Otherwise, the aliquots were stored deep 
frosen at -20°C and the analyses completed within one month.
The analytical 'performance' of the assay had been studied by Wong (587) 
and Ho (591). The results of recovery and intra-batch and inter-batch precision 
studies are summarised in Table 5a and Table 5b.
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Table 5 a. Results of recovery and intra-batch precision study.
Concentration Measured
of standard (nM) concentration (nM) % Recovery
Intra-batch 
CV (%)
DA 0 1002 1.0
500 1472 94.0 1.0
1000 2003 100.1 3.1
2000 3031 101.5 1.1
NA 0 304 _ 3.2
200 503 99.5 3.0
400 715 102.8 2.2
600 905 100.2 1.4
A 0 58 _ 17.4
100 147 89.0 3.6
200 246 94.0 8.4
300 346 96.0 3.2
Data from Ho (591).
Table 5b. Inter-batch precision study using 2 quality control urine samples.
Quality control Free Mean
sample catecholamines concentration (nM) CV (%)
A (n  = 97) DA 1011 4.8
NA 279 2.0
A 69 11.6
B (n = 47) DA 612 6.2
NA 91 9.9
A 27 29.6
Data from Ho (591).
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As can be seen in Table 5a, the average recovery of free DA was 98.5%. The 
intra-batch coefficient of variation ranged from 1.0 to 3.1%. The average recovery 
of free NA was 100.8%. The intra-batch coefficient of variation ranged from 1.4 to 
3.2%.
As can be seen in Table 5b, the inter-batch coefficient of variation for free 
DA was 4.8-6.2%. The figure for free NA was 2.0-9.9%.
The method used since 1996 (boric acid used as preservative for urine collection!
In the past, the roles of renal DA, the SNS and the renal kallikrein-kinin 
system in ECF volume and BP homeostasis were studied in isolation. Attempts to 
study these systems simultaneously were hampered by incompatibility of the urine 
preservatives for catecholamines and kallikrein.
In order to measure acid-stable DA and NA and acid-labile kallikrein enzyme 
together, Lee & Critchley (30,595) compared the use of boric acid and HCl as the 
preservative for urine collection before measurements by HPLC using the method of 
Wong & Ho described above. As can be seen in Table 5c, the variations between the 
DA and NA concentrations preserved in HCl or boric acid at different time intervals 
(tested by 2-way analysis of variance) were not statistically significant. The aliquots 
could be stored at -20°C for up to three months. Hence, in our studies of renal DA 
since 1996, boric acid was used as the urine preservative. The advantage of using 
boric acid is that it would not interfere with the measurement of urinary kallikrein 
(Section 5.2.5). The inter-assay coefficients of variation were 4.8% at 1,011 nmol/L 
for DA and 2.9% at 279 nmol/L for NA. The intra-assay coefficients of variation 
were 1.0% at 1,472 nmol/L for DA and 3.0% at 503 nmol/L for NA. The mean 
recovery of urinary free DA and NA was 92% and 93 %, respectively (30,595).
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Table 5c. Urinary free DA and NA concentrations (nmol/L) in 10 human urine 
samples containing 0.5 M HCl or 2 g/L boric acid at ambient 
temperature over 48 hours and -20°C over 3 months.
Time Temp
fC )
HCl 
(0.5 M)
Boric acid 
(2 g/L)
Two-way
ANOVA
DA 0 hour Ambient 1,286 + 163 1,286+ 163 Timer factor:
( n = 10) (Plain) 
24 hours Ambient 1,337 + 178 1,289 + 176
p = 0.950 
Acid factor:
48 hours Ambient 1,298 ± 176 1,211 + 172
p = 0.762 
Interaction of two
2 weeks -20 1,235 + 161 1,256 + 165
factors: P=0.971 
Time factor:
1 month -20 1,315 + 181 1,306+ 182
p = 0.988 
Acid factor
2 months -20 1,341 + 170 1,330+ 169
p = 0.964 
Interaction of two
3 months -20 1,343 + 182 1,315 + 178
factors:
p = 1.000
NA 0 hour Ambient 147 + 23 147 + 23 Timer factor:
( n -  10) (Plain) 
24 hours Ambient 146 + 25 145 + 25
p = 0.997 
Acid factor:
48 hours Ambient 148 + 24 145 + 24
p = 0.954 
Interaction of two
2 weeks -20 149 ± 23 150 + 24
factors: p = 0.999 
Time factor:
1 month -20 159 + 27 195 + 27
p = 0.944 
Acid factor
2 months -20 167 + 27 166 + 27
p = 0.889 
Interaction of two
3 months -20 161 + 27 162 ± 26
factors:
p = 1.000
Data from Lee (30).
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5.2.5 Measurement o f urinary kallikrein
The methodogy used and the performance of the assay have been described in 
detail elsewhere (30,595).
In brief, urinary kallikrein was mseasured by the method of Amundsen et al. 
(596). However, we used a 96-well ELISA plate instead of test tubes and curvettes. 
This modification saves on substrate volume, increases the number of samples being 
assayed and simplifies the absorbance measurement using an ELISA plate reader 
instead of measuring absorbance in curvettes one by one. This is an amidolytic assay 
in which urinary kallikrein is measured by its capacity to cleave the amido bond of a 
synthetic chromgenic tripeptide D-valyl-leucyl-arginine-/?-nitronailide, S-2266 (AR 
KABI Diagnostica, Stockholm, Sweden), which exhibits good specificity and 
sensitivity for glandular kallikrein. Aliquots were centrifuged at 2000 x g  for 10 
minutes at 4°C and the supernatant removed. Later, 50 pi of 0.2 mol/L Tris-HCL 
buffer with pH 8.2 (Merck) was added before incubation at 37°C for 5-10 minutes 
using a 96-well ELISA plate. Supernatants of urine or kallikrein standards of 
porcine origin (Bayer, Leverkusen, GFR) (120 pi) were mixed with the buffer and 
incubated at 37°C for 2-5 minutes. The reaction was started by adding 40 pi of 1.2 
mmoFL of S-2266 and was stopped by mixing with 30 pi of 50% acetic acid 
(Merck) after incubating at 37°C for 30 minutes. The absorbance at 405 nm was 
measured by the Dynatech MR5000 microplate spectrophotometer and compared 
with that of the same incubation mixture containing 50 klU/ml aprotinin (Bayer) 
within 4 hours. By adding aprotinin, a potent inhibitor of glandular kallikrein, to the 
sample blank, protease activities not inhibited by aprotinin as well as the colour from 
the urine itself can be subtracted. Results were expressed as units of kallikrein 
activity per litre (KU/L).
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The intra-assay coefficients of variation were 1.8% at 8.4 ±0.1 KU/L, 2.7% 
at 13.2 ± 0.3 KU/L and 1.2% at 300.4 ± 3 .4  KU/L. The inter-assay coefficients of 
variation were 2.4% and 5.6% at the kallikrein concentrations of 3.1 ± 0.01 KU/L 
and 322.4 ± 17.0 KU/L, respectively. The recoveries of urinary kallikrein at various 
concentrations ranged fi-om 90 to 100%. The stability of urinary kallikrein with time 
was analysed by one-way repeated measures ANOVA.
Table 5d. Urinary kallikrein concentrations (KU/L) in the 10 human urine 
samples preserved with and without 2 g/L boric acid at ambient 
temperature over 48 hours and -20°C over 3 months.
Time Temperature (°C) Urinary kallikrein concentration 
measured in urine preserved 
with 2 g/L of boric acid (KU/L)
One-way repeated 
ANOVA
0 h (plain) 82 + 26
24 hours Ambient 82 + 39
48 hours Ambient 81+38 p = 0.189
2 week -20 83 + 39
1 month -20 82 + 39
2 months -20 82 + 39
3 months -20 83 ±40 p - 0.198
Data fi'om Lee (30).
If HCl was used as the urine preservative, the recovery of urinary kallikrein 
was only 5.7% after storage at -20°C for up to three months (30). Hence, when urine 
was collected for measurements of kallikrein and/or free DA and NA, boric acid was
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used as the preservative. Aliquots were stored at -20°C and the analyses completed 
within one (for DA and NA) or three months (for kallikrein).
5.2.6 Statistical analysis
Throughout my thesis, data are expressed as mean ± SEM. In this study, 
significance of difference for all variables was assessed by analysis of variance 
(ANOVA). Correlation coefficients between urinary sodium, potassium, free DA 
and kallikrein were determined by linear regression analysis. P values of <0.05 were 
regarded as statistically significant.
5.3 Results
5.3.1 Study one
Thirty of the 89 normotensive subjects with a complete urine collection had 
one or more first-degree relatives with hypertension requring drug treatment. As can 
be seen in Table 5e, there was a female predominance across the three groups of 
subjects. This was due to the reluctance of the males to participate in a study like 
this, because they would have to take a few days off work. The two groups of 
normotensive subjects were otherwise comparable with respect to age, body height 
and weight and BP. When compared with the normotensive subjects, hypertensive 
patients were heavier and had a higher SBP and DBP (p<0.05 by ANOVA).
The 24-hour urinary excretion of sodium, potassium, creatinine and free DA 
did not differ between the normotensive subjects and hypertensive patients (p>0.05 
by ANOVA).
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Table 5e. Characteristics of 89 normotensive (NT) Chinese with or without a 
family history of hypertension (FH) and 24 hypertensive Chinese 
recruited in 1989-1991.
NT with no FH 
(n=59)
NT withFH 
(n=30)
Hypertensives
(n=24)
P value 
(ANOVA)
Males: females 21:38 5:25 8:16
Age (years) 43.4 ±2.0 48.3 ± 1.3 45.5 ± 1.7 NS
Height (cm) 157.3 ± 1.0 156.0 ± 1.3 157.9 ±2.0 NS
Weight (kg) 55.4 ± 1.1 55.3 ± 1.3 63.6 ± 1.9 <0.05
SBP (mmHg) 104.7 ±1.5 104.4 ± 1.6 161.2 ±2.3 <0.05
DBP (mm Hg) 69.5 ±1.1 68.8 ± 1.4 100.7 ±1.2 <0.05
24-hour urine
Volume (1) 1.54 ±0.1 1.46 ±0.1 1.59 ±0.1 NS
Creatinine (mmol) 9.0 ± 0.3 8.9 ± 0.4 10.0 ±0.7 NS
Sodium (mmol) 128.5 ±6.5 133.7 ±6.2 147.5 ±13.5 NS
Potassium (mmol) 37.4 ± 1.8 40.4 ± 2.7 40.2 ± 2.7 NS
Free DA (nmol) 1,461 ±78 1,540 ±86 1,593 ±71 NS
NS = not significant
As can be seen in Figure 5a, there was a positive correlation between 24-houi* 
urinary sodium and free DA outputs in normotensive subjects with no family history 
(r=0.42, p<0.001, X coefficient-5.02). However, such a relationship was not seen in 
normotensive subjects with a family history of hypertension (r=0.22, p<0.5) or 
hypertensive patients (r=-0.02, p>0.5).
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Figure 5a. Relationship between 24-hour urinary sodium and DA outputs in
normotensive Chinese with (b) or without (a) a family history of
hypertension and in (c) hypertensive Chinese recruited in 1989-1991.
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5.3.2 Study two
Twenty-seven of the 85 normotensive subjects had one or more first-degree 
relatives with hypertension requring treatment. The characteristics of these subjects 
and hypertensive patients are summarised in Table 5f.
Table 5f. Characteristics of 85 normotensive (NT) Chinese with or without a 
family history of hypertension (FH) and 47 hypertensive Chinese 
recruited in 1996-1998.
NT with no FH 
(n=58)
NT with FH 
(n=27)
Hypertensives
(n=47)
P value 
(ANOVA)
Males: females 23:35 14:13 25:22
Age (years) 42.1 ± 1.2 39.1 ± 1.4* 42.3 ± 1.0 NS
Height (cm) 158.3 ±0.9 162.7 ± 1.3 160.2 ± 1.3 <0.05
Weight (kg) 59.4+10.5 63.7 ± 10.0 69.6 ± 2.0 <0.05
SBP (mmHg) 115.9 ± 1.4 117.2 ±2.1 155.9 ±2.1 0.000
DBP (mm Hg) 69.3 + 1.4 69.4 ± 2.0 97.6 ±1.3 0.000
24-hour urine
Volume (1) 1.7 ±0.1 1.9 ±0.2$ 1.8 ± 0.1* NS
Creatinine (mmol) 9.9 ± 0.4 10.5±0.8§ 11.3±0.6§ NS
Sodium (mmol) 163.2 ±8.4 191.2 ± 15.0* 171.3 ±11.4 NS
Potassium (mmol) 42.0 ± 2.5 44.9 ± 2.8$ 43.8 ±2.0 NS
Free DA (nmol) 1,618 ±65 1,554 ± 108$ 1,857 ±93 <0.05
Kallikrein (KU) 8.1 ± 0.6$ 8.5 ±1.0* 7.0 ±0.6$ NS
Data from *1, j2 , $3 or §4 subjects were missing.
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The three groups of subjects were different (p<0.05 by ANOVA) with respect 
to the height, body weight, SBP and DBP (Table 5f). As expected, the SBP and 
DBP of patients with hypertension were much higher than those of normotensive 
subjects.
The 24-hour urinary excretion of sodium, potassium, creatinine and kallikrein 
did not differ between the normotensive subjects and hypertensive patients (p>0.05 
by ANOVA). However, the free DA output was 14.8-19.0% higher in hypertensives 
than in normotensive subjects (p<0.05 by ANOVA).
As can be seen in Figure 5b, there was a positive correlation between 24-hour 
urinary sodium and free DA outputs in normotensive subjects without a family 
history (r=0.36, p=0.006, x coefficient=2.77), normotensive subjects with a family 
history (r=0.57, p=0.004, x coeffrcient=4.0) and patients with hypertension (r=0.44, 
p=0.002, X coefficient=3.57).
As can be seen in Figure 5c, a positive correlation between urinary potassium 
and free DA outputs was seen in normotensives with a family history of hypertension 
(n=23, r=0.53, p=0.010, x coefficient=20.1) and patients with hypertensive (n=47, 
r=0.34, p=0.020, x coefficient=15.7). However, such a relationship was not seen in 
normotensives without a family history of hypertension (n=58, r=0.21, p<0.5).
As can be seen in Figure 5d, there was no correlation between 24-hour 
urinary sodium and kallikrein outputs in either normotensives (r=0.04, p>0.5 and 
r=0.17, p<0.5) or patients with hypertension (r=0.26, p<0.1).
As can be seen in Figure 5e, there was a positive correlation between urinary 
potassium and kallikrein outputs in patients with essential hypertension (n=44, 
r=0.35, p=0.020, x coefficien=0.10). However, such a relationship was not seen in 
normotensive subjects (n=55, r=0.18, p<0.5 and n=24,1-0.18, p<0.5).
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Figure 5b. Relationship between 24-hour urinary sodium and DA outputs in
normotensive Chinese with (b) or without (a) a family history of
hypertension and in (c) hypertensive Chinese recruited in 1996-1998.
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5.4 Discussion
Between 1989-1991 and 1996-1998, the salt intake among the local Chinese, 
as reflected by their 24-hour urinary sodium output, had increased considerably in 
both normotensive (27.0-43.0%) and hypertensive subjects (16.1%) (Table 5e and 
Table 5f). This increase in salt intake was accompanied by a trend for larger 24-hour 
urinary free DA output (0.9-10.7% and 16.6%).
As expected of ethnic groups living in salt-abundant regions (Table 3g), a 
positive correlation between the 24-hour urinary sodium and free DA outputs was 
seen in normotensive Chinese subjects in Hong Kong (Figure 5a and Figure 5b).
5.4.1 Variations in findings between study one and study two
Since these studies involved different subjects recruited at different times, 
direct comparison and interpretation of the findings may be difficult. Unlike in study 
one (Figure 5a), normotensive subjects with a family history of hypertension and 
patients with hypertension in studv two also showed a positive correlation between 
urinary sodium and free DA outputs (Figure 5b). The inclusion criteria (BP and its 
measurment), recruitment method (community-based or not) and characteristics of 
the participants (age, body weight, BP levels and salt intake) were different between 
the two studies and these could have contributed to the variations in findings.
It is always difficult to verify the parental history of hypertension in a study 
like this. Parents not known to have hypertension requiring treatment might not be 
available for BP measurment at the study centre. Hence, the offspring of patients 
having undiagnosed hypertension could have been 'misplaced' in the group without a 
family history. However, it is unlikely that my findings regarding the renal sodium- 
DA relationships would be much different in view of the small (if any) number of
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cases involved. Anyway, there was a positive coiTelation between 24-hour urinary 
sodium and free DA outputs in both groups of normotensives in studv two (Figure 
5b) and a trend for such a relationship among normotensives with a family history of 
hypertension in studv one (Figure 5a). It is possible that genetics (Section 4.1), salt- 
sensitivity (Section 2.6 and Section 4.1), other determinants (Section 3.2.2) and their 
interactions will influence the renal sodium-DA relationships in these subjects.
Patients with essential hypertension in studv two were younger (42.3 ± 1.0 vs
45.5 ±1.7 years) but heavier (69.6 ± 2.0 vs 63.6 ±1.9 kg) than patients in studv one 
(Table 5f and Table 5e). Their salt intake was also higher than patients in studv one 
(urinary sodium ouput 171.3 ± 11.4 vs 147.5 ± 13.5 mmol/day). They had less 
severe hypertension than patients in studv one (155.9 ± 2.1 / 97.6 ± 1.3 vs 161.2 ±
2.3 /100.7 ±1.2 mmHg). The group difference in BP should be larger in view of the 
falsely low readings due to the use of a random-zero sphymomanometer in studv one 
(590). Unfortunately, the duration of hypertension had not been recorded in detail in 
both studies. Their age and BP levels might indicate that patients in studv two had 
less severe hypertension of shorter duration. Their sodium-DA relationships tended 
to resemble those of the normotensive subjects. Unlike patients in studv one (Figure 
5a and Table 5e), they had a positive urinary sodium-DA correlation (Figure 5b) and 
hyperdopaminergic response (Table 5f) (see Section 4.1.1 and Section 5.4.5).
5.4.2 Published studies in Chinese
My findings regarding the renal sodium-DA relationship in Chinese subjects 
were confirmed by two other studies in Mainland China and Hong Kong. However, 
in both studies, the parental history of hypertension among the participants was not 
stated.
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Hou & Zhang (597) in Guangzhou studied the correlation between 24-hour 
urinary sodium and free DA outputs in 22 healthy volunteers (14 males, 8 females, 
aged 22-53 years, mean 31.4 years) on unrestricted diets. [Ten of these subjects also 
participated in an oral salt loading study and the results will be presented in Section 
7.4.3.] Their 24-hour urinary free DA outputs (measured by HPLC) varied greatly 
between 1,500 and 6,900 nmol. The mean ± SEM values for free DA and sodium 
outputs were not given. There was a strong positive correlation between the 24-hour 
urinary excretion of sodium and free DA (r=0.87, p<0.01).
Ho et al. (598) recruited 41 young healthy females aged 18-23 years from a 
study of determinants of bone mass in Hong Kong. Their 24-hour urinary sodium 
(132 ± 8.2, range 54-302 mmol) and free DA (1,463 ± 47.5, range 902-2,134 nmol) 
was significantly correlated (r=0.55, p<0.001). Stepwise multiple regression 
analysis with DA as the dependent variable and sodium, potassium, calcium and 
digoxin-like immunoreactive substance as independent variables showed that sodium 
was the only contributor to DA excretion.
5.4.3 Comparison with other ethnic groups
In cross-sectional studies of the relationship between 24-hour urinary sodium 
and DA outputs, the x coefficient or 'slope' of the linear regression (Section 3.1.6) 
provides an estimate of the factor by which free DA output is increased in proportion 
to an increase in sodium output. As can be seen in Table 3g and in this study, the x 
coefficient is higher among the Thais (5.93) and Zimbabweans (5.10) than in Hong 
Kong Chinese (2.77-5.02) and Caucasians (3.19).
Critchley et al. (361) pointed out that the correlations between 24-hour 
urinary sodium and free DA outputs are based on populations rather than individual
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data. In their study, the 'r' values for Caucasians, Zimbabweans and Thais only 
represented variances of 16%, 41% and 28% (Table 3g). The 'r' value for Caucasian 
subjects in the study of Patrick et al. (362) represented variance of 26%. The 'r' 
value for Japanese in the study of Saito et al. (363) represented variance of 27%. 
The 'r' values for Hong Kong Chinese in this study and the study of Ho et al. (552) 
represented 13-32% and 30%, respectively.
5.4.4 The West Africans and Iranians
In contrast. West Africans and Iranians do not show a positive correlation 
between 24-hour urinary sodium and free DA (Section 3.1.6). They come from 
regions of high ambient temperature and, previously, a salt-scarce environment. The 
evolutionary benefit of diminished salt excretion is obvious (Section 1.3). Lee (19) 
and Critchley et al. (361) proposed that the lack of or 'uncoupling' of the renal 
sodium-DA relationship in these subjects may be a mechanism to help conserve salt.
5.4.5 Patients with hypertension and their first-degree relatives
Previously, studies on the renal sodium-DA relationship in patients with 
hypertension have only focused on the 24-hour urinary free DA output under basal 
conditions (Section 4.1.1). Whether there is a positive correlation between urinary 
sodium and free DA outputs was never studied.
In Caucasian and Japanese patients with 'established' hypertension, urinary 
free DA excretion under basal conditions is decreased compared with normotensive 
subjects (509-513). In Caucasian patients, a hyperdopaminergic state with increased
24-hour urinary DA output is seen in the 'early' stage of hypertension - borderline 
(labile) hypertension (576). Once hypertension becomes established, the decreased
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urinary DA output typical of older patients with hypertension is seen. Unlike older 
patients (513), younger Japanese patients with hypertension have a higher 24-hour 
urinary free DA output than normotensive subjects (515). Taken together, these 
findings suggest that the increased intrarenal DA synthesis in younger patients with 
borderline or mild to moderate hypertension may represent an early antihypertensive 
compensatory mechanism (Section 4.1.1). Therefore, it is not entirely surprising that 
a hyperdopaminergic response under basal conditions is seen among the younger 
patients with less severe hypertension in studv two (Table 5f) but not in the older 
patients with more severe hypertension in studv one (Table 5e). The absence of a 
significant urinary sodium-DA relationship among older patients with more severe 
hypertension in studv one (Figure 5a) also suggest a dysregulation of the renal DA 
system in established hypertension.
Apart from older age and more severe hypertension, salt-sensitvitiy may be 
associated with a suppressed renal DA output (Section 4.1.1). In fact, decreased 
urinary free DA output under basal conditions is seen in Japanese patients with salt- 
sensitive hypertension and low-renin hypertension (512,513).
Previously, a lower 24-hour urinary free DA excretion under basal conditions 
among the relatives of hypertensive patients compared with healthy subjects without 
a family history of hypertension was reported in a Japanese study (513). However, 
this finding could not be confirmed in the present study (Table 5e and Table 5f) and 
previous studies of Japaneese (363) or Caucasian (371) subjects.
Unlike the Japanese subjects (363), the normotensive first-degree relatives of 
Chinese patients with hypertension did show a significant correlation between 24- 
hour urinary sodium and free DA outputs (Figure 5b).
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Hence, our findings regarding the renal sodium-DA relatiohships in 
normotensive subjects do not provide support for the presence of a dysregulated 
renal DA system at the prehypertensive stage.
5.4.6 Potassium intake and renal DA production
Potassium supplements given by mouth or as an intravenous infusion can 
increase urinary free DA excretion (306,453). A positive correlation between urinary 
potassium and free DA outputs was seen in the present study of hypertensives and 
some normotensives. These observations suggest that renal DA production is also 
determined by the potassium intake (Section 3.2.2). This could be one reason why 
higher potassium intake is associated with a lower BP in population studies (599) 
and dietary potassium restriction exacerbates hypertension (600). On the other hand, 
potassium supplementation can lower BP, and this effect is more pronounced in 
subjects with a higher sodium intake (601).
In the present study, a positive correlation between urinary potassium and 
free DA outputs was seen only in normotensives with a family history and patients 
with hypertension (Figure 5c). This observation might suggest that potassium intake 
as a determinant of renal DA production was more important in hypertensives and 
their close relatives. As can be seen in Table 5f, both subject groups had a higher 
sodium intake and/or BP than normotensives with no family history of hyertension.
5.4.7 Renal kallikrein-kinin system activity
Like renal DA, the renal kalliki'ein-kinin system plays an important role in 
ECF volume and BP homeostasis (Section 2.3.3).
162
Decreased 24-hour urinary kallikrein excretion under basal conditions could 
indicate suppressed activity in the renal kallikrein-kinin system. This was reported 
among hypertensive patients in Sweden (602) and Italy (603,604) and among salt- 
sensitive hypertensives in Italy (87). Urinary kallikrein output was even lower in 
low-renin hypertensives from Italty (604) and patients with malignant hypertension 
from Sweden (602). However, like Simonetti et al. (605) in Italy, I could not find 
any evidence of impaired production of renal kallikrein among patients with essential 
hypertension (Table 5f).
As in Japanese subjects (494,517), urinary kallikrein output in normotensive 
subjects with a family history of hypertension was found to be similar to those with 
no family history (Table 51). However, Rey et al. (606) reported that the boys with 
hypertensive parents had a lower ratio of urinary kallikrein to creatinine compared 
with boys with normotensive parents.
Previous studies rarely examined the environmental determinants of renal 
kallikrein production. Hunt et al. (607) in the U.S. studied 69 pairs of monozygous 
twins to investigate possible dietary, biochemical and anthropometric deteiminants 
of urinary kallikrein excretion. Urinary potassium and sodium excretion differences 
were significantly related to kallikrein differences (r=0.46, p=0.0001 and r=0.30, 
p“ 0.01). Urinary pH (r=0.23, p=0.03) and SBP (r=-0.25, p=0.03) differences were 
related to urinary kallikrein output differences independently of urinary potassium. 
Song et al. (86) studied the determinants of urinary kallikrein excretion in 204 
noimotensives from different ethnic groups living in the U.S. In a multivariate 
analysis, potassium excretion was found to be the strongest correlate of kallikrein 
excretion. Stimulation of renal kallikrein production could be the other reason why 
potassium intake is inversely related to BP (599-601).
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In the present study, there was no correlation between urinary sodium and 
kallikrein outputs in either normotensives or hypertensives (Figure 5d). This finding, 
which needs to be confirmed by a bigger study, may suggest that under basal states, 
renal kallikrein production is not linked to the prevailing salt balance. To determine 
the relative importance of renal kallikrein-kinin system in sodium balance, salt 
loading studies will be required (Chapter 10). A positive conelation between 24- 
houi* urinary potassium and kallikrein outputs was seen, only among hypertensives 
(Figure 5e). Thus, potassium intake appeared to be a factor affecting renal kallikrein 
synthesis. Potassium supplementation could lowers BP among hypertensives by 
stimulating both renal DA and kallikrein-kinin systems.
5.4.8 Significance and implications o f my findings
Among younger Chinese patients with less severe hypertension, but not older 
patients with more severe hypertension, 24-hour urinary free DA output under basal 
conditions is increased compared with normotensive subjects. This enhanced renal 
DA response may represent an early antihypertensive compensatory mechanism.
There is a positive correlation between 24-hour urinary sodium and free DA 
outputs in normotensive Chinese with or whout a family history of hypertension and 
younger patients with less severe hypertension. This may suggest that among these 
subjects, intrarenal DA synthesis is linked to the prevailing salt status and renal DA 
may regulate the renal excretion of sodium.
Normotensive subjects with or without a family history of hypertension do 
not differ with regards the 24-hour urinary free DA output under basal conditions 
and the urinary sodium-DA relationship. In other words, there is no evidence for any 
dysregulation of the renal DA system at the prehypertensive stage.
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Since these cross-sectional studies of renal sodium-DA relationship involved 
different subjects recruited at different times using slighly different methodology, the 
conclusions regarding hypertensive patients and their first-degree relatives cannot be 
considered to be definitive. A bigger comparative study using identical methodology 
is needed to confirm my findings
A positive correlation between urinary potassium and free DA outputs was 
seen in hypertensives and normotensives with a family history of hypertension, 
suggesting that renal DA production is also determined by the potassium intake of 
these subjects.
Renal kallikrein production under basal conditions, as indicated by 24-hour 
urinary kallikrein output, is not different between normotensives and hypertensives. 
The absence of a positive correlation between 24-hour urinary sodium and kallikrein 
outputs may suggest that renal kallikrein production is not linked to the prevailing 
salt balance among normotensives and hypertensives. However, acute salt loading 
studies will be more useful in determining the relative importance of renal kallikrein- 
kinin system in sodium balance. The presence of a correlation between 24-hour 
urinary potassium and kallikrein outputs may suggest that potassium intake is one 
factor affecting renal synthesis of kallikrein among hypertensives.
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Chapter 6 A sibling-pair analysis of renal dopamine and kallikrein-kinin 
system activities and their relationships to sodium excretion and 
BP
6.1 Background of the study and main objectives
Recognition that hypertension is part genetically determined has motivated 
studies to identify mutations that confer susceptibility. Mutations in at least 10 
genes have been shown to alter BP. These mutations alter BP through a common 
pathway, changing salt and water reabsorption in the kidney (608). The molecular 
genetics of salt-sensitity (Section 2.6) and hypertension were recently reviewed 
(609).
In view of the physiological role of endogenous DA (Chapter 3) and renal 
kallikrein-kinin system (Section 2.3.3) in ECF volume and sodium homeostasis, it 
would be of great interest to study the genetic influence on the activies of these 
natriuretic systems under basal states and during salt loading. There could be several 
approaches, as already discussed in Section 2.3.3, Chapter 3, Section 4.1 and Chapter 
5. For example, renal sodium-DA or sodium-kallikrein relationships and 24-hour 
urinary free DA and kallikrein outputs were compared between healthy subjects with 
or without a family history of hypertension and among different ethnic groups. The 
natriuretic response and renal DA response to salt loading were compared between 
normotensives with or without a family history of hypertension (also see Chapter 7 
and Chapter 8). The association between DA receptor gene polymorphisms with 
hypertension was studied. Pedigree analyses were used to study gene-environment 
interaction and the genetic influence on urinary kallikrein excretion and the risk of 
hypertension. Rat models of hypertension were also used.
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Siblings have approximately 50% of their genes in common. They are less 
likely to be subjected to environmental differences than unrelated individuals. Thus, 
sibling-pair studies reduce the variability inherent in population-based studies of 
multifactorial disorders, such as hypertension (610). This study was conducted to 
examine the renal DA and kallikrein-kinin system activies and their relationships to 
BP and sodium and potassium excretion in Chinese by studying siblings discordant 
for hypertension.
6,2 Subjects and methods
This study had been approved by the Clinical Research Ethics Committee of 
the Chinese University of Hong Kong. All subjects gave informed consent to the 
study.
As part of our studies on the genetics and clinical characteristics of metabolic 
syndrome in Hong Kong (611), Chinese patients with essential hypertension, aged
25-55 years, with at least one available normotensive sibling, were recruited from 
our Hypertension Clinic at the Prince of Wales Hospital. Those with diabetes, renal 
disease, secondary hypertension or hyperlipidaemia were not included. Hypertensive 
probands were either untreated or their antihypertensive drugs were withheld, under 
supervision, for at least four weeks. Sitting (after 10 minutes) BP was measured by a 
Dinamap. The mean of three readings taken at 1-minute intervals on two occasions 
was used for analysis. The hypertensive probands all had BP >140/90 mmHg, while 
their siblings all had BP <120/80 mmHg.
All the participants were asked to provide one 24-hour urine collection while 
on their usual diets, but alcohol and medications were avoided. Clear instructions on
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the need and the method for complete collection were given. Creatinine output was 
used as an index of completeness of urine collection. Subjects with values outside 
the reference range were asked to repeat the collection.
Urine was collected into 2.5-litre plastic bottles containing 40 ml of 2 g/L 
boric acid as preservative (Section 5.2.4). Bottles were returned on the same day of 
completion of collection. Aliquots were taken and stored at -20“C until analysis.
Urinary sodium and potassium were measured by indirect ion-selective 
electrodes. Urinary creatinine was measured by Jaffe reaction on a Beckman Astra-8 
Chemistry Analyser (Beckman Instruments, USA). Urinary free DA and kallikrein 
were measured as in studv two in Chapter 5 (Section 5.2.4 and Section 5.2.5). The 
24-hour urinary output was calculated for sodium, potassium, creatinine, free DA 
and kallikrein.
Significance of difference between groups was tested by Student’s unpaired t 
test. Correlation coefficients between urinary sodium, potassium, free DA and 
kallikrein and between BP and urinary free DA and kallikrein were determined by 
linear regression analysis. P values of <0.05 were regarded as statistically 
significant.
6.3 Results
The characteristics of these 43 hypertensive and normotensive sibling-pairs 
are summarised in Table 6a. The hypertensives were heavier (69.1 ± 1.7 vs 62.7 ±
1.6 kg, p<0.01) and had a larger urinary creatinine output. Their BP was also higher 
(147.0 ± 2.5 / 91.4 ± 1.5 vs 120.0 ± 1.3 / 71.8 ± 1.2 mmHg, p<0.01) than their 
normotensive siblings.
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Table 6a. Characteristics of 43 normotensive and hypertensive sibling-pairs.
Normotensives Hypertensives P value
Males: females 14:29 21:22
Age (years) 39.0+1.0 40.0 ± 0.9 NS
Height (cm) 160.0+1.2 160.5 + 1.2 NS
Weight (kg) 62.7+1.6 69.1 + 1.7 <0.01
SBP (mmHg) 120.0 ± 1.3 147.0 + 2.5 <0.01
DBP (mm Hg) 71.8 + 1.2 91.4+1.5 <0.01
24-hour urine
Volume (1) 1.72 + 0.1 1.90 + 0.1 NS
Creatinine (mmol) 9.4 ± 0.6 11.2 + 0.6 <0.05
Sodium (mmol) 196.7 ±13.8 188.2 + 14.9 NS
Potassium (mmol) 47.0 ± 2.4 47.6 + 2.4 NS
Free DA (nmol) 1,457 ±107 1,765 + 108 <0.05
Kallikrein (KU)* 7.5 ±0.7 7.0+ 0.5 NS
NS = not significant. *Data from 11 subjects were missing.
The sibling-pairs did not differ with respect to the 24-hour urinary sodium, 
potassium and kallikrein outputs. However, the 24-hour urinary free DA output was 
21.1% higher among the hypertensives (1,765 ± 108 vs 1,457 ± 107 nmol, p<0.05).
The correlations between urinary sodium, potassium, free DA and kallikrein 
outputs are summarised in Figure 6a, Figure 6b, Figure 6c and Figure 6d.
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Figure 6a. Relationship between 24-hour urinary sodium and DA outputs in 43
(a) normotensive and (b) hypertensive sibling-pairs.
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Figure 6b. Relationship between 24-hour urinary potassium and DA outputs in
43 (a) normotensive and (b) hypertensive sibling-pairs.
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outputs in 32 (a) normotensive and (b) hypertensive sibling-pairs.
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As can be seen in Figure 6a, there was a positive correlation between 24-hour 
urinary sodium and free DA outputs in normotensive (i^0.54, p=0.000, x coefficient 
=5.02) and hypertensive (r=0.37, p=0.015, x coefficient=3.23).
As can be seen in Figure 6b, free DA excretion was significantly related to 
urinary potassium in normotensives (r=0.44, p=0.003, x coefficient=2.28) but not in 
hypertensive (r=0.235, p=0.129) siblings.
As can be seen in Figure 6c, kallikrein excretion was related to urinary 
sodium in normotensives (r=0.37, p=0.038, x coefficient=5.32) but not in their 
hypertensive siblings (r=0.17, p=0.357).
As can be seen in Figure 6d, kallikrein excretion was related to urinary 
potassium in normotensives (r=0.46, p=0.009, x coeffîcient=8.28) but not in their 
hypertensive counterparts (r=0.19, p=0.300).
Among normotensive siblings, SBP was not related to 24-hour urinary free 
DA (r=0.133, p=0.39) or kallikrein (r=0.04, p=0.843) output. DBP was not related 
to 24-hour urinary free DA (r=0.01, p=0.973) or kallikrein (r=-0.28, p=0.190) output.
Among hypertensive siblings, there was a trend for an inverse relationship 
between SBP and urinary free DA output (i--0.30, p=0.052) and between DBP and 
urinary kallikrein output (r=-0.34, p=0.054). However, there was no correlation 
between DBP and 24-hour urinary free DA (r=0.01, p=0.931) or between SBP and 
urinary kallikrein (r=-0.22, p=0.230).
6.4 Discussion
These sibling-pairs discordant for hypertension were recruited during 1996- 
1998. Their sodium intake, as reflected by their 24-hour urinary sodium output (see
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Table 6a), was much higher than those of normotensives (47.1-53.1%) and 
hypertensives (27.6%) recruited during 1989-1991 (see Table 5e). There was a 
corresponding 10.8% increase in 24-hour hour urinary free DA output among the 
hypertensive siblings, whereas the free DA output among the normotensive siblings 
was similar to that of normotensives studied in 1989-1991. It was also obvious from 
Table 6a and Table 5e that normotensive siblings were also heavier and had a higher 
BP than the normotensive subjects in 1989-1991.
6.4.1 Renal sodium-DA relationships
In this sibling-pair study, I confirmed the finding from studv two of Chapter 
5 that there was a positive correlation between 24-hour urinary sodium and free DA 
outputs in both normotensives and hypertensives (Figure 6a). This may suggest that 
renal DA is an important natriuretic factor and dietary sodium is a major determinant 
of renal DA synthesis (Section 3.1.6) in Chinese normotensives and hypertensives. 
Of the variation in free DA excretion in normotensives and hypertensives in this 
study, 29% and 14% could be accounted by variation in sodium intake. These were 
comparable to the figures (13-32% and 19%) in studv two of Chapter 5.
In this study, I also confirmed the presence of a hyperdopaminergic response 
among younger patients with less severe hypertension (Table 6a). This could 
represent an early antihypertensive compensatory mechanism in these siblings 
(Section 4.1.1 and Section 5.4.5),
6.4.2 Potassium intake and renal DA production
Potassium intake can only affect renal DA production (Section 5.4.6), but the 
intrarenal mechanism involved is not known. In studv two of Chapter 5, a positive
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correlation was seen between 24-hour urinary potassium and free DA outputs among 
hypertensives and normotensives with a family history of hypertension (Figure 5c). 
It is possible that potassium intake has a greater effect on renal DA synthesis when 
the salt intake or the BP of the subjects is higher (Section 5.4.6). In the present 
study, there was a positive correlation between 24-hour urinary potassium and free 
DA outputs among normotensives but not in hypertensives (Figure 6b). Although 
salt intake was higher among normotensive siblings (Table 6a), the group difference 
was only 8.5 mmol. In the study of Ho et al. (598), there was no correlation between 
24-hour urinary potassium and free DA output among young healthy females.
Therefore, the findings so far seemed to suggest that potassium intake could 
affect renal DA synthesis in some subjects. Both the underlying mechanisms and the 
modulatory effects of salt intake, BP and other factors are not known.
6.4.3 Renal kallikrein-kinin system activity
I confirmed that renal kallikrein-kinin system activity under basal conditions 
was not different between hypertensives and normotensives (Section 5.4.7).
There were considerably variations in urinary cation-kallikrein relationships 
seen in this sibling-study and studv two of Chapter 5. Among the normotensives, 
24-hour urinary kallikrein output was related to the urinary excretion of sodium 
(Figure 6c) and potassium (Figure 6d). Such a correlation was not seen in studv two 
of Chapter 5 (Figure 5d and Figure 5e). Among the hypertensive siblings, urinary 
kallikrein output was not related to either urinary sodium (Figure 6c) or potassium 
(Figure 6d). A positive correlation between 24-hour urinary potassium and kallikrein 
outputs was seen in hypertensives in studv two of Chapter 5 (Figure 5e). Due to the 
variations in diet and the lack of consistency in findings regarding cation-kallikrein
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relatioships, cross-sectional studies are not very useful in determing the role of renal 
kallikrein-kinin system in ECF volume and BP homeostasis. Therefore, there is a 
need for salt-loading studies (Chaper 10).
6.4.4 BP in relation to urinary DA and kallikrein outputs 
Hyperdopaminergic response may be seen in younger hypertensives (Section
4.1.1, Section 5.4.5 and Section 6.4.1). SBP is inversely related to urinary kallikrein 
in monozygous twins (607). It will be of interest to find out if BP of normotensives 
and hypertensives is related to urinary free DA and kallikrein excretion.
Among normotensive siblings, neither SBP nor DBP was related to urinary 
free DA or kallikrein outputs. In contrast, a trend for an inverse relationship between 
SBP and urinary free DA excretion (r=-3.0, p=0.052) was seen in hypertensive 
siblings. Like the hyperdopaminergic response (Section 5.4.5 and Section 6.4.1), 
this may indicate the presence of an antihypertensive compensatory mechanism in 
these hypertensives. The inverse relationship between DBP and 24-hour urinary 
kallikrein output may suggest that hypertensives with suppressed renal kallikrein 
synthesis will be at risk of more severe hypertension (Section 2.3.3).
6.4.5 Significance and implications o f my findings
In this sibling-pair study, I have confirmed the presence of enhanced renal 
DA production hypertensive subjects. This may represent an early antihypertensive 
compensatory mechanism. In accord with this hypothesis is the finding of a trend 
for an inverse relationship between SBP and 24-hour urinary free DA output among 
hypertensive subjects.
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I have also shown that there is a positive correlation between 24-hour urinary 
sodium and free DA outputs in both normotensive and hypertensive siblings. This 
may suggest that in these subjects, intrarenal DA synthesis is linked to the prevailing 
salt status and endogenous DA may regulate the renal excretion of sodium.
A positive correlation between urinary potassium and free DA outputs was 
seen in normotensive siblings, suggesting that renal DA production is also 
determined by the potassium intake of these subjects.
I have confirmed that urinary kallikrein output under basal conditions was 
not different between hypertensives and normotensives. In hypertensive siblings, the 
presence of an inverse relationship between DBP and 24-hour urinary kallikrein 
output may suggest that subjects with suppressed renal kallikrein synthesis will be at 
risk of more severe hypertension. Cross-sectional studies of normotensvies and 
hypertensives so far have yielded inconsistent results regarding urinary cation- 
kallikrein relationships.
Salt-loading studies would be required in determining the relative importance 
of renal DA, renal kallikrein-kinin system and other neurohormones in ECF volume 
and BP homeostasis in Chinese with or without a genetic risk of hypertension.
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Chapter 7 Urinary free DA and NA outputs during acute changes in oral 
salt intake in healthy Chinese subjects
7.1 Background of the study and main objectives
I have shown that normotensive Chinese subjects with or without a family 
histoiy of hypertension show a positive correlation between 24-hour urinary sodium 
and free DA outputs (Chapter 5 and Chapter 6). This may suggest that DA has an 
important intrarenal natriuretic role in Chinese as well as normotensive Caucasians 
and Japanese and dietary salt is a major determinant of its intrarenal synthesis 
(Section 3.1.6). It was, thus, anticipated that they would respond to oral salt loading 
with an increase in urinary free DA output similar to that reported in Caucasians and 
Thais (Section 3.1.7).
In my preliminary investigation into the role of renal DA in the natriuretic 
response to oral salt loading (612) and the tolerability and feasibility of such studies 
in healthy volunteers, five normotensive Chinese subjects (4 males and 1 female, 
aged 23-35 years) without a family histoiy of hypertension received a 70 mmol 
sodium diet for three days (days 1 to 3) followed by their usual diets with 
unrestricted salt intake for six days (days 4 to 9). On days 4 to 6, they also received 
10 'Slow sodium' tablets (Ciba-Geigy) at 9 a.m. and 1 p.m. equivalent to 200 mmol 
of sodium per day. There was a 5- to 8-fold increase in mean daily sodium excretion 
(40 mmol on day 3 vs 216-389 mmol on days 4-6 and 183-317 mmol on days 7-9, 
p<0.05). As a group, the mean daily urinary free DA output did not change (1,284 
nmol on day 3 vs 1,298-1,408 nmol on days 4-6 and 1,481-1,670 nmol on days 7-9, 
p>0.05). None of these subjects had any discomforts during the study. I then 
realised that my results could have been affected by other confounding factors in the
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diet such as variations in protein, potassium, calcium and phosphate intakes (Section 
3.2.2). Furthermore, the basal sodium intake was only reduced to 70 mmol/day, 
compared with a daily intake of 20 mmol or lower in most published studies (Table 
3h). It was not known if my results would have been different if a basal sodium 
intake of 20 mmol/day had had been used. The use of a similar protocol would also 
enable me to establish if there is indeed an ethnic difference in renal DA response to 
oral salt loading.
Another mechanism which appears to contribute to the natriuresis following 
salt loading is a reduction in SNS activity, which can be demonstrated by a reduction 
in plasma concentration and/or urinary excretion of free NA (Section 2.4.2).
In this study, my main objective was to determine the roles of renal DA and 
suppression of SNS activity in the natriuretic response to oral salt loading in healthy 
Chinese subjects taking a constant diet with two different sodium intakes.
7.2 Subjects and methods
This study had been approved by the Clinical Research Ethics Committee of 
the Faculty of Medicine, the Chinese University of Hong Kong. After the nature and 
purpose of the study were explained, consent was obtained from each participant.
Eight healthy Chinese males (aged 22-24 years) were studied in July 1992 
after a routine physical and laboratory examination to rule out hypertension, diabetes 
mellitus, renal disease or other significant illness. These medics were living in the 
air-conditioned student hostel next to the Prince of Wales Hospital, where they had 
their clinical attachments. Their parents all had a BP <140/90 mmHg, as indicated 
by the recent readings recorded by the medics themselves or family doctors.
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The study was performed in the out-patient setting. During the 10-day study 
period, they had deliberately avoided outdoor activities so as to minimise sodium 
loss from sweating. All the meals they consumed during the study were prepared in 
the hospital kitchen. From days -4 to 0 and days 1 to 5, subjects were given the same 
basic diet containing 1,900 calories, 75 g protein, 20 mmol sodium and 45 mmol 
potassium. In addition, from days 1 to 5, subjects were given 20 'Slow sodium' 
tablets (Ciba-Geigy) equivalent to 200 mmol of sodium per day. These were taken in 
two divided doses with breakfast and lunch. After salt restriction (10 mmol/day), the 
amount of sodium excreted in urine on each day approaches the new intake within 
four days (613). Subsequent salt loading (350 mmol/day) results in a greatly 
increased urinary sodium output that reaches the new steady state within three days.
Body weight and BP after lying supine for 10 minutes were measured in the 
morning before breakfast at the end of each 5-day period. The mean of three 
consecutive readings measured by a Dinamap at intervals of one minute was taken as 
the subject’s BP. MAP was calculated by adding one-third of the pulse pressure to 
the diastolic pressure (phase V).
Urine was collected for 24 hours from 8:00 a.m. to 8:00 a.m. in plastic bottles 
containing 100 ml of 0.5M HCl on day -4 and from days 0 to 5. The bottles were 
kept in the air-conditioned hospital compound until urine collection was complete. 
The bottles were then returned immediately. Aliquots were stored at -20°C until 
assayed for sodium, potassium, creatinine, free DA and free NA.
Urinary sodium and potassium were measured by indirect ion-selective 
electrodes and creatinine by Jaffe reaction on a Beckman Astra-8 Chemistry 
Analyser (Beckman Instruments, USA). Urinary free DA and NA were measured by 
HPLC using electrochemical detection, as in studv one of Chapter 5 (Section 5.2.4).
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The 24-hour urinary output was calculated for sodium, potassium, creatinine, free 
DA and free NA.
Differences from the baseline and between each study period for all variables 
were tested using the Wilcoxon sign-rank test. P values <0.05 were regarded as 
statistically significant.
7.3 Results
Table 7a summarises the data on MAP, pulse rate and body weight observed 
at entry and on the last day of each of the study periods. There were no significant 
changes in MAP; the eight subjects were therefore regarded as 'salt-resistant' 
(369,371). As expected, sodium restriction resulted in a decrease in body weight and 
sodium loading resulted in subsequent increase in body weight.
Table 7a. MAP, pulse rate and body weight in eight healthy Chinese subjects 
during ingestion of 20 or 220 mmol of sodium per day.
At entry 
(day -4)
20 mmol sodium 
(day 0)
220 mmol sodium 
(day 5)
MAP (mmHg) 78.2 ± 2.4 76.8 ± 1.8 75.0 ±2.8
Pulse (beats/min) 65.9 ±3.3 63.5 ±2.4 61.6 ± 4.0
Body weight (kg) 58.3 ±1.9 57.3 ±1.9* 57.9± 1.9f
*p<0.05 when compared with 'at entry'. 
tp<0.05 when compared with '20 mmol sodium'.
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The daily excretion of sodium, potassium, creatinine, free DA and free NA 
and the urine volume in response to changes in sodium intake is shown in Table 7b 
and Figure 7a. As a group, there was an 8- to 9-fold increase in sodium excretion 
during salt loading (p<0.01). The rate of increase in urine sodium was the greatest in 
the first two days of salt loading during which an 8-17% increase in urinary DA 
excretion was seen (p<0.05). However, by day 4, urinary free DA output did not 
differ significantly from the baseline value on day 0. On day 5, there was a 22% 
reduction in urinary free NA output (p<0.05).
Table 7b. 24-hour urine volume and urinary excretion of sodium, potassium, 
and creatinine in eight healthy Chinese subjects during low (days -4 
to 0) and high (days 1 to 5) sodium intakes.
Days Sodium intake 
(mmol/day)
Volume
(1)
Sodium
(mmol)
Potassium
(mmol)
Creatinine
(mmol)
-4 20 1.8 ± 0.2 85 ± 8f 32.1 ±2.2 13.4 ±0.6
0 20 1.7 ±0.1 22 ± 4 38.9 ±3.1 13.3 ±0.6
1 220 1.8 ± 0.2 8 6 ± 1 7 t 50 .0±1 .2 t 14.8 ±0.9
2 220 2.8 ± 0,3t 199± 12t 49 .4± 2 .5 t 14.3 ± 0.8
3 220 2.2 ± 0.2 2 1 6 ± 1 9 t 42.1 ± 1.7 14.3 ±0.9
4 220 2.2 ± 0.2t 186± 18t 40.9 ± 2.3 14.4 ±0.9
5 220 2.1 ± 0.1* 260 ± 14f 44.1 ±3.5 19.0±1.3t
*p<0.05, tp<0.01 when compared with day 0.
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Figure 7a. Mean ± SEM of 24-hour urinary sodium, DA and NA outputs in eight 
healthy Chinese subjects when their sodium intake was increased 
from 20 mmol/day (days -4 to 0) to 220 mmol/day. *p<0.05, 
**p<0.01 when compared with day 0.
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7.4 Discussion
Dietary salt loading (Section 3.17) and the acute infusion of isotonic saline 
(Section 3.19) have been widely used to determine factors controlling natruiuresis in 
health and disease. Activation of the renal DA (Chapter 3) and other natriuretic 
systems (Section 2.3) and suppression of the SNS activity and other antinatriuretic 
systems (Section 2.4) are expected to facilitate sodium excretion. In the present 
study, I have investigated the role of two of these factors in modulating urinary 
sodium output in healthy Chinese subjects during periods of different sodium intake.
7.4,1 Effects o f salt loading on MAP
As in Caucasians (367-369,373), a high sodium intake of around 250 
mmol/day for about one week was not associated with an increase in MAP in healthy 
Chinese subjects. This is in marked contrast to normotensive American blacks in 
whom a modest increase in sodium intake from 40 to 180 mmol/day is associated 
with a 7% increase in MAP after 14 days (375).
Sodium kinetics differ considerably between normotensive whites and blacks 
when they are given 10, 200 and 400 mmol/day sodium for seven days in random 
order (614). With increasing salt intake, the half-life of sodium increases in both 
whites and blacks. Mean figures for whites are 1.08, 1.57 and 2.88 days compared 
with 1.65, 2.81 and 5.81 days for blacks. At the 400 mmol/day intake, whites on 
average accumulate 385 mmol of sodium compared with 909 mmol for blacks. It 
was previously observed that normotensive blacks excrete an intravenous salt load 
over 24 hours to a lesser extent than do normotensive white subjects (22). It has 
been suggested that a decreased renal production of DA may be an important
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pathogenic factor in the development and maintenance of hypertension in American 
blacks (370,375).
7.4.2 Effects o f salt loading on the renal DA response
A positive correlation between 24-hour urinary sodium and free DA outputs 
was seen in normotensive Chinese subjects with or without a family history of 
hypertension (Chapter 5 and Chapter 6). However, my preliminary study (Section
7.1) on the effects of oral sodium loading yielded conflicting results with regarding 
to the renal DA response; the expected increase in urinary free DA output was not 
seen. Apart from variations in protein, potassium, calcium and phosphate intakes 
before and after salt loading, differences in the basal levels of sodium intake (70 
mmol instead of 20-40 mmol/day used in the studies listed in Table 3h) before 
sodium loading might be of importance. For example, in healthy Caucasian subjects 
given intravenous saline infusion (520), those with a family history of hypertension 
differed from those without such a history in having lower urinary sodium and free 
DA outputs during the low (20 mmoFday) or medium (170 mmoFday) sodium 
intake. However, such differences in urinary sodium and DA responses were not 
seen during the high (340 mmoFday) sodium intake.
In this study, I have therefore used a constant diet containing either 20 or 220 
mmol sodium/day for five days each. I have shown that the renal DA response to 
oral salt loading in healthy Chinese subjects was relatively small and not sustained 
(see Figure 7a). The maximum increase in urinary free DA output after salt loading 
was only 17% in Chinese subjects. The increase in free DA output was attenuated 
by days 2 and 3 and the output was not different from the baseline by days 4 and 5.
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Moreover, a temporal relationship between urinary excretion of sodium and free DA 
was not seen in Chinese subjects (Figure 7a).
When changing from a low (9-40 mmol/day) to high (220-340 mmoFday) 
sodium intake (12,13,367-369,372-374), Caucasian subjects generally showed a 
much greater increase in renal DA of 26-59% (Table 3h). Studies (12,369,374) that 
measured 24-hour urinary free DA excretion only towards the end of the salt loading 
could have missed an early peak. In other words, the maximum increase in renal DA 
response among Caucasian subjects might even be greater than the range indicated 
above if daily urinary free DA output was measured in every study. In previous 
studies that included a daily 24-hour urine collection during the high sodium intake 
period (13,367,368,372,373), urinary free DA output remained elevated throughout 
the high salt intake period in Caucasian subjects (Table 3h). Moreover, a temporal 
relationship between urinary excretion of sodium and free DA was seen in Caucasian 
subjects (13).
Thus, healthy Chinese subjects show a relatively small renal DA response for 
three days after acute changes in salt intake, suggesting that renal DA contributes 
only partly to the early natriuretic response to salt loading. Ideally, to establish if 
there is an ethnic difference in rela DA response to salt loading, larger number of 
Chinese and Caucasian subjects living in the same environment should be studied 
using identical protocol.
7.4.3 Published studies on the renal DA response to salt loading in Chinese
Hou & Zhang (597) in Guangzhou studied the renal DA response to salt 
loading in 10 healthy Chinese volunteers. They were put on a constant diet with two 
different sodium intakes (34 and 170 mmoFday) each given for four days. On the last
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day of each salt intake, 24-hour urine and blood samples were collected. HCl was 
added to the aliquots to maintain a pH of 3.5-4.0. Urinary free DA was measured by 
HPLC with electrochemical detection. Following salt loading, an increase in mean 
urinary sodium (50.8 to 168 mmoFday) and free DA (1,020 to 1,550 nmoFday) 
outputs was seen. There was a 92-93% reduction in PRA and plasma aldosterone 
concentration. Thus, the increase in free DA excretion (52%) appears much larger 
than that of my subjects (17%). Basal BP (Section 4.1.1) and salt intake (Section 
7.4.2) in these subjects and exact constituents of the diet (Section 3.2.2) were not 
known but could have influenced the results. Moreover, the subjects in Guangzhou 
could have a genetic background that is different from my subjects.
7.4.4 Effects o f salt loading on the SNS activity
Another mechanism which may contribute to the natriuresis following salt 
loading is a reduction in SNS activity, which may be refleeted in a reduction in urine 
free NA output (Section 2.4,2). Impaired suppression of SNS activity during sodium 
loading, which is seen in salt-sensitive hypertensives but not in normal subjects or 
salt-resistant hypertensives, is assoeiated with greater sodium retention and an 
increase in MAP.
In this study, a 22% reduction in urinary NA was seen on day 5 when the 
subjects were in sodium balance (Figure 7a). The lack of a temporal relationship 
between urine sodium and urine NA during the first four days of oral salt loading 
suggests that a reduction in the SNS activity does not contribute to salt-induced 
natriuresis in healthy Chinese subjects. However, any tendency to hypervolaemia- 
related increases in BP might have been partly offset by an appropriate reduction in 
SNS activity towards the end of the high salt intake period (Section 2.4.2).
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Previous studies on the relationship between SNS aetivity and natriuresis in 
healthy subjects never reported the daily urinary NA excretion during the high salt 
intake. In the study of Alexander et al. (12), an average of the last three eoliections 
on a low sodium intake (9 mmoFday for eight days) and last four collections on a 
high sodium intake (209 or 259 mmoFday for 10 days) were used; a 44% reduction 
in urinary free NA output was seen. In the study of Luft et al. (201), the 24-hour 
urinary free NA on the last day of each level of sodium intake (each given for at least 
three days) was used. A 28% fall in urine free NA was seen after the daily sodium 
intake was increased from 10 to 300 mmol. In the study of Turner & Reilly (203), 
subjects were given one week of low sodium (10 mmoFday) diet and one week of 
high sodium (200 mmoFday) diet. A 28% fall in the 24-hour urinary free NA output 
on the 6th day was seen. In the study of Gill et al. (369), the response of five 
subjeets to sodium intakes of 9 and 249 mmoFday each given for seven days was 
studied by comparing the plasma NA and the urinary free NA output on the last day 
of each intake. Plasma NA concentration fell by 6%, but mean urinary NA output 
did not change (124 to 89 nmoFday, p>0.1). Since 24-hour urinary free NA output 
was not measured throughout the salt loading period, the possibility of an earlier 
reduction in SNS activity could not be excluded.
7.4.5 Significance and implications o f my findings
Findings from this study suggest that in healthy Chinese subjects, renal DA 
contributes only partly to the natriuretic response to oral salt loading. The lack of a 
temporal relationship between the natriuretic response and urinary free NA output in 
the first four days of salt loading suggests that a reduction in SNS activity plays no 
significant role. However, any tendency to hypervolaemia-related increases in BP
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may be partly offset by an appropriate reduction in SNS activity towards the end of 
the high salt intake period.
Since their MAP remains unchanged and the natriuretic response to a high 
sodium diet for five days is similar to those reported previously, Chinese subjects 
must have other mechanism(s) for dealing with a salt load.
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Chapter 8 Urinary free DA and NA outputs during acute changes in oral 
salt intake in healthy Chinese subjects with a family history of 
hypertension
8.1 Background of the study and main objectives
There is a strong association between genetic factors and hypertension 
(608,609) and between salt intake and hypertension (Section 1.1). Among young 
normotensive subjects, BP is higher in the offspring of hypertensive parents than in 
the offspring of normotensive parents (615). The normotensive first-degree relatives 
of patients with hypertension have a blunted natriuretic response to an intravenous 
salt load (204) and are more likely to be salt-sensitive (Section 2.6). A prevailing 
hypothesis to explain the familial predisposition to hypertension is that inherited 
factors have effects that impair the kidney’s ability to excrete sodium (616), and this 
primary renal 'defect' may be related to the dysregulation of one or more of the 
natriuretic or antinatriuretic systems (Chapter 2 and Chapter 3).
I have already established that the renal DA response to oral salt loading in 
healthy Chinese subjects without a family history of hypertension is 'unusual' in that: 
(a) the increase in renal DA output is small; (b) the increase becomes attenuated from 
day 2 (Chapter 7). However, any tendency to hypervolaemia-related increases in BP 
may be partly offset by a reduction in SNS activity towards the end of the high salt 
intake period. Subjects with a family history of hypertension also have a significant 
renal sodium-DA relationship (Chapter 5) and should show a renal DA response to 
oral salt loading. Previous oral salt loading studies by others had only focused on 
normotensives or hypertensives (Section 4.1.1).
191
In this study, my main objective was to determine if the effects of oral salt 
loading on BP and the natriuretic response are different in normotensives without a 
family history of hypertension. If this is the case, I wanted to know if  these are 
related to a defect in intrarenal DA synthesis or an abnormal SNS response.
8.2 Subjects and methods
This study had been approved by the Clinical Research Ethics Committee of 
the Faculty of Medicine, the Chinese University of Hong Kong. The study setting 
and design were as described in Section 7.2.
Seven healthy Chinese male medical students (aged 21-31 yeai's) were 
studied in February 1995. One (n=3) or both (n~4) of their parents were known to 
have hypertension requiring regular drug treatment.
During the 10-day study period (days -4 to 0 and days 1 to 5), subjects were 
given the same diet containing 1,900 calories, 75 g protein, 20 mmol sodium and 45 
mmol potassium. From days 1 to 5, they also took 20 'Slow sodium' tablets (Ciba- 
Geigy) equivalent to 200 mmol of sodium per day. Body weight and supine BP were 
measured in the morning before breakfast at the end of each 5-day period.
Urine was collected for 24 hours in bottles containing 100 ml of 0.5M HCl 
on day -4 and from days 0 to 5. Aliquots were refrigerated until assayed for sodium, 
potassium, creatinine (as in Section 5.2.3), free DA and free NA (as in studv one in 
Chapter 5, see Section 5.2.4).
To assess the 'synergistic' effect of activation of renal DA and suppression of 
the SNS activity on urinary sodium excretion (617), changes in the 'natriuretic index' 
(the ratio of 24-hour urinary free DA to NA output) were also examined.
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The significance of differences between variables was tested using the 
Wilcoxon sign-rank test. The data were compared with those from subjects without 
a family history of hypertension (Chapter 7). Significance of differences between 
the two groups was tested using the Mann-Whitney U test.
8.3 Results
The seven subjects with a family history of hypertension were heavier (Table 
8a). After salt loading, their MAP slightly increased and their pulse rates decreased. 
These changes were not seen in the eight subjects without a family history.
Table 8a. MAP, pulse rate and body weight in seven healthy Chinese subjects 
with a family history of hypertension during ingestion of 20 or 220 
mmol of sodium per day. [The corresponding figures from the eight 
subjects without a family history (Chapter 7) are given in brackets.]
At entry 
(day -4)
20 mmol sodium 
(day 0)
220 mmol sodium 
(day 5)
MAP (mmHg) 81.0 + 2.0 
(78.2 ± 2.4)
80.1+2.5* 
(76.8 + 1.8)
83.1 ± 2 .1 t 
(75.0±2.8)§
Pulse (beats/min) 73.4 ± 4.6 
(65.9 + 3.3)
69.4 + 4.4 
(63.5+2.4)
64.7 + 4.5$ 
(61.6 + 4.0)
Body weight (kg) 75.5 ±3.4 
(58.3 + 1.9)§
73.9 ±3.2 
(57.3 + 1.9)
73.6 + 3.2 
(57.9 + 1.9)11
*p<0.02 when compared with at entry. 
tp<0.05, îp<0.02 when compared with day 0.
§p<0.001 when comparing the two groups.
||p<0.05 when comparing the two groups with regards the changes from baseline.
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The urinary outputs of sodium, potassium, creatinine, free DA, free NA and 
DA/NA ratio and urine volume in response to changes in salt intake are shown in 
Table 8b and Figure 8a. Following salt loading, there was a 7- to 10-fold increase in 
sodium excretion (p<0.02). The natriuretic response was not different from that seen 
in subjects without a family history of hypertension. There was also a tendency for 
urine volume and the urinary excretion of potassium and creatinine to increase.
There was a 23% increase in urinaiy free DA output (p<0.02) on the first day 
of high sodium intake (Table 8b and Figure 8a). From days 2 to 5, the increase in 
urinaiy DA output also became attenuated (12-15% higher than the baseline) but still 
reached statistical significance compared with baseline on days 2 and 5. Throughout 
the high sodium intake period, urinary free DA output appeared to be consistently 
higher among those with a family history of hypertension (Table 8b). However, the 
difference between the two groups was not statistically significant (p>0.05).
Unlike the subjects without a family history of hypertension who showed a 
22% reduction in free NA output on day 5, those with a family history showed no 
significant changes in urinary NA output throughout the high sodium intake period. 
Subjects with a family history tended to show a higher urinary free NA output 
throughout the study period (Table 8b) and the difference was statistically significant 
on the second day of salt loading.
There was a 20% increase in the DA/NA ratio (p<0.02) only on day 2 of high 
sodium intake (Table 8b). Subjects without a family history of hypertension showed 
an increase in the DA/NA ratio on day 1 (22.4%), day 2 (25.9%) and day 5 (13.8%). 
The DA/NA ratio appeared to be consistently lower in those with a family history of 
hypertension, but this difference reached statistical significance only on day 1.
194
(D (D
<U
(U
g
g
w
IPM
(D
>
I
o
«30 4— y—\
CO r~ vn 1—( IN 00 OO oq ON N; t-H O
o o T-4 CO r—1 CO T—4 <d r—4 r-H
+1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1
O ) CN NO ON CN ON NO N- CN ON ON CN
o rn ON ON Tf 1—H T|- cn O CN o cn1—I rH T—4
4*4-IT) T—4 NO /—N 1— I NO ON 00 l> oT—1 C7N CN ON CN CN t-H t-H
+1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1
oo 'D o OO ON NO 'It oo NO ON CN 00o\ cn ON ro CO OO CN ON o m 1—(
CN 1—1 t-H CN t-H
4— * *NO CN CN o in in in CNm \o O NO o Th O oo o cn TTOn r-4 ON 1—4IN 1—4
+1 +1 +1 +1 +1 +1 +1 -H +1 +1 +1 +1 +1 +1
in o Tf ON ÇN o ON IN in ON 00 t-H INcn ON m ON IN ON (ON in t- H cno NO ON O N O N- o N- o inCN Y—( t-H CN 1— 1 CN CN CN f-H CN 1—1
* *
O) 00 O cn in
o r-H CO r-4 t-H
+1 +1 +1 +1 +1 +1 +1
<N oo oo ON cn
iri NO NO iri irir—4
-f—oo <N C- 00 o
r4 iri in cn iri NO
+1 +1 +1 +1 +1 +1 +1
<—i ON IN o
o ON 0Ô NO N ONro in '(t cn TT
4— 4— 4-— 4—
CN 4— in ON 0 \ cn 00 CNCN oo ON CN '—1 f—( r—4 CN
+1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +i
in CN (N O NO O ON NO ON NO CN oCN NO IN (ON o NO OO in NOw CN CN 1—H CN CN
<N CN CN cn cn cn
O O CO <d CO <o d
+1 +1 +l +1 +1 +1 +l
in CN in 00 Tj- CN
CS CN CN CN CN CN CN
CN m lO
I
I
I
I
II
xi
OT
§-
p
d> 5 )
g
"O
1 ê
"5ra
& &
O o
Ü o
e C
(D <D
tO TP
CN CN
O O
<=) C3V V
P h P ,
4— (X/3
m mo o
( 3 d>V VCu p* 4*4*
195
I
o>
Q
3000
2000
1000
300
§o
1
§Q
T3
eg
200
100
400
200
0
Sodium
Intake
20 mmol 220 mmol
-4 -3 -1 0 1 
Days
Figure 8a. Mean ± SEM of 24-hour urinary sodium, DA and NA outputs in 
seven healthy Chinese subjects with a family history of hypertension 
when their sodium intake was increased from 20 mmol/day to 220 
mmoFday. *p<0.05, **p<0.02 when compared with day 0.
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8,4 Discussion
Both clinic and ambulatory BP is higher in the normotensive offspring of 
hypertensive parents than in the offspring of normotensive parents even before 
sustained hypertension occurs (618). Normotensive offspring of hypertensive 
parents also differ from offspring of normotensive parents in having an exaggerated 
rise in BP following oral (619) or intravenous (204) sodium loading and a blunted 
renal sodium excretion after saline infusion (204,620). This enhanced effect of 
sodium on BP and an impaired natriuretic response to a salt load may be related to 
abnormalities in some regulating factors of BP and sodium balance (Chapter 2 and 
Chapter 3). Surprisingly, the role of renal DA has rarely been evaluated (520), 
despite its known natriuretic and vasodilatory actions in humans (Chapter 3).
8.4.1 Effects o f salt loading on MAP
Unlike Chinese subjects without a family history of hypertension, those with 
a positive family history showed an increase (average 3.7%) in MAP on changing 
from a 20 to 220 mmol sodium diet (Table 8a).
Similar findings have been reported by previous studies. Pusterla et al. (619) 
in Switzerland studied the BP responses to a low (15-18 mmol/day) or high (>200 
mmol/day) sodium diet for one week each in 23 healthy males (aged 20-32 years, 13 
with a positive family history of hypertension). Following salt loading, BP increased 
only in subjects with a positive family history (119/76 ± 3/2 vs 126/80 ± 4/2 mmHg). 
Myers & Morgan (621) in Australia studied the BP responses to a low (70 
mmoFday) or high (200 mmoFday) sodium diet for two weeks each in 154 healthy 
volunteers. In those aged 20-49 years with a positive family history of hypertension, 
BP was higher at entry [actual figures not given in their publication]. These
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volunteers also showed a greater increase in MAP after salt loading than the subjects 
with a negative family history (males 3.0 ± 1.0 vs -0.2 ±1.7 mmHg, p<0.05; females
3.0 ± 2.8 vs 2.3 ±1.3 mmHg, p-NS). Overlack et al. (622) in Germany studied the 
BP responses to a low (20 mmoFday) or high (300 mmoFday) salt diet for one week 
each in 163 Caucasian, non-obese healthy subjects (98 men and 65 women). 
Compared with subjects with a negative family history of hypertension, subjects with 
a positive family history were younger (33.0 ± 1.6 vs 40.7 ± 1 .7  years) and had a 
higher MAP at baseline (89.1 ± 1.1 vs 85.9 ± 0.8 mmHg). Only those with a positive 
family history showed a rise in MAP (mean 0.9%) after salt loading. Salt sensitivity 
(an increase in MAP of >5 mmHg) was seen in 25.6% of subjects with a positive 
family history and 14.4% of those with a negative history.
Other investigators reported that the offspring of hypertensive parents do not 
differ in their responses to salt loading from those whose parents are normotensive. 
Weissberg et al. (623) in the U.K. recruited 20 male medical students who reduced 
their sodium intake to 40 mmoFday for one week by adhering to a diet sheet. Then, 
they returned to their normal diets supplemented by sodium 200 mmoFday (20 Ciba- 
Geigy 'Slow sodium' tablets) for one week. The change in diet was associated with a 
rise in supine SBP of 6.0 ± 1.1 mmHg and standing SBP of 4.8 ±1.3 mmHg. The 12 
subjects with a family history of hypertension did not differ in their responses from 
subjects without a family history. Turner & Reilly (203) in the U.S. studied the 
changes in MAP after one week of a low (10 mmoFday) and high (200 mmoFday) 
sodium diet in 11 normotensive sons (aged 46.9 ± 1.6 years) of two hypertensive 
parents and 11 normotensive sons (aged 41.4 ± 1.2 years) of two normotensive 
parents. MAP remained 7 mmHg higher in sons of hypertensive parents (low salt 
diet 100 ± 2 vs 93 ± 2 mmHg, high salt diet 97 ± 3 vs 90 ± 2 mmHg).
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8.4.2 Effects o f  salt loading on natriuresis
In my study, daily excretion of sodium did not differ between subjects with 
or without a family history of hypertension on any day of the high salt diet (Table 
8a). Hence, there is no evidence that the renal excretion of sodium after salt loading 
is impaired in healthy Chinese subjects with a family history of hypertension.
Turner & Reilly (203) in the U.S. have determined whether renal sodium 
excretion is impaired and whether tubular reabsorption of sodium is increased in 
normotensive sons of hypertensive parents. Urinary sodium excretion after one 
week of low (10 mmoFday) or high (200 mmoFday) salt diet did not differ between 
normotensive sons of normotensive or hypertensive parents. On day 7 of each diet, 
filtered load of sodium, absolute excretion of sodium, fractional excretion of sodium 
(an index of total tubular sodium reabsorption) and fractional excretion of lithium 
(an inverse index of proximal tubular sodium reabsorption) also did not differ 
between the two groups. They suggested that higher BP (see Section 8.4.1) in the 
offspring of hypertensive parents may have compensatory renal effects that restore 
renal sodium handling to normal (see Section 2.2). Compensatory changes in the 
natriuretic and antinatriuretic systems (Section 8.4.3 and Section 8.4.4) may also 
help restore renal sodium handling to normal.
Stadler et al. (624) in Switzerland compared the renal tubular handling of 
sodium in normotensive subjects with or without a family history of hypertension. 
After changing from a low (15-18 mmoFday) to high (>200 mmoFday) sodium diet, 
GFR, as estimated by the clearance of inulin, is similar in the two groups. The renal 
plasma flow, as estimated by the clearance of para-aminohippurate (PAH), tended to 
be slightly, but not significantly, higher in those with a positive family history. The 
tubular reabsorption of sodium fi'om the proximal tubule, as estimated by the
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difference between the clearances of inulin and lithium, or from the distal tubule, as 
estimated by the difference between the clearances of lithium and sodium, were 
comparable in the two groups. These findings do not support the concept of a 
familial predisposition to hypertension being associated with an enhanced proximal 
reabsorption of sodium.
8.4.3 Effects o f salt loading on the renal DA response
If DA is an important intrarenal natriuretic hormone and dietary sodium is the 
major determinant of its intrarenal synthesis, there should be a positive correlation 
between urinary sodium and free DA (Section 3.1.6). Like healthy Chinese subjects 
without a family history of hypertension, those with a family history show a positive 
correlation between 24-hour urinary sodium and free DA outputs (Chapter 5). It is 
expected that healthy Chinese subjects with a family history of hypertension will 
show a urinary DA response to oral sodium loading.
In the present study of healthy subjects with a family history of hypertension, 
an increase in urinary free DA output (15-23%) was seen during the first two days of 
sodium loading (Figure 8 a). This increase in urinary DA excretion preceded the 
major component of the natriuretic response by one day, suggesting that renal DA 
leads, rather than follows, sodium excretion (13). Like the normotensive Chinese 
subjects without a family history of hypertension (Table 7b and Figure 7a), the renal 
DA response was relatively small (15-23% and 8-17%) and tended to be attenuated 
after 2-3 days (Table 8b and Figure 8a). Thus, renal DA response to oral salt loading 
differs between Chinese and Caucasian subjects both quantitatively and qualitatively. 
Moreover, the increase in urinary DA in both groups of Chinese subjects was 
obviously small compared to the 7- to 10-fold increase in sodium excretion. These
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results suggest that renally produced DA only contributes partly to the acute 
natriuretic response to oral sodium loading in Chinese and the renal DA response to 
salt loading does not differ significantly between the offspring of normotensive and 
hypertensive parents (Table 8a).
Compared with normotensive subjects, urinary free DA output under basal 
conditions is higher in some normotensive Japanese subjects with a family history of 
hypertension (363), young Japanese patients with essential hypertension (515) and 
Caucasian patients with borderline hypertension (516). It has been suggested that the 
increased intrarenal DA synthesis in these subject groups may represent an early 
antihypertensive defense response (Section 4.1.1, Section 5.4.5 and Section 6.4.1).
Compared with subjects without a family history of hypertension, there was a 
trend (p=NS) for a higher urinary free DA outputs after salt loading among subjects 
with a family history (Table 8b). This 'enhanced' renal DA response may represent 
an early antihypertensive defense response (Section 4.1.1, Section 5.4.5 and Section
6.4.1) or a compensatory response to an overactive SNS activity that persists during 
oral salt loading (see Section 8.4.4).
Krzesinski et al. (520) in Belgium compared the renal DA response to salt 
loading in 20 young normotensive subjects with (n=12) or without (n=8) a family 
history of hypertension. While these subjects were on three different sodium diets 
(20, 170 and 340 mmol/day) each for one week, one liter of 0.9% saline was infused 
over 30 minutes with urine being collected for three hours for measurements of 
sodium and free DA. During the low and medium sodium diets, but not during the 
high sodium diet, the natriuresis and DA excretion were lower in the subjects with a 
positive family history. Thus, a genetic predisposition to hypertension seems to be 
characterised by a lower urinary sodium excretion and an impaired renal DA
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synthesis during acute salt loading while on a normal or low sodium diet. It is 
conceivable that subjects with a family history of hypertension might be able to 
show an apparently normal renal DA response during large acute changes in salt 
intake.
Gerlo et al. (625) in Belgium and Young et al. (626) in the U.S. reported an 
inverse correlation between age and 24-hour urinary free DA excretion among free 
living subjects. In my cross-sectional study (Chapter 5), normotensive subjects with 
a family history of hypertension were considerably older (39.1 ±1 .4  and 48.3 ± 7.2 
years) than subjects in salt loading study (21-31 years). It will be of great interest to 
find out if  there is an age-related difference in the renal DA response to salt loading.
8.4.4 Effects o f salt loading on the SNS activity
During salt loading, a reduction in SNS activity will facilitate renal sodium 
excretion (Section 2.4.2) and help offset any tendency to hypervolaemia-related rises 
in BP (Section 7.4.4). This has been shown in healthy subjects as well as patients 
with salt-resistant hypertension (Section 2.4.2).
In the present study, urinary free NA output remained unchanged throughout 
the high salt intake period (Table 8b and Figure 8a). Thus, there was no evidence 
that a reduction in SNS activity plays a role in the natriuretic response to oral salt 
loading in Chinese subjects with a family history of hypertension. This may be one 
reason why they showed an increase in MAP after salt loading (Table 8a). In 
contrast, subjects without a family history of hypertension showed a reduction in 
SNS activity towards the end of high sodium intake and their MAP was unchanged 
(Chapter 7).
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In the study of Turner & Reilly (203), urinary free NA output on day 6 of a 
low (10 mmoFday) and high (200 mmoFday) sodium diet each given for seven days 
was compared between normotensive subjects with or without a family history of 
hypertension. On a low sodium diet, mean NA excretion was 139 nmoFday greater 
in the sons of hypertensive parents (466 ± 171 vs 327 ± 60 nmoFday, p=0.20). On a 
high sodium diet, it was only 53 nmoFday greater in the sons of hypertensive parents 
(286 ± 66 vs 236 ± 79 nmoFday, p=0.10). With the shift from a low to high sodium 
diet, there was a greater reduction in mean NA excretion among the sons of 
hypertensive parents (177 vs 91 nmoFday). The authors suggested that increased 
SNS activity may mediate the increase in vascular resistance and higher BP in the 
sons of hypertensive parents.
8.4.5 Effects o f salt loading on the urinary free DA/NA ratio
Weinberger et al. (617) reported a close correlation between the ratio of urine 
free DA to urine free NA and the state of sodium balance in normal white subjects 
receiving a low (10 mmoFday) or high (800 mmoFday) sodium diet. The natriuretic 
response to salt loading was accompanied by an increase in this 'natriuretic index' 
(due to activation of renal DA synthesis and suppression of SNS activity).
In the present study, the expected increase in DA/NA ratio after salt loading 
was seen in subjects with a family history of hypertension on day 2 and in subjects 
without a family history from day 1 to day 3 (Table 8b). Despite the difference in 
the 'natriuretic index', subjects with a family history of hypertension had a natriuretic 
response similar to those with a family history (Figure 8a and Figure 7a). Higher BP 
in the offspring of hypertensive parents (Section 8.4.1) may have compensatory renal
203
effects that help restore renal sodium excretion to normal (Section 2.2). There could 
also be compensatory changes in other neurohormonal systems (see Section 8.4.6).
8.4.6 Effects o f salt loading on other neurohormonal systems
To identify factors that might account for differences in sodium handling and 
BP responses to salt loading between healthy subjects with or without a family 
history of hypertension, several investigators also assessed indexes of SNS activity 
and circulating natriuretic and antinatriuretic substances after salt loading. Turner & 
Reilly (203) reported a similar reduction in urinary aldosterone but no changes in 
urinary PGEj or plasma endothelin. Pusterla et al. (619) reported similar reductions 
in plasma levels of NA, renin and aldosterone but no changes in urinary PGEj or 
PGp2„ output. Weissberg et al. (623) reported similar reductions in PAC, plasma 
aldosterone and sodium pump activity.
Ferrari et al. (627) in Switzerland measured the plasma ANP in 51 offspring 
of normotensive parents and 45 offspring of hypertensive parents during liberal salt 
intake. Groups were subdivided according to their 24-hour sodium excretion. In the 
offspring of hypertensive parents, plasma ANP was slightly lower on a modest 
sodium intake (5.3 ± 0.7 vs 7.7 ± 0.7 finol/L, p<0.05) and markedly reduced when 
on a high salt intake (8.0 ± 1.3 vs 15.0 ±1.3 fmoFL, p<0.001). Moreover, the slope 
of the relationship between plasma ANP and 24-hour urinary sodium was flatter 
among the subjects with hypertensive parents (z test=2.4). Twenty men were studied 
after four days of low (70/mmoFday) and high (350 mmol/day) salt intake. After 
salt restriction, plasma ANP did not differ between subjects with or without a family 
history. On salt loading, plasma ANP increased only in the subjects with 
normotensive parents. After four days of a 130 mmol sodium diet, 16 men were
204
given two litres of 0.9% saline over 90 minutes. The acute plasma ANP response 
did not differ between the subjects with or without a family history of hypertension. 
Thus, an altered ANP response in hypertension-prone subjects becomes apparent 
during chronic, rather than acute, stimulation of ANP release by salt intake.
8.4.7 Effects o f salt loading on urinary creatinine output
In this study and in my previous study (Chapter 7), there were 15-43% and 8- 
43% increases respectively in urinary creatinine output following salt loading. There 
could be two possible explanations. Firstly, creatinine clearance tends to increase 
when changing from a low to high salt intake (628,629). Secondly, when plasma 
creatinine is measured using the Jaffe reaction or other methods, interference by DA 
is now recognised (630). To what extent urinary DA may interfere with the 
measurement of urinary creatinine has not yet been determined.
8.4.8 Implications and significance o f my findings
As in healthy Chinese subjects without a family history of hypertension, 
those with a family history show an early but unsustained rise in urinary free DA 
during oral sodium loading. Such an increase is relatively small compared to the 7- 
to 10-fold increase in urinary sodium excretion. These data suggest that renal DA 
only contributes partly to the natriuretic responses to sodium loading. Unlike those 
with normotensive parents, subjects with a family history of hypertension show an 
increase in MAP after oral sodium loading, possibly because of the inappropriately 
high SNS activity. Subjects with a family history tend to have a higher urinary free 
DA output during sodium loading. This might represent an early antihypertensive 
defense response or a compensatory response to increased SNS activity.
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Chapter 9 Urinary free DA and NA outputs in response to gradually 
increasing oral sodium intake over eight days in healthy Chinese 
subjects
9.1 Background of the study and main objectives
I have so far described that renal DA appears to contribute only partly to the 
acute natriuretic response to oral salt loading in healthy Chinese subjects (Chapter 7 
and Chapter 8). This conclusion is based on the observations that following acute 
changes in oral sodium intake from 20 to 200 mmoFday: (a) the increase in free DA 
is relatively small, compared to the 7- to 10-fold increase in urine sodium and the 
DA response reported in Caucasian subjects; (b) the increase in urine DA becomes 
attenuated after two to three days.
All previous studies on the effects of oral salt loading on the renal DA 
response and hence the role of renal DA in sodium homeostasis (Section 3.1.7) have 
used sudden and large changes in salt intake (e.g. from 20 to 220 mmol sodium/day). 
Such an approach has a major limitation as it does not test the sensitivity of the renal 
DA and other natriuretic or antinatriuretic systems to small and 'physiological' 
changes in salt intake. If renal DA system plays an important role in sodium and 
ECF volume homeostasis in Chinese, it should be sensitive to small and gradual 
increases in sodium intake. Similarly, a prompt response in SNS activity might also 
be expected.
Therefore, in this study, I have focused on the natriuretic response and the 
sensitivity of renal DA and SNS activity to small and gradual increases in sodium 
intake in healthy Chinese subjects.
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9.2 Subjects and methods
This study had been approved by the Clinical Research Ethics Committee of 
the Faculty of Medicine, the Chinese University of Hong Kong. After the nature and 
purpose of the study were explained, consent was obtained from each participant.
Seven healthy Chinese males (aged 23-25 years) were studied in September- 
October 1995 after a physical and laboratory examination to rule out any significant 
illness. They were medical students living in the air-conditioned student hostel next 
to the Prince of Wales Hospital. The BP of their parents was said to be <140/90 
mmHg, as indicated by the recent measurements by the students or family doctors.
The study was performed in the out-patient setting. During the 12-day study 
period, they had deliberately avoided outdoor activities so as to minimise sodium 
loss from sweating. From days -3 to 0 and days 1 to 8, they were given the same diet 
prepared by the Prince of Wales HospitaTs kitchen containing 1,900 calories, 75 g 
protein, 20 mmol sodium and 45 mmol potassium. From days 1 to 8, the subjects 
also received 'Slow sodium' tablets (Ciba-Geigy) equivalent to 50 mmol on day 1, 
100 mmol on day 2, 150 mmol on day 3, 200 mmol on day 4, 250 mmol on day 5, 
and 300 mmol on days 6 to 8. These were taken in three divided doses with the main 
meals.
Body weight and 10-minute supine BP was recorded in the morning before 
breakfast on entry and at the end of the low and high sodium intake periods. The 
mean of three consecutive readings measured by a Dinamap at intervals of one 
minute was taken as the subject’s BP. MAP was calculated.
Urine was collected for 24 hours from 8 a.m. to 8 a.m. in bottles containing 
100 ml of 0.5M HCl on day -3, day 0 and days 1 to 8. Aliquots were stored at -20°C 
until assayed for sodium, potassium, creatinine, free DA and free NA.
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Urinary sodium and potassium were measured by ion-selective electrodes and 
creatinine by the Jaffe reaction on a BM/Hitachi 911 automatic analyzer (Boehringer 
Manheim, Germany). Urinary free DA and NA were measured as in studv one in 
Chapter 5 (Section 5.2.4).
Differences from baseline and between the study periods for all variables 
were tested using the Wilcoxon sign-rank test. P values of less than 0.05 were 
regarded as statistically significant.
9.3 Results
After four days of salt restriction, the subjects showed a mean reduction in 
their MAP and body weight of 4.3% and 1.3%, respectively (Table 9a). Following 
salt loading, their average heart rate fell by 10.5%, but their body weight and MAP 
did not change.
Table 9a. MAP, pulse rate and body weight in seven healthy Chinese subjects at 
entry and during the ingestion of 20 or 70-320 mmol of sodium/day.
At entry 
(day -3)
20 mmol sodium 
(day 0)
70-320 mmol sodium 
(day 8)
MAP (mmHg) 83.0 ± 1.3 79.4 + 0.5* 81.6 + 2.1
Pulse (beats/min) 63.1+2.4 64.1+2.8 57.4 + 2.6$
Body weight (kg) 70.2 + 3.1 68.3 + 3.01 68.5 + 2.9
*p<0,05, tp<0.02 when compared with at entry. 
$p<0.02 when compared with day 0.
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The mean daily outputs of sodium, potassium, creatinine, free DA and NA 
and the urine volume in response to changes in sodium intake are shown in Table 9b 
and Figure 9a. By the last day of the low salt intake period (Day 0), urinary sodium 
excretion was 29 + 3 mmol/day. As the oral sodium intake was gradually increased, 
there were corresponding increases in urinary sodium excretion. By the last day of 
salt loading period, sodium excretion had increased 13-fold (p<0.02). There were no 
significant changes in urine volume or urinary potassium and creatinine outputs.
Table 9b. 24-hour urine volume and urinary excretion of sodium, potassium and 
creatinine in seven healthy Chinese subjects during low (days -3 to 0) 
and high (days 1 to 8) sodium intakes.
Days Sodium intake 
(mmol/day)
Volume
(1)
Sodium
(mmol)
Potassium
(mmol)
Creatinine
(mmol)
-3 20 2.4 + 0.3 116 ±27 46.1+3.6 14.7 + 0.6
0 20 2.1 ± 0.2 29 + 3 50.9 + 3.3 16.1+0.9
1 70 1.9+ 0.2 4 1 + 9 51.7 + 4.0 16.2 + 0.8
2 120 1.7+ 0.3 64 ± 8* 56.1+4.9 16.9 + 0.8
3 170 1.9 ± 0.2 152 + 24$ 55.6 ±2.1 16.2+1.0
4 220 1.9 ± 0.2 186 + 26$ 47.3 + 3.7 17.2 + 0.7
5 270 2.1 ± 0.2 283 ± 12$ 44.7 ±2.8 16.6 + 0.9
6 320 2.1 + 0.1 362 + 17$ 45.1+3.2 15.5 + 0.6
7 320 2.3 ±0.3 337 + 22$ 44.7 ± 5.5 15.9 + 0.5
8 320 2.3 + 0.2 403 + 12$ 51.1+5.3 16.3 + 0.7
*p<0.05, tp<0.02 compared with day 0.
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Figure 9a. Mean ± SEM 24-hour urinary sodium, DA and NA outputs in seven 
healthy Chinese subjects when their sodium intake was increased 
gradually from 20 to 320 mmoFday. *p<0.03, **p<0.02 when 
compared with day 0.
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There were no significant changes in urinary free DA output throughout the 
high sodium intake period.
In contrast, there was a 19.9-26.5% reduction (p<0.03) in urinary free NA 
output four and six days after the start of the increase in sodium intake.
9.4 Discussion
The results from this study demonstrated that small, gradual increases in oral 
sodium intake in healthy Chinese subjects resulted in corresponding increases in 
urinary sodium excretion. This was not, however, accompanied by any increase in 
urinary free DA excretion. Instead, a reduction in SNS activity towards the end of 
the high salt intake period was seen.
To have a better appreciation of how sensitive the neurohormonal systems to 
changes in ECF volume can be, the only other published study of the effects of 
gradual changes in oral sodium intake (631) is reviewed below.
9.4.1 Effects o f gradual increases in salt intake on plasma ANP and the RAS
Sagnella et al. (631) in the U.K. studied the sensitivity of plasma ANP and 
the RAS to gradual changes in dietary salt intake in six normal subjects (19-21 years, 
4 men, 2 women). After two days on their normal sodium intakes, they were put on 
a low salt intake diet of 10 mmoFday for four days (days -3 to 0). Sodium intake 
was then gradually increased in increments of 50 mmoFday (day 1) up to 350 
mmol/day (day 7). Subjects were maintained on this level for the subsequent two 
days (days 8 to 9). Blood was taken for the measurements of ANP, PAC and
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aldosterone, and 24-hour urine samples were collected for the measurements of 
sodium, potassium and creatinine outputs.
By the fourth day on the low salt diet (day 0, Table 9c), mean urinary sodium 
excretion was 12.2 mmol, which was similar to the dietary intake. As the sodium 
intake was gradually increased by 50 mmoFday, there were corresponding increases 
in urinary sodium excretion. Throughout the study, there were no significant 
changes in BP, urinary potassium excretion and creatinine clearance.
Table 9c. Urinary sodium, plasma ANP, aldosterone and PRA in six healthy 
Caucasian subjects during gradual increases in dietary salt intake.
Days Sodium
intake
(mmoFday)
Urinary
sodium
(mmoFday)
Plasma
ANP
(pg/ml)
Plasma
aldosterone
(pmol/ml)
PRA
(ng/ml/h)
0 10 12.2 ±4.2 9.9 ±1.1 2,520 ± 147.4 7.1 ± 1.3
1 50 13.3 + 2.8 11.4± 1.6 1,393 ± 125.4* 7.5 ± 1.9
2 100 27.2 ± 7.4* 14.4 ± 1.8* 785.8 ±75.6* 3.6 ± 1.0*
3 150 89.6 ±21.8* 16.9±2.1* 360.5 ±60.3* 2.0 ±0.4*
4 200 169.8 ± 17.8* 20.9 ±2.9* 291.1 ±43.3* 1.8 ±0.5*
5 250 268.5 ±36.5* 20.9 ± 3.7* 496.8 ± 118.8* 1.9 ±0.5*
6 350 295.8 ± 15.9* 23.3 ± 2.2* 204.8 ± 26.5* 1.1 ±0.3*
7 350 314.8 ±31.4* 23.1 ±2.2* 251.6 ±78.7* 1.6 ±0.4*
Data from Sagnella et al. (631). *p<0.05 vs basal levels (day 0).
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It can be seen from the study of Sagnella et al. (631) that with gradual 
increases in sodium intake (50 mmoFday), there were corresponding increases in 
plasma ANP (Table 9c). There was a 15.2% increase in mean plasma ANP even on 
day 1, but this did not reach statistical significance. There were also marked 
reductions in plasma aldosterone from days 1 to 7 (Table 9 c). Changes in PRA 
paralleled those in plasma aldosterone concentration with the exception that there 
was no significant change in PRA on the first day of the raised salt intake (Table 9c). 
These results indicate that plasma ANP and the RAS are extremely sensitive to 
relatively small increases in sodium intake.
9.4.2 Effects o f gradual increases in salt intake on the renal DA response
In my study, I have clearly shown that healthy Chinese subjects did not show 
any renal DA response at all during gradual increases in oral salt intake (Figure 9a). 
In particular, there were still no changes in urinary free DA output, despite a sodium 
intake that was much larger (320 vs 220 mmoFday) than that used in the preceding 
studies (Chapter 7 and Chapter 8) and resulted in a larger (13- vs 9-10-fold) increase 
in urinary sodium excretion. This finding is surprising since sudden, large changes 
in oral salt intake (20 to 220 mmoFday) produced an early, although unsustained, 
increase in free DA output (Chapter 7 and Chapter 8).
9.4.3 Effects o f gradual increases in salt intake on the SNS activity
Another mechanism which contributes to the natriuretic response to sodium 
loading is a reduction in SNS activity (Section 2.4.2). Impaired suppression of SNS 
activity after salt loading, which is seen in patients with salt-sensitive hypertension
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(Section 2.4.2) and healthy Chinese subjects with a family history of hypertension 
(Chapter 8), is associated with greater sodium retention and an increase in MAP.
In my study, the temporal profile of urinary NA output did not resemble that 
of urinary sodium output (Figure 9a), again suggesting that a reduction in SNS 
activity is not the mediator of the natriuretic response to salt loading in healthy 
Chinese subjects. This is not surprising since I had already found that sudden, large 
changes in sodium intake (20 to 220 mmoFday) did not produce an early reduction in 
urinary free NA in normotensive Chinese subjects (Chapter 7 and Chapter 8). 
However, as in the offspring of normotensive parents given sudden, large changes in 
oral salt intake (Chapter 7), a late reduction in SNS activity (Figure 9a) may 
counteract any tendency to hypervolaemia-related rises in BP towards the end of the 
high salt intake period.
9.4.4 Significance and implications o f my findings
My findings described so far indicate that the renal DA system in Chinese is 
insensitive to gradual and small increases in oral salt intake. A relatively small and 
unsustained renal DA response is seen only after sudden and large changes in oral 
salt intake. Furthermore, when Chinese subjects are subjected to both sudden, large 
increases and gradual, small increases in dietary salt intake, a reduction in SNS 
activity is not seen until towards the end of the high salt intake period. This finding 
suggests that increased activity of the SNS does not contribute to the early natriuretic 
response to salt loading. However, the late reduction in SNS activity seen in the 
offspring of normotensive parents may offset a tendency to hypervolaemia-related 
increases in BP.
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Chapter 10 Urinary free DA and NA outputs in response to intravenous 
saline infusion in healthy Chinese subjects
10.1 Background of the study and main objectives
Sodium intake is considered to be the most important factor regulating the 
synthesis of free DA by the proximal tubules in the kidney (Section 3.2).
I have so far demonstrated that the renal DA response to oral salt loading in 
normotensive Chinese subjects is less than that reported in Caucasian subjects 
(Chapter 7 and Chapter 8) or absent (Chapters 9), depending how the salt load is 
given. It was thus of great interest to find out if normotensive Chinese would exhibit 
a renal DA response to intravenous saline infusion in a manner similar to that 
described in Caucasians (Section 3.1.9). The renal DA responses to salt loading 
might be different when the oral or intravenous administration route is used. Few 
investigators have used both methods of salt loading to evaluate the renal DA 
response in their subjects (Section 3.1.7 and Section 3.1.9). There are marked ethnic 
differences in renal sodium-DA relationships both under basal conditions (Section 
3.1.6) and after salt loading (Section 3.1.7 and Section 3.1.9). Since their MAP is 
unchanged and the natriuretic response to a high salt diet is similar to those reported 
previously (Chapter 7 and Chapter 9), Chinese subjects without a family history of 
hypertension must have other mechanism(s) for dealing with a salt load. In view of 
the role of the renal kallikrein-kinin system in the control of ECF volume, BP and 
sodium and water excretion (Section 2.3.3) and its aetiological role in salt-sensitivity 
(Section 2.5.8), our group has developed in 1996 an assay for the simultaneous 
measurement of acid-labile urinary kallikrein and acid-stable free catecholamines 
using boric acid as a preservative (Section 5.2.4 and Section 5.2.5).
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In the present study, my main objective was to determine the relative roles of 
the renal DA and kallikrein-kinin systems and suppression of SNS activity in the 
natriuretic response to an intravenous salt load in Chinese subjects.
10.2 Subjects and methods
This study had been approved by the Clinical Research Ethics Committee of 
the Faculty of Medicine, the Chinese University of Hong Kong. Informed consent 
was obtained from each participant after the nature and purpose of the study were 
explained.
Eight healthy, male Chinese medical students (aged 23-25 years) were 
studied in April 1996 after a routine physical and laboratory examination to rule out 
hypertension, diabetes mellitus, renal disease or other significant illnesses. None of 
their parents had hypertension (BP >140/90 mmHg), which was verified during 
recent BP measurements by family physicians or the medical students themselves.
All subjects continued to take their usual diets. In order to quantify their 
usual sodium intake, they collected their urine for the 24-hour period preceding the 
study.
All subjects were fasted overnight. On arrival in our Clinical Pharmacology 
Studies Unit, they drank 400 ml of distilled water. At 08:30 (time 0), they emptied 
their bladder and discarded this urine. An intravenous Venflon cannula was inserted 
into a vein in each forearm. After an equilibration period of one hour (hour 0), they 
received an intravenous infusion of 0.9% saline (1,000 ml) over two hours (hours 1 
and 2), followed by a 4-hour recovery period (hours 3 to 6). From hours 0 to 4, the 
subjects remained in the supine position, except to void urine which was collected
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hourly. To ensure an adequate diuresis, about 200 ml/h of distilled water was given 
orally at hourly intervals from hours 1 to 6. From hours 0 to 4, supine BP and pulse 
measurements and blood sampling (for renal function tests and plasma protein) were 
followed by urine voiding. The means of three consecutive SBP and DBP readings, 
measured by a Dinamap at intervals of one minute, were taken. MAP was then 
calculated. Body weight was measured after urine voiding from hours 0 to 4. I was 
present throughout the study to ensure that the study run smoothly and the volunteers 
did not have any discomfort.
Urine was collected into plain bottles. Aliquots were then taken and stored in 
boric acid at -20°C. Free DA and NA were measured by an alumina extraction 
procedure followed by quantitation by HPLC with electrochemical detection, as in 
studv two of Chapter 5 (Section 5.2.4). Urinary kallikrein was measured as in studv 
two of Chapter 5 (Section 5.2.5).
Urinary sodium and potassium were measured by ion-selective electrodes. 
Urinary creatinine was measured by Jaffe reaction on a BM/Hitachi 911 automatic 
analyzer (Boehringer Manheim, Germany). Renal function tests and total protein 
were measured on a DuPont Dimension AR chemistry analyser using standard 
routine laboratory methods.
Differences from baseline (hour 0) for all variables were tested using the 
Wilcoxon Sign-Ranks test. P values of less than 0.05 were regarded as statistically 
significant.
10.3 Results
The 24-hour urinary sodium excretion in the eight subjects prior to the study 
day ranged from 125 to 339 mmol (mean 232 mmol).
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Following intravenous saline infusion, MAP and pulse rate in the eight 
subjects did not change (Table 10a). There was a small increase in body weight of 
about 1% (p<0.05).
Table 10a. MAP, pulse rate and body weight in eight healthy Chinese subjects 
before (hour 0), during (hours 1 to 2) and after (hours 3 to 4) the 
intravenous infusion of 0.9% saline (1,000 ml over 2 hours).
Time (hours)
0 1 2 3 4
MAP
(mmHg)
80.4 + 2.5 79.6 ± 3.2 81.8 ±3.6 79.2 ±2.7 80.7 ± 1.8
Pulse
(beats/min)
64.3 ±2.9 64.1 ± 3.6 66.3 ±3.7 65.7 ±2.6 66.6 ± 4.2
Body
Weight
(kg)
64.9 ± 1.9 65.0 ±1.8 65.4 ± 1.8* 65.5 ±1.8* 65.5 ±1.8
^p<0.05 when compared with the baseline (hour 0).
The plasma electrolytes and total protein of these subjects during the saline 
infusion are summarised in Table 10b. As a result of the haemodilution, their plasma 
urea, creatinine and total protein concentrations all decreased.
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Table 10b. Plasma electrolytes and total protein in eight healthy Chinese subjects 
before (hour 0), during (hours 1 to 2) and after (hours 3 to 4) the 
intravenous infUsion of 0.9% saline (1,000 ml over 2 hours).
Time (hours)
0 1 2 3 4
Sodium
(mmoFL)
140.6 ± 0.9 140.9 ± 0.7 140.8 ± 0.8 140.9 ± 0.6 140.8 ± 0.7
Potassium
(mmoFL)
4.2 ±0.1 4.1 ±0.1 4.0 ±0.1 4.1 ±0.1 4.1 ±0.1
Urea
(mmol/L)
5.3 ±0.5 5.1 ±0.5* 4.8 ± 0.4t 4 .5 ± 0 .5 t 4.4 ± 0.4t
Creatinine
(pmol/L)
86.3 ±2.8 84.9 ± 2.6 82.4 ±3.5* 83.4 ±2.9 79.5 ±1.7*
Protein
(g/L)
76.6 ±1.6 73 .3±1 .4 t 70.8± 1.6t 71.6± 1.5t 72.5±1.3f
^p<0.05, tp<0.02 when compared with the baseline (hour 0).
The hourly urinary outputs of sodium, potassium, creatinine, free DA, free 
NA and kallikrein and urine volume in response to the saline inftision are shown in 
Table 9c and Figure 9a. There was a 31-39% increase in sodium excretion (p<0.05) 
during the second hour of infusion (hour 2) and first hour of recovery period (hour 
3). There were no significant changes in urinary free DA throughout the study. 
Urinary free NA did not change while the subjects remained supine. However, an 
increase in free NA output of 91-105% (p<0.02) was seen following ambulation 
(hours 5 to 6). Urinary kallikrein excretion showed a sustained increase during the 
saline infusion (103.0-140.4%) and for the first hour of the recovery period (74.1%).
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Figure 10a. The effects of intravenous saline infusion on the mean ± SEM hourly 
urinary sodium, DA, NA and kallikrein outputs in the healthy Chinese 
subjects. *p<0.05, **p<0.02, ***p<0.01 when compared with hour 0.
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10.4 Discussion
In this study, I have demonstrated that both urinary free DA and NA outputs 
in healthy Chinese subjects were not altered by the acute ECF volume expansion 
induced by an intravenous saline infusion. In contrast, this manoeuvre significantly 
increased the urinary excretion of kallikrein. These findings suggest that only the 
renal kallikrein-kinin system contributes to the acute natriuretic response to saline 
infusion in Chinese subjects.
10.4.1 Effects o f salt loading on the renal DA response in Chinese subjects
Subjects in this study did not show an increase in renal DA output following 
acute saline infusion despite a 31-39% increase in urinary sodium excretion (Figure 
10a). This finding suggests that renal DA is not an important natriuretic system in 
Hong Kong Chinese subjects. However, before reaching this conclusion, I must 
consider other possible explanations.
First, the intravenous salt load used in my study (1,000 ml over 2 hours or
15.4 ml/kg/2 hours) was small compared to that used in the studies done by other 
groups and discussed in Section 10.4.2. However, this was unlikely to be the reason 
for the absence of a renal DA response in my subjects. Even this modest salt load 
was enough to elicit a 31-39% increase in urinary sodium output and a 103.0-140.4% 
increase in urinary kallikrein output (Figure 10a). As already discussed in Chapter 9, 
if renal DA were an important natriuretic system in Chinese, this system should be 
sensitive to even small changes in ECF volume and body sodium status. In the 
published studies using Caucasian subjects (Section 10.4.2), a clear-cut, dose- 
response relationship between the infusion of 0.9% saline and the urinary free DA 
response was not seen. In other words, a mild to moderate expansion of the ECF
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volume may still elicit a renal DA response. In fact, both Chen & Lokhandwala 
(408) and Bass & Murphy (409) have shown in rats that renal DA system appeal's to 
be relatively more important in promoting natriuresis at the lower (physiological) 
range of hypervolaemia (see Section 3.1.9).
The preceding level of dietary sodium intake could have a profound influence 
on the natriuretic response to acute saline infusion in normotensive Caucasian 
subjects with or without a family history of hypertension (203). Prior dietary salt 
restriction resulting in activated antinatriuretic systems may alter the natriuretic 
response to acute saline infusion and the associated changes in neurohormone 
systems. This was demonstrated in the study by Krzesinski et al. (520). Compared 
with healthy subjects without a family history of hypertension, Caucasian subjects 
with a family history had reduced natriuretic and renal DA responses to saline 
infusion after a low (20 mmol/day) or medium (170 mmol/day) sodium diet for one 
week. However, there were no differences between the two groups after a high (340 
mmol/day) sodium diet for one week. Hence, variations in the dietary intake of 
sodium, and other nutrients, prior to the saline infusion could have been a 
confounding factor in my study.
Studies in Caucasian subjects have indicated that oral salt is a more potent 
stimulus to renal DA formation than intravenous saline (see Section 10.4.2). Since 
Hong Kong Chinese subjects have a smaller and less sustained renal DA response to 
oral salt loading compared with Caucasian subjects (Chapter 7 and Chapter 8), it is 
not entirely surprising that subjects in the present study did not show a renal DA 
response to intravenous saline infusion.
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10.4.2 Effects o f  salt loading on the renal DA response in Caucasian subjects
Healthy Caucasian subjects generally show a renal DA response to saline 
infusion (Section 3.1.9). Alexander et al. (12) in the U.S. studied seven healthy 
women (aged 19-23 years) who were receiving a 59 mmol/day sodium diet for three 
days. An intravenous infusion of 5% dextrose (240 ml over 80 minutes) was 
followed by 0.9% saline (2,400 ml over 160 minutes). The data they published were 
the means of the three 20-minute intervals immediately preceding saline infusion and 
the means of the last four 20-minute periods of saline infusion. On changing to 
saline infusion, a 236% increase in sodium excretion (6.4 ± 0.8 vs 21.5 ± 2.8 
mmol/hour, p<0.01) and a 28% increase in free DA excretion (42.7 ± 4.3 vs 54.7 ±
3.7 nmol/hour, p<0.01) were seen.
Castellano et al. (391) in Italy studied eight normal subjects (four males and 
four females, aged 19-57 years) without a family history of hypertension. They were 
given a 120 mmol/day sodium and 80 mmol/day potassium diet for five days. Urine 
was collected for 24 hours on the first day under basal conditions and on the second 
day after intravenous 0.9% saline infusion (2,000 ml over two hours). The average 
urinary DA excretion increased by 18% following the infusion (128 to 150 nmol/mol 
creatinine, p<0.01).
Jeffrey et al. (392) in the U.K. studied nine healthy males (aged 20-38 years). 
Dietary advice was given to encourage a moderate salt intake over the preceding 48 
hours. Tap water was given at intervals to ensure an adequate urine output. After a 
2-hour baseline period (hours 0 to 2 ), the subjects were administered an intravenous 
infusion of 0.9% saline (20 ml/kg/hour) for three hours (hours 2 to 4) followed by a 
2-hour recoveiy period (hours 5 to 7). The subjects were reclining during this 5-hour 
period but, thereafter, they were allowed to rise, and their urine was collected for a
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further four hours (hours 7 to 11). Sodium excretion increased steadily from 9.0 ±
1.8 mmol/hour during the baseline period to 43.8 ± 7,2 mmol/hour in the hour after 
the infusion (p<0.01), representing a 5-fold increase. Levels declined after this point 
but remained well above control during hours 7 to 11. During the entire study, only 
26% of the administered salt load was excreted. A modest but significant increase in 
the free DA excretion of an average of 26% was detected during the inftision (79.8 ±
7.2 to 100.2 ± 7.8 nmol/hour, p<0.01). This increase in urine DA was maintained 
until the end of the study. In other words, the increase in urinary free DA output 
persisted during and after the saline infusion.
Stenvinkel et al. (393) in Sweden studied nine healthy men (mean age 33, 
range 31-40 years). The subjects continued their usual diets with ad libitum sodium 
and protein intakes. On the morning of study, 500 ml of tap water was given orally, 
followed by 300 ml each hour. After a baseline period of one hour, an inftision of
0.9% saline was given for two hours at a rate of 25 ml/kg. The subjects were 
observed for a further two hours. The subjects remained in a supine position except 
to void urine, which was collected hourly. During the inftision, sodium excretion 
increased by an average of 46% (11.5 ± 1.5 to 16.2 ± 2.4 and 16.2 ±1.8 mmol/hour, 
p<0.01). One and two hours after termination of the saline infusion, urinary sodium 
excretion was still well above the basal level (19.1 ± 1.9 and 22.1 ± 2.3 mmol/hour, 
p<0.01). A 12.8% increase in urinary free DA occurred during the second hour of 
the saline infusion (63.1 ± 9.1 to 71.2 ± 8.0 nmol/hour, p<0.01). The urinary free 
DA excretion remained 16.2% and 9.5% higher than the baseline output even one 
and two hours after the completion of the saline inftision (73.3 ± 9.0 nmol/hour, 
p<0.01 and 69.1 ± 9.8 nmol/hour, p<0.05).
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Stenvinkel et al. (394) repeated their study in 14 healthy men (mean age 34, 
range 25-47 years) using an identical protocol (393). During the second hour of the 
saline infusion, the urinary free DA excretion increased by 16.0% (77.4 ± 5.4 to 89.8 
± 5.8 nmol/hour, p<0.025 and remained 16.5% higher than the basal value even one 
hour after the completion of the infusion (90.2 ± 6.8 nmol/hour, p<0.025).
Stenvinkel et al. (396) extended their study to 15 healthy men (mean age 34, 
range 20-51 years) using an infusion rate of 0.9% saline 12.5 ml/kg for two hours. 
Urinary sodium excretion increased by 19.8% and 28.2% during the infusion (13.1 ±
1.3 to 15.7 ± 1.7 and 16.8 ± 1.5 mmol/hour, p<0.05). The urinary sodium output 
was even higher (45.8 and 69.5%) one and two hours after the completion of the 
infusion (19.1 ±1.4 and 22.2 ±1.7 nmol/hour, p<0.01). There was a 14.5% increase 
in urinary free DA excretion during the second hour of the saline inftision (81 ± 6 to 
93 ± 7 nmol/hour, p<0.01). The urinary free DA excretion remained 16.0% and 
14.8% elevated one and two hours, respectively, after the completion of the saline 
inftision (94 ± 7 and 93 ± 9  nmol/hour, p<0.01).
Stokes et al. (395) in Australia studied 20 healthy volunteers (14 men, 6 
women, mean age 28 years). The subjects received a 100 mmol/day sodium, 60-80 
mmol/day potassium diet for six days. On the morning of the study, 500 ml of water 
was given by mouth, followed by 200 ml hourly. After a baseline period of 90 
minutes, two litres of 0.9% saline were given over three hours. Urine was collected 
every 90 minutes. The natriuretic response to the intravenous saline inftision was 
accompanied by an increase in the urinary free DA/NA ratio, i.e. an increase in free 
DA but a decrease in free NA excretion. [Data were presented in this abstract as 
graphs but absolute figures were not given.]
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Stokes et al. (397) repeated their study in 10 healthy volunteers without a 
family history of hypertension (mean age 27, range 18-64 years; mean body weight 
74, range 61-90 kg) using the same regimen of saline infusion (395). The natriuretic 
response was accompanied by a renal DA response, with the increase in urine free 
DA being greater in the post-infusion period. The increase in urinary free DA 1.5- 
3.0 hours after the completion of the saline infusion was 57 ± 23%. However; a 
figure of 225 ± 97% was obtained if the urine had been acidified to a pH of 1-1.5 
instead of 2.0-2.5 before storage (see Section 3.1.9).
A greater increase in urinary free DA output is generally seen after oral salt 
loading (Section 3.1.7) compared with intravenous saline infusions (Section 3.1.9), 
suggesting that oral salt is the more potent stimulus to renal DA formation. Lee 
(632) suggested that an increased oral sodium intake over several days is more 
effective in expanding ECF volume than an equivalent amount of sodium given 
intravenously. However, it is difficult to explain why an increase in urinary free DA 
is seen in Caucasian and Japanese patients with essential hypertension after an 
intravenous saline load but not an oral salt load (see Section 4.1.1).
10.4.3 Effects o f salt loading on the SNS activity
A reduction in SNS activity might be expected to facilitate the renal excretion 
of a salt load (Section 2.4.2). However, in the eight healthy Chinese subjects I 
studied, urinary free NA output remained unchanged even after the completion of the 
saline infusion (Figure 10a). This observation suggests that the natriuretic response 
to an intravenous salt load in Hong Kong Chinese does not depend on a reduction in 
SNS activity.
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The role of SNS activity in modulating the natriuretic response to intravenous 
saline infusion was studied less often. In the study of Alexander et al. (12), the 
combined urinary outputs of free NA and free adrenaline were used as a marker SNS 
activity and were unchanged after the saline infusion. In the study of Castellano et 
al. (391), a 17.3% reduction in mean free NA output was seen (17.0 to 14.0 
pmol/mol creatinine, p<0.01). In the studies of Stokes et al. (395,397), the increase 
in urinary free DA/NA ratio was consistent with an activation of the renal DA 
system and/or a suppression of SNS activity during and after the saline infusion.
10.4.4 Effects o f  salt loading on renal kallikrein-kinin activity
The renal kallikrein-kinin system may modulate the renal excretion of 
sodium and water (Section 2.3.3). Furthermore, an association between defects in 
the renal handling of salt and water by the kallikrein-kinin system and hypertension 
has been suspected. Kallikrein is synthesised in the kidney and excreted into the 
urine. Most of the kallikrein in the urine is in the active form and predominantly 
reflects kallikrein secretion by the kidney (633). Thus, urinary kallikrein output has 
been used an index of renal kallikrein-kinin activity (see below).
In my study, the eight subjects showed a 103.0-140.4% increase in their 
urinary kallikrein output during the saline infusion (Figure 10a). Urinary kallikrein 
excretion was still much higher (74.1%) than at baseline one hour after completion 
of the infusion. The brisk urinary kallikrein response despite a relatively small salt 
load suggests that the renal kallikrein-renin system might play an important role in 
ECF volume and sodium homeostasis in Hong Kong Chinese.
Watson et al. (634) in the U.S. administered three litres of 0.9% saline over 
60 minutes to 10 healthy men (aged 30 ± 6 years). The urinary sodium output
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increased by 100% during the inftision. The urinary sodium output remained 
elevated 30 minutes (3-fold increase) and two hours (2-fold increase) after the 
completion of the infusion. The urinary kallikrein excretion increased rapidly 
(within 20 minutes of the start of the saline infusion) to a peak, 2-fold increase, at 40 
minutes. A persistent elevation in the urinary kallikrein output was seen up to 30 
minutes after the completion of the saline infusion.
Ohman & Karlberg (83) in Sweden studied the effects of the intravenous 
infusion of 0.9% saline (2,000 ml over four hours) on 15 healthy subjects (mean age 
43, range 28-58 years) and 14 age-matched patients with essential hypertension. 
Urinary kallikrein excretion increased only in the healthy subjects, during the third 
and fourth hour of saline infusion (44%).
Nishimiya et al. (635) in Japan studied nine normotensive subjects, who were 
receiving a 200 mmol/day sodium diet. The subjects were given an intravenous 
infusion of 0.9% saline (1,000 ml over two hours). Urine volume, urinary sodium 
excretion and the fractional excretion of sodium were all increased. There was also 
an increase in urinary kallikrein excretion during the saline infusion, but the basal 
values and % increases were not stated in their publication.
However, two other studies failed to confirm an increase in urinary kallikrein 
excretion after intravenous saline infusion. Lieberthal et al. (636) in the U.S. studied 
six Caucasian males, who were on a diet containing 180 mmol sodium and 100 
mmol potassium per day. The subjects were given 3 ml/kg water orally. Two litres 
of 0.85% saline were given over one hour. Both in the 3-hour period after the 
cessation of the saline infusion and in the subsequent 20-hour period, there were no 
changes in kallikrein excretion. Lewis et al. (637) in the U.K. studied seven healthy 
females (aged 20-29 years) on two days (a control and a saline infusion day). The
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subjects were given an oral water load (20 ml of tap water/kg, followed by 300 ml 
every 30 minutes for six hours). Two litres of 0.9% saline were given over one hour. 
Urinary sodium excretion increased by 167% 60-90 minutes after the start of the 
inftision and then remained higher than that on the control day. However, the 
urinary kallikrein output did not differ significantly from the time-matched 
measurements on the control day.
10.4.5 Effects o f salt loading on other neurohormones in Chinese subjects
In the present study, since 30% of the sodium load was excreted during the 
inftision and the MAP remained normal, it is conceivable that Hong Kong Chinese 
subjects might be dependent on other mechanisms for handling an intravenous salt 
load. These include the pressure-natriuresis mechanism and other neurohormones 
(Chapter 2).
Indeed, investigators in Taiwan reported that other neurohormones may also 
play a role in ECF volume and BP homeostasis in Chinese subjects. In the study of 
Chen et al. (638), nine healthy adults were given an intravenous infusion of 0.9% 
saline (2,000 ml over four hours). The natriuretic response was accompanied by a 
suppression of the PRC and plasma aldosterone concentration. In another study by 
Chen’s group (639), nine healthy subjects taking their usual diet without salt 
restriction were given an intravenous infusion of 0.9% saline (2,000 ml) over four 
hours. Hourly urine collections revealed a 9-fold increases in urinary sodium 
excretion, from 10.2 ±2 .6  mmol at the baseline to 103.8 ± 13.5 mmol during the 
infusion. Their MAP remained unchanged throughout the study but plasma ANP 
increased by 24-33% during the third and fourth hour of infusion. A progressive fall 
in PRC of 58-87% ccurred during the infusion. In the study of Hsieh et al. (640),
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nine healthy subjects received two litres of 0.9% saline intravenously over four 
hours. A rise in plasma ANP was observed which became statistically significant by 
the fourth hour of the infusion. These three Taiwanese studies suggest that increased 
ANP release and suppression of the RAS may play a role in the regulation of ECF 
volume and BP homeostasis in Chinese.
10.4.6 Significance and implications o f my findings
This was the first study to measure the simultaneous changes in renal sodium, 
DA, NA and kallikrein outputs in response to an intravenous salt load among healthy 
subjects. The absence of any changes in urinary free DA output despite a significant 
increase in sodium excretion after the intravenous saline infusion suggests that the 
renal DA system does not contribute significantly to the natriuretic response in 
Chinese subjects. Since the urinary free NA outputs also remain unchanged during 
and after the saline infusion, SNS activity also does not seem to be involved in their 
natriuretic response. However, the increase in urinary kallikrein output is much 
greater than that in sodium excretion, suggesting that the renal kallikrein-kinin 
system plays an important role in ECF volume and sodium homeostasis in these 
subjects.
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Chapter 11 Conclusions
Over the past 30 years, the pioneer work of several investigators strongly 
suggests the importance of endogenous DA and renal DAj receptors in the regulation 
of sodium and EOF volume homeostasis (Chapter 3). There is substantial evidence 
that a defective renal DA system contributes to the development and maintenance of 
hypertension (Section 4.1). For example, some individuals may be less efficient in 
excreting a salt load as a result of defective renal DA production (Section 1.3). Such 
individuals may develop hypertension if  they are frequently exposed to high salt diet.
The Chinese subjects in Hong Kong have a higher dietary sodium intake than 
before (Section 1.5). Hypertension and related complications such as intracerebral 
haemorrhage and heart failure are (increasingly) common. In my work, my aim is to 
establish whether Chinese subjects in Hong Kong have an efficient renal DA system 
that enables them to handle dietary salt loads effectively without developing an 
increase in BP (Section 1.6).
11.1 Are Hong Kong Chinese particularly 'salt-sensitive'?
With a substantial increase in dietary salt intake among the local population 
(Section 1.5), it is most important to find out whether Hong Kong Chinese are 
particularly 'salt-sensitive'. To address this question, I have studied the effects of 
oral and intravenous salt loading on BP in Chinese subjects recruited from our local 
population.
I have shown that the MAP in healthy Chinese subjects without a family 
history of hypertension remained unchanged despite large increases in sodium intake
232
from 20 to 220 mmol/day for five days (Chapter 7). Similar findings have been 
reported for Caucasian subjects (367-369,373). I have shown that the MAP in these 
subjects remained unchanged after gradual increases in sodium intake (50 mmol/day) 
over eight days (Chapter 9). In particular, there were no changes in their MAP 
despite a sodium intake of 320 mmol/day at the end of the salt loading period. I have 
also shown that an intravenous salt load (1,000 ml of 0.9% saline over two hours) 
was not associated with any changes in MAP in these subjects (Chapter 10). 
Therefore, sudden, large changes in dietary salt intake to an extent likely to be 
encountered in daily life do not alter the BP in healthy Chinese subjects without a 
family history of hypertension.
In contrast, healthy Chinese subjects with a family history of hypertension 
showed an increase (3.7%) in MAP after acute changes in dietary sodium intake 
from 20 to 220 mmol/day for five days (Chapter 8). Similar findings have been 
described for Caucasian subjects in Switzerland (619), Australia (621) and Germany 
(622). Others (248) have reported that subjects with a family history of hypertension 
are more likely than those without such a history to show a fall in BP after salt 
restriction.
11.2 Does the renal DA system have an important role in the natriuretic 
response to salt loading in Hong Kong Chinese?
To establish if the renal DA system has an important role in the natriuretic 
response to salt loading in Hong Kong Chinese, I have studied the relationship 
between 24-hour urinary sodium and free DA outputs in healthy subjects under basal 
conditions and their renal DA response to oral and intravenous salt loading.
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11.2.1 Positive correlation between 24-hour urinary sodium and free DA outputs
If DA is an important intrarenal natriuretic substance in Chinese and dietary 
sodium is the major determinant of its intrarenal synthesis, there should be a positive 
correlation between 24-hour urinary sodium and free DA outputs (Section 3.1,6).
In my cross-sectional studies of Chinese subjects living in Hong Kong, a 
positive correlation between 24-hour urinary sodium and free DA outputs was seen 
in normotensive subjects with or without a family history of hypertension (Chapter 
5), younger patients with less severe hypertension (Chapter 5 and Chapter 6), and 
normotensive and hypertensive sibling-pairs (Chapter 6). In contrast, patients with 
more severe hypertension did not show a positive correlation between 24-hour 
urinary sodium and free DA outputs (Chapter 5). A bigger comparative study using 
identical methodology is needed to confirm my findings (Section 5.4.8),
Two other studies in Guangzhou (597) and Hong Kong (598) also confirmed 
that there was a positive correlation between 24-hour urinary sodium and free DA 
outputs among healthy Chinese subjects. Similar findings have been reported in 
ethnic groups originating from salt-abundant regions (Table 3g).
11.2.2 Hyperdopaminergic response in patients with hypertension
Under basal conditions, Chinese patients with hypertension had a higher 24- 
hour urinary free DA output than normotensive subjects (Chapter 5 and Chapter 6). 
In view of the known cardiovascular and renal effects of DA in the body (Chapter 3), 
this increased intrarenal DA synthesis in patients with hypertension may represent an 
early antihypertensive compensatory mechanism.
Such a hyperdopaminergic response has also been reported in Caucasian and 
Japanese patients during the early phases of hypertension (Section 4.1.1).
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11.2.3 Small, unsustained renal DA response to large, acute increases in oral salt
intake
If DA is an important intrarenal natriuretic substance in Chinese and dietary 
sodium is the major determinant of its intrarenal synthesis, there should be a marked 
increase in urinary free DA output during the natriuretic response to oral salt loading 
(Section 3.1.7). However, when healthy Chinese subjects without a family history of 
hypertension were given a diet containing either 20 or 220 mmol sodium/day for five 
days each (Chapter 7), they only showed a 8-17% increase urinary free DA output 
and this increase was only sustained for three days. A similar renal DA response 
was seen in healthy Chinese subjects with a family history of hypertension (Chapter 
8). On changing from a 20 to 220 mmol/day sodium diet, subjects with a family 
history showed a 23% increase in free DA output excretion on the first day of high 
salt intake. From day 2 to day 5, the increase in urinary free DA output became 
attenuated (12-15% higher than the baseline) but still reached statistical significance 
on days 2 and 5.
In contrast, when changing from a low (90-40 mmol/day) to high (220-340 
mmol/day) sodium intake, Caucasian subjects showed a much greater increase in 
urinary free DA output of 26-59% and the urinary free DA output remained elevated 
throughout the high salt intake period (Table 3h).
Since the renal DA was small (compared to the 7- to 10-fold increase in urine 
sodium and the DA response reported in Caucasians) and the increase in urinary free 
DA output became attenuated after two to three days of salt loading, the renal DA 
system contributes only partly to the early natriuretic response to dietary salt loading 
in Chinese.
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11.2.4 Absence o f a renal DA response to small, gradual increases in oral salt 
intake
If renal DA plays an important role in acute sodium and ECF volume 
homeostasis in Chinese, it should be sensitive to small, gradual increases in dietary 
salt intake (Section 9.1). However, during gradual increases in salt intake (50 
mmol/day) over eight days, urinary free DA output did not change in healthy 
Chinese subjects without a family history of hypertension (Chapter 9). In particular, 
despite a sodium intake of 320 mmol/day on the last three days of the high salt 
intake period, daily urinary free DA output remained unchanged. These findings 
suggest that the renal DA system in Chinese is insensitive to gradual, small increases 
in oral salt intake.
11.2.5 Absence o f a renal DA response to intravenous saline infusion
If DA has an important natriuretic role in Hong Kong Chinese, there should 
be a concomitant increase in urinary free DA output during the natriuretic response 
to an intravenous salt load (Section 3.1.9). However, when healthy Chinese subjects 
without a family of hypertension were given an intravenous 0.9% saline infusion 
(1,000 ml over two hours), their hourly urinary free DA output remained unchanged 
(Chapter 10).
11.2.6 Renal DA is not an important natriuretic factor in Hong Kong Chinese
My findings so far indicate that in Hong Kong Chinese, the renal DA system 
is insensitive to gradual, small increases in oral salt intake and a modest intravenous 
salt load. Even sudden, large increases in oral salt intake are associated with a
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relatively small and unsustained renal DA response. Thus, renal DA does not appear 
to be an important natriuretic system in Hong Kong Chinese.
11.3 Do Chinese have another mechanism(s) to deal with a salt load?
I have shown that the MAP in healthy Chinese subjects without a family 
history of hypertension remained unchanged despite large increases in sodium intake 
(Chapter 7 and Chapter 9). Their natriuretic response to oral or intravenous salt 
loading was brisk and comparable to that reported in other ethnic groups (Chapter 7, 
Chapter 9 and Chapter 10). Therefore, it is reasonable to investigate what other 
mechanism(s) are involved in the natriuretic response to a salt load.
11.3.1 The role o f a reduction in the SNS activity
A reduction in the SNS activity may contribute to the natriuretic response to 
salt loading, as a concomitant fall in plasma NA concentration or urinary free NA 
output has been demonstrated in Caucasian subjects (Section 2.4.2). However, on 
changing from a low to high sodium diet, healthy Chinese subjects without a family 
history of hypertension showed no changes in urinary free NA output in the first four 
days of the high salt intake period (Chapter 7). During gradual increases in dietary 
salt intake, their urinary free NA output also remained constant during the first three 
days of increasing salt loading (Chapter 9). In both situations, a reduction (about 
20%) in urinary free NA was seen towards the end of the high salt intake period, 
which might help offset any tendency to hypervolaemia-related increases in BP. The 
urinary free NA output also remained unchanged in healthy Chinese subjects during 
the natriuretic response to an intravenous sodium load (Chapter 10). These
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observations suggest that a reduction in the SNS activity does not contribute to the 
natriuretic response to salt loading in Hong Kong Chinese.
11.3.2 The role o f the renal kallikrein-kinin system
The renal kallikrein-kinin system also plays an important role in ECF volume 
and BP homeostasis (Section 2.3.3). Renal kallikrein production, as indicated by 24- 
hour urinary kallikrein output, was not different between Chinese normotensives and 
patients with hypertension (Chapter 5) or between normotensive and hypertensive 
sibling-pairs (Chapter 6). Cross-sectional studies of the interrelationships between 
24-hour urinary sodium, potassium and kallikrein outputs among normotensives and 
hypertensives failed to show consistent results (Chapter 5 and Chapter 6). Hence, 
salt-loading studies would be the better means to determine the importance of renal 
kallikrein-kinin system in ECF volume and sodium homeostasis in Chinese.
In my study, healthy Hong Kong Chinese subjects without a family history of 
hypertension showed a 103-140% increase in urinary kallikrein excretion during an 
intravenous 0.9% saline (one litre over two hours) infusion (Chapter 10). Urinary 
kallikrein output was still 74% higher than the basal level one hour after completion 
of the infusion. This brisk urinary kallikrein response to a modest intravenous salt 
load suggests that the renal kallikrein-kinin system might play an important and 
substantial role in ECF volume and sodium homeostasis in Hong Kong Chinese.
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11.4 Do the offspring of hypertensive parents respond to a salt load
differently?
BP is higher in the offspring of hypertensive parents than in the offspring of 
normotensive parents (Section 8.1). Subjects with a family history of hypertension 
also tend to have a blunted natriuretic response to an intravenous salt load and are 
more likely to be salt-sensitive. I have therefore compared the effects of oral salt 
loading on BP (Section 11.1), sodium excretion, renal DA response and SNS activity 
in healthy Chinese subjects with or without a family history of hypertension 
(Chapter 8). After the sodium intake was increased from 20 to 220 mmol/day, both 
the natriuretic (Section 8.4.2) and renal DA (Section 8.4.3) responses were similar in 
the two groups. As in subjects without a family history of hypertension, subjects 
with a family history showed no changes in urinary NA output (Section 8.4.4) over 
the first four days of the high salt intake period. These findings suggest that the 
natriuretic response in both groups is not mediated by a reduction in SNS activity. 
However, unlike subjects without a family history, the offspring of hypertensive 
parents showed no changes in urinary free NA output even by the fifth day (Section 
8.4.4). This lack of a fall in SNS activity might contribute to the increase in their 
MAP during high salt intake (Section 8.4.1).
11.5 Implications of my findings and the need for future studies
In healthy Chinese subjects, the renal DA response to salt loading is either 
attenuated (Section 11.2.3) or absent (Section 11.2.4 and Section 11.2.5). The nature 
of the defect in renal DA mobilisation is not known at present. In particular, it is not 
known if there is impaired intrarenal conversion of L-dopa to DA after, for example,
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salt loading and protein meals (Section 3.2.2). Since healthy Chinese subjects in 
Hong Kong do not have an efficient renal DA response to salt loading, they might be 
more prone to salt-induced hypertension unless they have other mechanism(s) to deal 
with a salt load. Although my subjects without a family history of hypertension 
showed no changes in their BP after modest salt loading, the effects of a higher salt 
intake (e.g. 300 mmol/day) are not known. In those with a family history of 
hypertension, an increase in BP was seen when their sodium intake was increased to 
220 mmol/day. The effects of a higher sodium intake in Chinese subjects with other 
risk factors for salt sensitivity (e.g. diabetes and obesity) are also not known. These 
questions and the relative importance of the renal kallikrein-kinin system and other 
natriuretic (Section 2.3) and antinatriuretic (Section 2.4) systems in ECF volume and 
BP homeostasis need to be addressed in future studies. To confirm if there is indeed 
an ethnic difference in the renal DA system, subjects of different ethnic backgiound 
living in the same environment should be studied in future.
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